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Abstract
Infectious diseases are a significant threat to public health. Though society enacts
practices to prevent the spread of these dangerous diseases, challenges remain. Therefore,
continual advancements in treatment and prevention are required. Wastewater treatment
and viral clearance in pharmaceutical applications are two key health measures that
prevent the spread of infections.
A low-cost, low-technology biosolids treatment process was developed to
improve wastewater treatment by collecting key information on storage temperature,
ammonia, volatile solids, moisture content, pH, and pathogen inactivation in biosolids
over long-term storage at two wastewater treatment plants located in northern climates of
the United States. Inactivation of pathogens in the biosolids was enhanced by freeze-thaw
cycles, intermediate moisture contents (16% total solids), and time. Biosolids required
over a year of long-term storage to reach standard pathogen limits for treatment in
northern climates.
To improve viral clearance in therapeutic protein manufacturing, the use of
arginine and buffers was studied at pH ≥ 4 to retain the stability of the final protein
product. A stabilized virus membrane structure, resulting from lipid packing density or
membrane proteins, hindered the inactivation efficacy of arginine and buffers. The
influence of membrane properties on arginine and buffer interactions supports the
inactivation mechanisms of viral membrane deformation. Increased hydrophobicity and
clustering enhanced the inactivation of enveloped viruses by arginine at pH 4 and 7.
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Electrostatic interactions increased the inactivation of enveloped viruses by buffers at pH
4.
Overall, the mechanisms for pathogen inactivation were further understood for the
improvement of biosolids treatment and therapeutic protein manufacturing to facilitate
the prevention of infectious diseases.

xxiii

1 Introduction and Chapter Summaries
1.1 Introduction
Infectious diseases affect billions of people annually, significantly impacting
world health1. Infectious diseases are caused by microorganisms and are spread from one
person to another2. These highly dangerous diseases resulted in 3 million mortalities in
2016 through lower respiratory infections alone, ranking as the fourth top cause of death1.
Recent coronavirus outbreaks that produce severe respiratory infections include the
Middle East Respiratory coronavirus (MERS-CoV), severe acute respiratory syndrome
coronavirus (SARS-CoV), and the novel coronavirus (SARS-CoV-2)3. Additional
infections including diarrheal diseases (1.4 million deaths) and tuberculosis (1.3 million
deaths) were also classified in the top ten causes of death worldwide1. For this reason,
considerable safety measures must be taken to minimize the threat of infectious diseases.
In order to prevent infectious diseases, society has enacted practices to protect
itself through immunization, health measures, surveillance, and treatment4 . Though
many barriers exist that impede infectious diseases from causing harm to public health,
humans still remain vulnerable to these microorganisms. For this reason, advancements
need to continually be implemented to fight current obstacles in treatment and prevention
of infectious diseases4.
Wastewater treatment and viral clearance during pharmaceutical applications are
two examples of health measures that society enacts to minimize the spread of infectious
diseases. Wastewater is liquid or water-transported wastes originating from residential,
business, industry, or natural sources5. Wastewater processes remove and treat infectious
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materials from residential areas to prevent the spread of disease. Viral clearance in
pharmaceutical applications prevents infections by removing or inactivating viruses from
biological medical products6. Examples of biological medical products include
recombinant therapeutic proteins, monoclonal antibodies, glycoproteins, and tissue/ blood
products6. This dissertation investigates various processes that improve wastewater
treatment and viral clearance in therapeutic protein manufacturing to protect the public
from infectious diseases.

1.2 Chapter Summaries
The chapters of this dissertation describe different projects focused around the
removal of infectious pathogens that can cause human disease.
Chapter 2 focuses on the improvement of wastewater treatment through a lowcost, low-technology biosolids treatment method. Many wastewater treatment plants are
looking to upgrade their biosolids treatment systems to open additional avenues for land
application and distribution of biosolids7. However, a large majority of wastewater
treatment plants lack the resources to implement the high-tech and high-costs processes
required to upgrade their biosolids treatment. Therefore, there is a growing need for lowcost, low-tech treatment options. One example of low-cost, low-tech treatment is the
inactivation of pathogens in biosolids through long-term storage. However, long-term
storage is not widely used since universal conditions required to meet treatment standards
are not known. To further understand the conditions required to meet pathogen
inactivation standards during long-term storage, a year-long pilot-scale study was
undertaken at Gogebic Iron Wastewater Authority (GIWA) and Portage Lake Water and
2

Sewer Authority (PLWSA). Fundamental information was collected on the impact of key
parameters including storage temperature, organic matter content, ammonia, pH, and
moisture on the rate of inactivation of pathogens. The data collected provided insight into
the conditions required for low-cost, low-technology biosolids treatment processes.
Chapter 3 is a literature review on the mechanisms of enveloped virus inactivation
by the amino acid arginine. Arginine inactivates enveloped viruses at conditions that
retain protein stability, making it a desired viral clearance process during therapeutic
protein manufacturing. Conditions for optimal inactivation include arginine
concentrations of 0.7-1 M, an incubation time of 60 minutes, and a synergistic factor of
either ≥ 40°C, ≤ pH 4, or Tris buffer 8-16. However, not all enveloped viruses are fully
inactivated by arginine at these optimal conditions. Viruses that are resistant to arginine
have increased protein stability or increased membrane stability17. Arginine interacts with
both proteins and lipids, and therefore, either interaction may be key to understanding the
mechanisms of inactivation. Three hypotheses are drawn to explain the mechanisms of
inactivation by arginine. Hypothesis 1 describes inactivation through inhibition of viral
protein function. Hypothesis 2 describes inactivation through membrane destabilization.
Hypothesis 3 describes inactivation by membrane pore formation. Understanding the
mechanisms of arginine may elucidate the use of functional groups, charges, or additives
to enhance inactivation.
Chapter 4 dives into the mechanisms and improvement of enveloped virus
inactivation by arginine. First, the effect of virus structure on inactivation by arginine was
explored. Enveloped viruses with highly stable membranes were less affected by arginine
than enveloped viruses with less stable membranes. Additionally, the sensitivity of
3

viruses to membrane cholesterol depletion correlated to arginine sensitivity. The
influence of membrane properties on inactivation supported the mechanism of membrane
deformation by arginine. To enhance the inactivation of viruses with stabilized
membranes, arginine-derivatives, arginine clustering, hydrophobicity, and buffer type
were examined. Overall, higher hydrophobicity and arginine-clustering increased
inactivation by arginine. Dynamic light scattering (DLS) and transmission electron
microscopy (TEM) were used to determine structural changes to viruses after arginine
exposure. Increasing virus size after arginine exposure was observed, supporting lipid
expansion or arginine binding as the mechanism for inactivation. Overall, the data
supports membrane deformation as the mechanisms of arginine inactivation. Inactivation
can be enhanced through added hydrophobicity or increased arginine clustering.
Chapter 5 explores the influence of virus properties, buffer properties, and time on
the inactivation of viruses at pH 4. Enveloped viruses including pseudorabies virus
(SuHV-1), herpes simplex virus 1 (HSV-1), and equine arteritis virus (EAV), and the
non-enveloped porcine parvovirus (PPV) were tested with glycine, acetate, and citrate
buffers at concentrations ranging from 20-500 mM. Inactivation levels were dependent
on all properties tested. The stabilized membrane of small EAV protected the virus
against inactivation at pH 4. Similarly, the non-enveloped PPV was also unaffected by
pH 4, likely resulting from the absence of a lipid bilayer. EAV and PPV may require
harsher conditions for inactivation, such as lower pH or higher temperatures. Larger
viruses with less stabilized membranes (HSV-1 and SuHV-1) were inactivated to the
highest levels by citrate and the lowest levels by glycine. Higher buffer concentrations
either increased or had no effect on inactivation. Buffers with opposite charges to the
4

virus produced higher inactivation. It is hypothesized that electrostatic interactions
between the virus and the buffer promote inactivation. Overall, inactivation by buffers at
pH 4 is virus-specific, however, solution conditions can be optimized to increase
inactivation.
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2 Low-Cost, Low-Tech Biosolids Treatment
2.1 Introduction
Clean water and sanitation are essential for life. Wastewater processes support life
by treating and removing contaminated water from populated areas to prevent the
accumulation of infectious materials. Wastewater contains liquid or water-transported
wastes originating from residential, business, industry, or natural sources (groundwater,
surface water, or stormwater)18. In the absence of wastewater treatment, infectious waste
would accumulate in populated areas, leading to poor sanitation and disease.
Treatment of wastewater in the United States commonly includes preliminary,
primary, secondary, and tertiary processes, illustrated in Figure 2-118. Treatment
processes remove solids, nutrients, pathogens, organic compounds, and odors to convert
wastewater into an effluent that is safe for human and environmental health18.
Preliminary treatment applies bar screens and grit chambers to separate large materials
such as rags or grit. A portion of suspended solids and organic matter are removed via
primary sedimentation. Secondary treatment uses biological treatment to remove
additional suspended solids and biodegradable organics. Tertiary treatment employs final
disinfection for safe discharge. Examples of final disinfection practices include chemicals
or ultraviolet light (UV). After treatment is completed, the final effluent is discharged
into a surface water body.
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Figure 2-1. Wastewater originates from residential industry/business or stormwater
sources. Treatment includes preliminary, primary, secondary, and tertiary processes.
Solids can be disposed of by incineration, landfill, or land application.
Wastewater solids contain pathogens and use an oxygen demand, and therefore,
solids must be removed before safe discharge. Solids are typically removed from
wastewater during primary and secondary treatment through clarifiers. Though termed
solids, this wastewater constituent is a semisolid liquid between 0.25-12% solids18. Solids
disposal options include incineration, surface landfills, or reuse by land application after
treatment18. Treated wastewater solids contain high nutrient and organic matter content,
and, therefore reuse through land application is a sustainable and cost-effective means of
disposal.
Because of the presence of pathogens and the potential to attract vectors (e.g.
7

rodents, insects, and birds), treatment of wastewater solids is required to protect human
and environmental health before reuse. Treated residual wastewater solids are termed
biosolids (Figure 2-2). The United States Environmental Protection Agency (U.S. EPA)
regulates biosolids treatment, quality, use, and disposal under the Code of Federal
Regulations, Title 40, Part 503 rule19. Under the EPA regulations, biosolids products are
classified into two distinct levels: Class A and Class B. Class A biosolids undergo an
advanced sludge process train, reducing pathogens below detectable limits, while Class B
biosolids receive a less aggressive treatment and contain low but detectable levels of
pathogens. As a consequence of advanced treatment, Class A biosolids can be re-used
with limited regulations.

Figure 2-2. Treated sewage solids are termed biosolids. Biosolids
can be land applied as a fertilizer or soil amendment.
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Wastewater Treatment Plants (WWTPs) throughout the U.S. are pursuing Class A
biosolids treatment systems to open additional avenues for land application and
distribution of biosolids7. Public scrutiny, lack of resources and high energy costs are
only a fraction of challenges that WWTPs face20. To adequately treat wastewater, plants
utilize 2-4% of the total energy generated in the U.S. in a given year, producing high
operation costs21. Rural WWTPs pay ~$0.16 per cubic meter of wastewater treated or
about $700,000 per year22. By producing Class A biosolids, WWTPs can land apply
biosolids without the extra costs associated with lower quality biosolids, while gaining
revenue for the final product to supplement energy costs. However, the majority of Class
A biosolids treatment processes are high-tech and high-cost, leaving many WWTPs
without the resources to implement the design. Consequently, there is an increasing
demand for low-cost, low-tech (LCLT) treatment options to produce Class A biosolids.

2.2 Literature Review
2.2.1

Pathogens in Biosolids
Numerous pathogenic organisms exist in wastewater solids including bacteria,

viruses, protozoa, helminths, and fungi (Table 2-1)23, and therefore, solids must be
treated to reduce pathogens before reuse. If solids are improperly treated, pathogens can
spread to agricultural soil during land application. Therefore, it is important to understand
the quantity and type of microorganism present in the solid waste for effective treatment
and safe re-use.
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Table 2-1. Pathogens commonly found in biosolids include bacteria, viruses, and
parasites.
Pathogen
Bacteria

Virus

Parasite

Size Range

Common in Biosolids
Salmonellae
Escherichia coli
~1-3 µm
M. tuberculosis
Clostridium perfringens
Adenovirus
Enterovirus
~20-200 nm
Hepatitis A virus
Rotavirus
Ascaris lumbricoides
Ascaris suum
~1 µm-30 m
Taenia
Anclostoma duodenale

High concentrations of bacteria exist in wastewater treatment solids. The most
prevalent bacteria include species that infect the human gut. Typical conditions for gut
bacteria survival are high organic content in mesophilic temperatures of around 37 °C23.
Over 140 different types of viruses have been found in biosolids23. These viruses
commonly cause respiratory illness, acute gastroenteritis, conjunctivas, and diarrhea.
Feces of infected individuals contain very high levels of virus. The infectious dose of
enteric viruses, ranging from 10-100 infectious units, is very low, making proper
treatment necessary for human safety23.
The majority of parasites found in biosolids are classified under helminth ova,
which include Ascaris ova, or protozoa. These parasites are prevalent around the world
causing many illnesses. Parasite infectivity can range from 1-10 cysts egg per person24.
With low infectivity dose, it is crucial to properly treat for parasites. Parasites are the
most resilient pathogen in biosolids due to their protective outer shell, and therefore, are
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commonly used as indicator organisms. Indicator organisms are organisms whose
abundance suggests the presence of various pathogenic species. Whether it be bacteria,
viruses, or parasites, it is important to properly treat sewage solids to reduce pathogens.

2.2.2

Biosolids Treatment
In 1984, the U.S. EPA created a policy that endorsed the beneficial reuse of

biosolids as a fertilizer or soil amendment. The EPA defines biosolids as “a primarily
organic solid product produced by wastewater treatment processes that can be
beneficially recycled19.” For this reason, biosolids are seen as an item for re-use.
Biosolids refer to sewage solids that have undergone treatment to reduce pathogens and
the potential for vector attractions. Class A biosolids can be applied to agricultural land,
disturbed areas, forests, recreation areas, cemeteries, and residential gardens19. The U.S.
EPA regulates biosolids monitoring, testing, treatment, and pathogen levels.
Class A and Class B biosolids are two distinct levels of treated sewage solids.
Class A biosolids undergo an advanced process train to reduce pathogens below
detectable limits. Class A biosolids can be disposed of with limited EPA regulations due
to undetectable pathogen levels. Class B biosolids receive less aggressive treatment and
contain detectable, but low, levels of pathogens. Class B biosolids are more restricted
than Class A when it comes to reuse as a result of pathogen levels as well as metals
content and vector attraction criteria. Required pathogen limits for Class A and B
biosolids are included in Table 2-219.
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Table 2-2. Class A and B Pathogen Limits. Class A has stricter pathogen limits but a
wider range of land application options compared to Class B Biosolids.
Pathogen

Class A Limit

Class B Limit

Fecal
coliforms

< 1000 MPN/g dry solids

< 2 million
MPN/g dry solids

Enteric
viruses

< 1 plaque with a 3-log10
reduction

N/A

Helminth
ova

< 1 viable ovum/4 g dry solids
with a 2-log10 reduction shown

N/A

2.2.2.1 Alternatives to Meet Class A Pathogen Requirements
Both Class A and B biosolids have several treatment options to meet EPA standards.
As discussed further below, six alternatives exist for producing Class A biosolids under
the EPA part 503 regulations19:
Alternative 1: Thermally Treated Biosolids
Specific time and temperature regimes must be met.
Alternative 2: Sewage Sludge Treated in a High pH-High Temperature Process
Specific pH, temperature, time and air-drying methods must be met.
Alternative 3: Sewage Sludge Treated in Other Processes
Fecal coliform or Salmonella, the density of enteric viruses, and the density of
helminth ova are all at or below the EPA pathogen limits through a specific
treatment process. Once this has been met, the plant may maintain operating
conditions for pathogen reduction.
Alternative 4: Sewage Sludge Treated in Unknown Processes
12

EPA regulatory limits for Salmonella or fecal coliform bacteria, enteric viruses,
and viable helminth ova at the time of biosolids disposal are met. Monitoring for
pathogens must occur before all biosolids disposal applications.
Alternative 5: Biosolids Treated in a Process to Further Reduce Pathogens (PFRP)
Solids must be treated in one of the PFRPs listed in Appendix B of the EPA 503
regulations. The PFRP’s include:


Composting: aerobic decomposition of solids using a within-vessel or
static aerated pile method. Temperatures must remain at 55°C (131°F) or
higher for 3 consecutive days.



Heat Drying: sewage solids are dried to 10% total solids or lower by hot
gases. Temperatures of the solids must exceed 80°C (176°F) or the wet
bulb temperature exposed to the solids must exceed 80°C (176°F).



Heat Treatment: solids reach a temperature of ≥180°C (356°F) over 30
minutes.



Thermophilic Aerobic Digestion: solids maintain aerobic conditions for 10
consecutive days at 55°C to 60°C (131°F to 140°F).



Beta Ray and Gamma Ray Radiation: solids are treated with beta rays or
gamma rays at doses of at least 1.0 megarad at room temperature.



Pasteurization: solids temperature is maintained at 70°C (158°F) or higher
for 30 minutes or longer.

Alternative 6: Use of a Process Equivalent to PFRP
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Solids are treated with a process equivalent to a PFRP that meets EPA pathogen
regulations. The permitting authority determines the equivalency of the process.

2.2.2.2 Vector Attraction Reduction
Vectors are organisms that are attracted to biosolids and could contribute to the
spread of pathogens19. Insects, birds, and rodents are examples of vectors. To prevent the
spread of pathogens, vector attraction is reduced through the breakdown of volatile
solids, inhibition of microbial activity, or enacting a physical barrier. The 503 regulations
state that pathogen and vector attraction reduction (VAR) can occur simultaneously with
other biosolids treatments. A total of 12 options exist to satisfy vector attraction reduction
requirements:
VAR Option 1: 38% volatile suspended solids reduction.
VAR Option 2: anaerobic digestion.
VAR Option 3: aerobic digestion.
VAR Option 4: anaerobic digestion system meets specific oxygen uptake rates.
VAR Option 5: aerobic processes greater than 40°C.
VAR Option 6: pH raised to 12 and maintained at pH 11.5 for 24 hours.
VAR Option 7: solids content exceeds 75% and the product contains stabilized
solids.
VAR Option 8: unstabilized solids must be over 90% total solids before it can be
added and mixed with other materials.
VAR Option 9: injected into the earth’s surface to create a barrier between the
vectors and biosolids.
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VAR Option 10: incorporated into the soil within eight hours from discharge.
VAR Option 11: covered on-site with soil or other material.
VAR Option 12: pH of domestic septage must be raised to 12 and held for 30
minutes.

2.2.3

Low-Cost, Low-Tech Treatment
From the above alternatives and VAR options, it is clear that there are several

ways to treat biosolids. However, what alternatives can be used to meet low-cost, lowtech demands for producing Class A biosolids? Alternative 6 for Class A biosolids
treatment can be used to produce an equivalent process to a PFRP, allowing for the
creation of a low-cost, low-tech certified process. Under Alternative 6, a Pathogen
Equivalency Committee (PEC) provides guidance and expertise to create an equivalent
process to a PFRP. The guidance includes a three-log10 reduction of enterovirus and a
two-log10 reduction of helminth ova. Though a specific log-reduction must be met,
pathogen limits must also be satisfied (Table 2-2).
Sustainable LCLT treatment alternatives for producing Class A biosolids do exist
and have been successfully implemented. Options for LCLT treatment include long term
storage, air drying, and cake storage25. Many large WWTPs currently implement LCLT
treatments, including Chicago, Illinois and San Jose, California25,26. The Stickney Water
Reclamation Plant (Metropolitan Water Reclamation District of Greater Chicago)
combines long-term storage, air drying, and cake storage to treat their biosolids to a Class
A level27. Biosolids are first treated in Chicago with the use of anaerobic digestion (35° C
for 20 days), followed by two solid process trains to obtain a final product that is Class A
15

certified and yields 60% total solids. The two sludge process trains include a high solids
sludge process train (HSSPT) and a low solids sludge process train (LSSPT). The HSSPT
and LSSPT produce equal amounts of treated biosolids throughout the year. During the
HSSPT, solids are conditioned with a cationic polymer followed by dewatering with
centrifuges to 25% total solids. This material is transported to a storage lagoon
throughout the year, except when the temperature is below -4°C. In the LSSPT, solids are
pumped straight from the anaerobic digesters into a separate set of lagoons. Both the
LSSPT and HSSPT lagoons are filled for a period of 1 to 3 years. Solids settle to the
bottom, while supernatant is recycled back to the WWTP. Lastly, the solids are air-dried
to achieve a final product of 60% total solids.
Though many WWTPs are beginning to enact LCLT practices, widespread adoption
and regulatory approval of these methods have been hindered by a lack of information on
the impacts of environmental factors and biosolids properties on pathogen inactivation.
Most determinations of equivalency for LCLT treatment are based on environmental
conditions at each individual site. However, if similar conditions exist and pathogens
requirements are met across various sites, the process could qualify for national
equivalency. Reduced testing, increased public confidence, and a sustainable and safe
process are benefits for national equivalency. However, the application for equivalency
can be time-consuming and expensive. The best way to obtain this certification is to
provide the EPA with a full record of pathogen inactivation related to environmental
conditions at various sites. If mechanisms for pathogen reduction are well enough
understood, new low-cost, low-tech processes could be realized on a national basis.
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2.2.3.1 Long-Term Storage
One of the most effective LCLT treatment options is long-term storage. Longterm storage (lagoon storage) is defined as a process where biosolids are stored and left
unfed for a specific period of time, allowing for pathogen inactivation and organic matter
decomposition25. To initiate long-term storage, lagoons are filled with biosolids
continuously or intermittently, which can take several months to a year to accomplish.
Biosolids are typically aerobically or anaerobically digested prior to this process. During
the filling of the lagoon, solids settle and the supernatant is collected and returned to the
beginning of the wastewater treatment process. This system is then left unfed to allow for
pathogen destruction and organic matter breakdown. Once pathogens in the lagoon have
dropped to levels certified by the EPA, biosolids can be used as a fertilizer or soil
amendment. Figure 2-3 shows a schematic of the lagoon storage process. Inactivation of
pathogens during long-term storage occurs through a variety of mechanisms including
chemical action, storage time, temperature, and freeze-thaw cycles.

Figure 2-3. Long-Term Lagoon Storage/Treatment18. During long-term storage, lagoons
are filled and left to sit for a period of time to allow for pathogen inactivation and organic
matter breakdown.

17

Chemical Action
Chemical action refers to any process of inactivation that involves the
composition or structure of active chemical substances. Specific properties of the solids
that aid in pathogen die-off during chemical action include unionized ammonia (NH3)
content, pH, total solids, volatile solids, and volatile fatty acid content.
Biosolids that undergo anaerobic digestion contain large amounts of ammonia28. The
fraction of toxic ammonia, NH3, is minor at normal operating conditions (pH 5.0-7.0),
because the dominant species is NH4+, ammonium ion. Even at low levels, NH3 produces
toxic effects against pathogens, including enteric viruses29-31, pathogenic bacteria32,33, and
Ascaris ova32,34,35. Ammonia in urea concentrations of 0.4% inactivates Ascaris eggs and
Salmonella to Class A limits after short treatment times at 28°C32. Poliovirus and F2
bacteriophage are undetectable after treatment with 800 mg of NH3/L within hours at
20°C29. Overall, the levels of toxic ammonia in biosolids can inactivate pathogens.
Total solids (TS) and volatile solids (VS) are principle factors affecting pathogen
reduction in lagoon storage. It is widely accepted that increasing total solids reduces
pathogens through desiccation and autolysis of cells27,36-41. For example, fecal coliforms
were reduced to Class A levels at 90% total solids at 38°C in less than 10 days37.
Inversely, high moisture content increases the decay rate for pathogenic bacteria as a
result of the increased non-pathogenic bacterial competition42. Volatile solids also affect
pathogen growth and decay in biosolids. Volatile solids are organic matter that act as a
food source for bacteria in biosolids. At low ratios of volatile solids, the food source is
low, decreasing bacteria growth43. However, at a high ratio of volatile solids, increased
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growth of non-pathogenic bacteria can occur, inhibiting pathogenic bacterial growth.
Both total solids and volatile solids affect pathogen inactivation at high and low levels.
Volatile fatty acids (VFAs) are fatty acids containing two to six carbon atoms and
are naturally occurring in wastewater solids44. VFAs reduce bacteria growth45-53 and
produce toxic effects on Ascaris ova54,55. Inactivation of Salmonella occurs within 12
days during anaerobic digestion at a VFA concentration of 5000 mg/L at pH 6.0 46. VFAs
have been more effective in pathogen inactivation at lower pH values where the acids
exist primarily in the uncharged form. Because of the hydrophobic nature of the
uncharged form, the acid can readily cross the lipid bilayer to distress the pathogen and
cause inactivation54. Overall, unionized ammonia (NH3) content, pH, total solids, volatile
solids, and volatile fatty acid content all affect pathogenic growth and decay in biosolids
treatment (Table 2-3).
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Table 2-3. Literature Review on the Inactivation of Pathogens by Chemical Action

Concentration

Conditions

Pathogen
Reduction

0.4 % Urea

28C, days

Class A limits of
Ascaris eggs and
salmonella32

800 mg NH3/L

20C, Hours

Poliovirus and F2
bacteriophage to
undetectable
limits29

TS

90% TS

38C, 10 days

FC to Class A
levels37

VFAs

5000 mg/L

pH 6.0, 12 days

Salmonella to
undetectable
limits46

Chemical
Action

NH3

Storage Time and Temperature
Information exists at different temperature ranges (elevated and ambient) about
the time of exposure in inactivating pathogens during long-term storage34. Microbial
activity in biosolids can produce high temperatures of up to 60C that aid in the reduction
of pathogens56. In biosolids at 55C, E. coli and Salmonella were reduced by 8-log10 in
60 min and 10 min, respectively57. At 49.5C in anaerobically digested, vacuum filtered,
and air-dried biosolids, an 8-log10 reduction in Salmonella, poliovirus, and Ascaris suum
eggs occurred in 7, 10, and 40 days, respectively58. Natural ambient temperatures can
also inactivate pathogens in biosolids to Class A levels. In the southern hemisphere,
where ambient temperatures remain around 13.3C with little variability, Class A
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pathogen inactivation in biosolids occurs within 1-3 years59-64. In northern climates that
have greater temperature variability and can reach below freezing, pathogen inactivation
can take longer62,65,66; however, Class A biosolids can still be produced in these climates.
The amount of time needed to meet EPA standards is primarily based on the degradation
of Ascaris ova, which are the most resilient pathogen because of their protective outer
shell. Time and temperature can be varied in diverse climates to meet Class A regulations
for biosolids (Table 2-4).

Table 2-4. Literature Review on the Inactivation of Pathogens by Storage Time and
Temperature.

Temperature

Time

Pathogen Inactivation

60 min

8-log reduction E. Coli57

10 min

8-log reduction
salmonella57

7 days

Salmonella58

10 days

Poliovirus58

40 days

Ascaris Ova58

Southern Hemispheretemps around 13.3C with
little variability

1-3 years

Class A Levels59-61,64

Norther Hemispheresgreater temp variability

> 3 years

Class A Levels62,65

55C

49.5C
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Freeze-Thaw Cycles
Freeze-thaw cycles are widely known to increase dewaterability (or ability to lose
water) in biosolids through structure modifications67-70. Recent investigations have
demonstrated that freeze-thaw cycles can inactivate bacterial pathogens71-73 in dewatered
sanitary wastewater (blackwater)74, stabilization ponds75, activated sludge76,77, reed
beds66, untreated wastewater treatment solids77 and biosolids slurries treated via aerobic
or anaerobic digestion78.
The ideal conditions (i.e. temperature, freezing rate, # of cycles, and moisture
content) for freeze-thaw cycles to reduce pathogens are not well understood. The rate of
freezing and thawing is thought to be the key component of inactivation77. At slow rates
of freezing (~1C/min), liquid water molecules diffuse out of cells through the membrane
in response to the chemical potential gradient and contribute to the formation of
extracellular ice crystals79,80. Cellular damage under these conditions may result from cell
desiccation and/or the stress exerted by extracellular ice crystals as they grow and
squeeze cells in diminishing unfrozen channels containing high concentrations of rejected
solutes71,79. In contrast, at high rates of freezing (~100C/min), ice crystals form at rates
faster than liquid water molecules can diffuse through the cell membrane. If sufficiently
large, the resulting intracellular ice crystals disrupt the cell membrane and inactivate
cells. For example, freezing to -65C in yeast cells at a cooling rate of 1C/min leaves a
cell density of 30% of the initial concentration, while a cooling rate of 200C/min leaves
a cell density of 21% the original concentration80. Cellular damage and/or inactivation
can also occur during thawing, e.g., resulting from osmotic shock.
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Summary
From the literature, it is apparent that chemical action, temperature, storage time, and
freeze-thaw cycles have a large impact on pathogen reduction during long-term storage.
The mechanisms needed to inactivate pathogens are known to change across differing
climates, operating parameters, and biosolids properties. However, the correlation
between these essential mechanisms in pathogen die-off is not well understood.
Fundamental information on how key environmental parameters affect pathogen
inactivation is needed so that conditions necessary to achieve Class A pathogen
inactivation requirements in LCLT biosolids treatment systems can be accurately and
reliably predicted.

2.3 Objectives
The overall goal of this multi-phase project is to develop a universal approach for a
long-term storage process to serve as a Class A treatment alternative. First, a preliminary
study was performed to determine the relationship between total solid content and
pathogen reduction in biosolids subjected to freeze-thaw cycles. After the preliminary
study was completed, a broad research effort was initiated to determine the impact of key
process parameters on the inactivation of pathogens during long-term storage. Pilot-scale
studies for long-term storage were performed in conjunction with two collaborating
WWTPs; the Portage Lake Water and Sewage Authority (PLWSA) in Houghton, MI, and
the Gogebic-Iron Wastewater Authority (GIWA) in Ironwood, MI.
This overall goal was investigated through the following specific research objectives:
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Objective 1: Determine the relationship between total solids and pathogen reduction
in biosolids subjected to freeze-thaw cycles.
We hypothesize the total solids content of the biosolids sample will affect the rate
of biosolids freezing, which affects pathogen inactivation.
Pathogen inactivation may occur during biosolids storage under ambient
conditions; however, the mechanisms and rates of pathogen inactivation under these
conditions are not well understood. Objective 1 used a combination of field and
laboratory experiments to quantify the effects of freeze-thaw cycles on the inactivation of
fecal coliforms in biosolids with varying moisture levels. This information is needed
because WWTPs can use natural freeze-thaw cycles in cold regions to predict and
optimize pathogen inactivation in biosolids.

Objective 2: Evaluate the pathogen inactivation under long-term storage as a
function of environmental conditions.
We hypothesize that the mechanisms inactivating pathogens during lagoon
storage can be understood by ambient environmental conditions, storage temperature,
moisture, organic matter, ammonia (NH3), volatile fatty acids (VFAs), alkalinity, and pH.
To further understand the mechanisms of pathogen inactivation during long-term
storage, a year-long pilot-scale study was conducted at GIWA and PLWSA to meet
objective 2. Fundamental information was collected on the impact of key parameters,
e.g., storage temperature, organic matter content (measured as volatile solids (VS)), NH3
content, pH, and TS on the rate of pathogen inactivation. This data can be used to
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develop a rational and universal approach for the design of a LCLT Class A biosolids
treatment process.
Completing the above research objectives will improve our understanding of
pathogen inactivation under a broad range of conditions, enabling rational design of
LCLT treatment systems for high-quality biosolids production. This will contribute to the
greater implementation and EPA approval of LCLT treatment processes under alternative
6 for Class A biosolids treatment, thus allowing more wastewater treatment plants to
sustainably and economically produce high-quality biosolids.

2.4 Materials and Methods
2.4.1

Study Sites

Study sites for objectives 1 and 2 included Gogebic Iron Wastewater Authority
(GIWA, Ironwood, Michigan, USA) and Portage Lake Water and Sewage Authority
(PLWSA, Houghton, Michigan, USA) (Figure 2-4). The two WWTPs are similar in size
and have comparable treatment processes. GIWA treats an average wastewater flow of
3.4 million gallons per day (mgd) and PLWSA treats an average flow of 3.1 mgd. Table
2-5 provides information for wastewater treatment schemes. The key differences in
biosolids treatments are seen during secondary treatment where GIWA undergoes
oxidation ditch activated sludge, while PLWSA uses a conventional activated sludge
process.
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Figure 2-4. Location of GIWA and PLWSA Study Sites. GIWA is located in Ironwood,
Michigan while PLWSA is located in Houghton, MI.

Treatment Process

GIWA

Pretreatment

Screening and grit removal

Primary Treatment

Primary clarification
Oxidation ditch activated
sludge
Phosphorus removal via
chemical addition,
chlorination,
dechlorination and effluent
aeration

Secondary Treatment

Tertiary Treatment

PLWSA
Screening and grit
removal
Primary clarification
Conventional activated
sludge
Phosphorus removal via
chemical addition and UV
disinfection

Table 2-5. Comparison of GIWA and PLWSA Wastewater Treatment Processes.
Differences in biosolids treatments are seen during secondary treatment where GIWA
undergoes oxidation ditch activated sludge, while PLWSA uses a conventional activated
sludge process.
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GIWA and PLWSA perform mesophilic anaerobic digestion for vector attraction
reduction, followed by dewatering via belt-filter press during the solids process train.
Both plants produce materials that are classified as Class B biosolids. Large uninsulated
storage sheds are currently used for winter biosolids storage at PLWSA and GIWA.

2.4.2

Objective 1: Effect of Freeze-Thaw Cycles on Biosolids

2.4.2.1 Field Study
A 3 ft high biosolids pile was constructed with freshly dewatered biosolids in the uninsulated biosolids storage shed at PLWSA in May of 2013. Temperature profiles were
monitored at 3 locations within the pile. For each temperature profile, four Thermochron
iButton temperature data loggers (Embedded Data Systems; Lawrenceburg, KY), with
temperature ranges of -5 to 26 ˚C, were waterproofed with a silicone sealant, secured to a
wooden stake at 0, 5, 10, 20, and 50 cm depths (measured from the top of the pile) and
programmed to record the temperature at 4 h intervals for one year. When the biosolids
were not frozen, samples were collected monthly at each depth for analysis of total solids
and fecal coliforms. Total solids and fecal coliform levels were quantified in each sample
using the EPA Method 168481, and the Most Probable Number Method EPA Method
168182, respectively.

2.4.2.2 Freeze-Thaw Cycle Pathogen Inactivation
A 200 g biosolids sample, collected from GIWA or PLWSA, was diluted with sterile
deionized water to achieve desired total solids concentrations, which ranged from 5 to
25% total solids. Initial total solids and fecal coliform levels were quantified in each
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sample using the EPA Method 168481, and the Most Probable Number Method EPA
Method 168182, respectively. The sample was then divided into 100 g subsamples, placed
in Erlenmeyer flasks, and covered tightly with Parafilm. One subsample served as the
control and was incubated at 4 °C for 48 hr. The other subsample was incubated at -20 °C
for 48 hr and then thawed for 24 hr at 4 °C. After 72 hr, the subsample subjected to the
freeze-thaw cycle and control were analyzed for fecal coliforms.

2.4.2.3 Freezing Rate
Tests were performed to relate percent total solids to the freezing rate of biosolids.
Figure 2-5 illustrates the basic approach of the freezing rate experiments. Insulated
biosolids were placed on top of a water bath at 5 ˚C and in a freezer at -5 ˚C. A belowfreezing temperature on top and an above-freezing temperature on the bottom of the
biosolids created a temperature gradient. The temperature gradient caused the cooling
front in the biosolids to move from top to bottom to simulate conditions in natural lagoon
storage freezing83. The system was operated in this manner for 24 hr. Temperature
profiles in the biosolids were obtained every 100 s (1.67 min) in all of the freezing rate
experiments.
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Figure 2-5. Schematic of the biosolids freezing rate experiments. Biosolids were placed
between insulation with a water bath at 5°C beneath, and air at -5°C to ensure the cooling
front moved top to bottom.
2.4.2.4 Scanning Electron Microscopy
Prior to analysis with a FEI Philips XL 40 Environmental Scanning Electron
Microscope, biosolids were oven-dried at 40°C for 1.5 days, directly mounted onto a
sample button using carbon tape, and coated with a 10 µm-thick platinum-palladium
alloy. Images of biosolids were taken from 10-100 µm in diameter at a resolution of 15.0
kV.
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2.4.3

Objective 2: Pilot-Scale Studies

2.4.3.1 Pilot-Scale Test Boxes
Whether biosolids are stored indoors or outdoors affects solar radiation, temperature,
and moisture content. Therefore, two pilot-scale tests were assembled in triplicate at each
site, with pilot test boxes located inside and outside the storage shed. The pilot-scale
boxes were designed to meet four main specifications. First, the boxes had to maintain
structural integrity while holding ~two tons of solids, plus precipitation throughout the
year, and undergoing freeze/thaw cycles of the biosolids. Next, the boxes had to remain
watertight for up to two years, not allowing leachate to leak from the structure. Thirdly,
the boxes had to allow drainage water from the biosolids to be collected and disposed of
properly. Lastly, the boxes had to withstand ambient temperatures (~20°F to 95°F). To
simulate average dimensions of a biosolids pile, boxes were built 4' high, 4' wide, and 8'
long, using exterior-grade plywood, 2-in x 4-in braces, and additional reinforcements
(Figure 2-6),
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A

B

Figure 2-6. Wooden box construction A) during assembly and B) after completing
assembly and painting.
Liners, a drainage system, and temperature sensor stacks were installed in the
pilot boxes to meet design criteria. First, a sand layer was added to the bottom of the
boxes to protect the liner from the wood (Figure 2-7A). Custom-made, potable water
grade vinyl liners (Tri-City Vinyl, Saginaw, MI) were placed inside the interior of the
box and attached to the outside by wood cleats (Figure 2-7B). Next, a hole was cut in the
liner and the box to fit a polyvinyl chloride (PVC) drainage pipe (ASTM No. D2729
specifications) at the bottom of the box (Figure 2-7C). Small gravel was added to the box
below the drainage pipe (Figure 2-7D) followed by size 6A gravel to a depth of ~ 2” to
ensure proper drainage and prevent clogging (Figure 2-7E). Over the gravel, filter fabric
was laid down to allow leachate to drain while holding solids in place (Figure 2-7F).
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A

B

C

D

E

F

Figure 2-7. Boxes showing A) 1.5-2’’ base sand layer, B) vinyl liner, C) drainage pipe,
D) small gravel layer, E) 6A gravel to a level of ~2” and, F) cross braces, sensor stacks,
and filter fabric on bottom.
To begin filling the boxes, biosolids were carefully placed around the filter paper
to prevent exposure to any of the sand or gravel. Boxes were filled by shoveling biosolids
from a front-end loader to attain even packing consistency across all boxes to a level of 3
feet (Figure 2-8).
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Figure 2-8. Final construction of pilot scale boxes. A front-end loader was used to evenly
fill boxes with biosolids.
2.4.3.2 Enumeration of Microorganisms
To meet the requirements for alternative 6 of Class A biosolids production, or a
“Process Equivalent to a PFRP", pathogen limits of ≥ 3-log10 reduction of total enteric
viruses, ≥ 2-log10 reduction of viable Ascaris ova, and ≥ 1-log10 reduction of fecal
coliforms had to be met19. However, biosolids in the U.S. do not contain high enough
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levels of Ascaris ova or enteric viruses to demonstrate adequate pathogen reduction. For
this reason, Ascaris ova and enteric viruses were seeded into the pilot-scale boxes to
levels of 104 Ascaris ova/g total solids and 105-106 plaque-forming units (PFU) enteric
virus/g total solids. The vaccine-grade type 1 human poliovirus (ATCC) was used as the
enteric virus and is an attenuated virus that is noninfectious.
Sentinel Chamber Design
Chambers were designed for spiking pathogens into the biosolids. Separate
chamber designs for Ascaris ova (~35 to 50 µm diameter)84 and poliovirus (~28 nm
diameter)85 were created based on pathogen size. Chambers included a membrane
system that prevented the release of pathogens while allowing for an exchange of gas and
liquid with the biosolids. Therefore, conditions inside and outside the chambers in the
biosolids boxes were essentially the same.
The ova chambers followed the design from Gould et al86. ANKOM F57 filter
bags (ANKOM Technology, Macedon NY) were used because their pore size (25 µm)
was small enough to contain the ova. Additionally, the filter bags were chemically
resistant and capable of being heat-sealed. A complete ova sentinel bag is shown in
Figure 2-9.
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Figure 2-9. Complete Ascaris ova chamber with a pore size of 25 µm to contain the ova.
Sentinel chambers for poliovirus followed the design of Sidhu and Toze87. The
sentinel chambers were composed of a Teflon tube that was open on both ends. The tube
was secured at each end by a membrane (25 mm-diameter, 0.025-µm pore size,
Millipore). The membrane was protected by a marine-grade stainless steel mesh (0.5
mm). An O-ring secured the membrane and mesh within a groove at the end of the
chamber. Brass pressure plates, screws, and nuts held the full assembly together.
The Teflon chambers were fabricated by the Michigan Tech College of Engineering
Machine Shop. Figure 2-10A illustrates the brass pressure plates that are on the top and
bottom of the Teflon chamber. Figure 2-10B shows the side view of the chamber. The
screws and nuts were made from stainless steel to prevent corrosion and rust. Figure 210C illustrates the top view of the chamber. The area between the first and second
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circles were notched so that an O-ring and membrane could sit on the grove in the
chamber. Figure 2-10D shows the final view of a complete sentinel chamber.
A

B

C

D

Figure 2-10. Sentinel chamber design for poliovirus. A) pressure plate, B) side view of
sentinel chamber, C) top view of Teflon chamber, D) complete poliovirus sentinel
chamber.
Sentinel Chamber Seeding and Safety
Sentinel chambers were seeded through the use of biological safety procedures to
prevent environmental release or worker exposure. Before the release of sentinel
chambers into the environment, precautions were taken to ensure accurate quantity and
safety of pathogens.
The Ascaris eggs sentinel chambers were filled in a designated biosafety area.
Three grams of biosolids were placed at the bottom of each bag, ensuring the top of the
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bags were free of biosolids. After, ova were added and mixed into the biosolids to a final
concentration of 104 ova/gram. The bags were sealed three times with a heat sealer
(ANKOM HS). Any bags that could not be sealed properly (biosolids inhibiting sealing
of bags) were properly disposed of by autoclaving for 60 min at 121°C. The integrity of
all ova bags was tested before use by placing two ova spiked bags into a biosolids pile for
seven days. The bags were then stirred in a beaker of deionized water for 24
hours. Double centrifugation was used with water and then magnesium chloride to
retrieve any helminth ova that could have escaped from the bag into the water. Looking
under the microscope, no eggs were found from this test, ensuring the safety of the sealed
bags.
A biological safety cabinet (BSC) was used to assemble and spike the poliovirus
sentinel chambers. The Teflon chamber, bottom membrane, mesh, O-ring, and two brass
plates were assembled. Five grams of biosolids were then weighed and added to the semicompleted chamber. The chamber was placed inside the BSC, and the virus was added
and mixed into the biosolids to a concentration of 105 MTT50/ gram. The top membrane,
mesh, O-ring, and two brass plates were assembled to the structure. The top and bottom
brass plates were fastened tightly to secure the O-rings in place. To ensure that the virus
would not escape the chamber, ample time and attention were taken to guarantee the
membranes and mesh were correctly positioned in the Teflon chamber. The complete
chambers were wiped down with 10% bleach followed by deionized water. To test the
structural integrity and safety of the chambers, one chamber underwent 5 freeze/thaw
cycles over the course of a week. The chamber was disassembled to check the membrane
and mesh for any damage. No damage was observed.
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Sentinel Chamber Installation and Retrieval
Ascaris ova chambers were placed in a nylon monofilament drawstring bag with a
25-µm mesh size (filterbag.com) and hung from a pipe for biosolids installation. The
drawstring bag hung in a "low" position, a "middle" position, and a "high" position to
represent different heights within the biosolids. Each pipe was placed inside an outer
PVC pipe that was placed in the bulk biosolids and packed with biosolids to surround the
chambers. To sample the ova, the inner pipe was lifted out, and a chamber was randomly
chosen for analysis.
The poliovirus sentinel chambers were installed in the pilot-scale test boxes using a
similar design as the Ascaris ova chambers. (Figure 2-11). The chambers were inserted
through holes on each side of a square pipe and secured with a zip tie (Figure 2-11B).
The square pipe was then inserted in an outer PVC pipe (Figure 2-11A) placed in the
bulk biosolids and packed with biosolids to surround the chambers. As a control,
chambers with pathogen-spiked biosolids were stored in plastic bags at 4°C. Controls
were measured at each sampling event.

Figure 2-11. Installation of poliovirus sentinel chambers in pilot-scale boxes. A) Pipe in
pipe design and B) poliovirus sentinel chamber installation.
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2.4.3.3 Sample Characterization
Environmental Conditions
Biosolids temperature was measured in triplicate at 0.5', 1.5' and 2.5' from the top
of the 3’ high bulk biosolids using Thermochron iButton sensors (Embedded Data
Systems). The iButton sensors have an accuracy of ± 1°C and an operating range of -40
to + 85°C. These devices measure and store temperature data every 2 hours for up to 2
years. The first two stacks, made from PVC, had iButton cables running from the
iButtons to the top of the biosolids. These cables were connected to a computer with the
use of an iButton Adaptor (Embedded Data Systems) to download the temperature data.
The third iButton stack was not connected to cables, therefore, data could not be
downloaded unless the iButtons were taken out of the test box and connected to an
iButton probe cable reader (Embedded Data Systems, Cat. No. DS1402-RP3+). The third
stack was a safety measure in case the main iButtons failed. All iButtons were
waterproofed with Marine Adhesive Goop (Eclectic Products, Inc.) and mounted with the
use of a clip holder (Embedded Data Systems)
Physical/Chemical Parameters
Pilot-scale test boxes were sampled monthly at each WWTP while the biosolids
were unfrozen. Samples were analyzed for total solids, volatile solids, pH, VFAs, and
ammonia. Sampling was performed based on the guidance for sampling dewatered sludge
drying beds under the USEPA (1989)88. Sampling practices included compositing four
samples from separate quarters of each box, and preserving samples for analysis.
Total and volatile solids were measured by the EPA method 168489. EPA Method
9045D90 was used to measure the pH of the biosolids. Volatile fatty acids, bicarbonate
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alkalinity, and total alkalinity were determined through the use of the Anderson and Yang
titration method91. The HACH company TNTplus 832 (range 2 to 47 mg/L NH3-N)
Ammonia Method 10205 colorimetry procedure, equivalent to the USEPA Method
350.192, was used to measure the content of ammonia-nitrogen in the biosolids.
Microbial Assays
Levels of fecal coliforms, infectious enteric viruses, and Ascaris ova were
monitored throughout the study for compliance with Class A pathogen requirements19.
Coliphage levels were measured for comparison to enteric viruses.
Fecal coliforms were measured by the most probable number (MPN) EPA Method
168193. Briefly, a sample of 30 grams of collected biosolids was homogenized in a
blender with 270 mL of water. After, the sample was diluted several times in phosphatebuffered water. Samples from four separate serial dilutions were then placed in glass
tubes with 2 mL of sterile A-1 Media and an inverted gas collection tube. There were 5
tubes per dilution, with 4 dilutions tested, making a total of 20 tubes per sample. These
tubes were incubated at 35°C ± 5°C for 2 hours, and then at 44.5°C ± 5°C for 22 hours.
A most probable number program was used to calculate the fecal coliform concentration
based on the number of positive gas bubbles found in the inverted collection tubes.
Quality control included on-going precision and recovery samples, spiked samples, and
duplicated analyses.
Enteric virus levels were measured based on a two-step process. First, poliovirus
was recovered from the biosolids using the methods of ASTM D4994-8994. After, the
virus was quantified using either the 1) plaque assay from Appendix H in Control of
Pathogens and Vector Attraction in Sewage Sludge95 or the 2) quantal assay from
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Chapter 15 of the USEPA Manual of Methods for Virology96. The plaque assay was used
at the beginning of the study to measure high levels of poliovirus, whereas the quantal
assay was used at the end of the study to measure low levels of poliovirus.
Ascaris ova were measured following the method of Bowman et al.97. First, biosolids
were collected from the sentinel bags, broken up, homogenized and sieved (20, 60, 80,
and 100 mesh) to remove large particles. The remaining particles were allowed to settle
overnight in a solution containing an anionic detergent (7x) to release eggs adhered to
particles. Eggs were then separated from particles with the use of settlement, flotation,
and sieving. After, eggs were suspended in formalin and incubated at 22-28°C for a
minimum of 28 days. Eggs were centrifuged after the incubation period, treated with 10%
sodium hypochlorite (bleach) to decolorize the outer shell of the eggs, centrifuged, and
suspended in water. A 100 µL of the sample was placed on a slide, and 1st stage, 2nd
stage, and 3rd stage viable ova were counted. The sub-sample results were multiplied for a
representative sample.
Levels of coliphage reduction are not required to meet PFRP equivalency. However,
coliphages were measured because of their similar size, morphology, and structure to
enteric viruses. Coliphages are abundant in wastewater and measured with a simple and
rapid culture-based assay. The single agar layer EPA Method 160298 was used to measure
coliphages. Both the male-specific coliphage (MS2, ATCC #15597-B1) and host (E. coli
HS (pFamp) R, ATCC #700891), and the somatic coliphage (phi-X 174, ATCC #13706B1) and host (E. coli CN-13, ATCC #700609) were used for the study. Coliphages were
propagated in their host, filtered through a 0.22 µm syringe filter, and mixed with 40%
glycerol to allow for frozen storage. These phages were used as a positive control for the
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study. To begin the single agar layer procedure, 12 grams of biosolids were mixed with
100 mL of water in a sterile container. Dilutions were made using phosphate-buffered
dilution water. The log-phase host was added to each dilution and mixed with tryptic soy
agar, warmed to 49°C ± 5°C, and appropriate antibiotics were added. Agar at 11 mL and
the phage solution were poured into five 150-mm Petri dishes. After the agar hardened,
the Petri dishes were sealed with parafilm to hold in moisture and placed in an incubator
for 16-24 hours at 36°C ± 5°C. After, the plate was counted in plaque-forming units to
determine a coliphage quantity.

2.5 Results and Discussion
2.5.1

Objective 1: Effects of Freeze-Thaw Cycles on Biosolids

Freeze-thaw cycles naturally occur in biosolids over winter storage in northern
climates. Freeze-thaw cycles increase dewaterability (or ability to lose water) of
biosolids67-70 and can inactivate pathogens in biosolids. However, little is known about
the effect of pathogen inactivation in anaerobically digested biosolids. Here we study the
influence of freeze-thaw cycles on pathogen inactivation in anaerobically digested
biosolids as a function of moisture content. Understanding the correlation of freeze-thaw
cycles to pathogen inactivation in sewage solids will allow WWTPs to utilize a natural
process to treat biosolids.

2.5.1.1 Visual Analysis of Physical Changes
Biosolids properties after winter storage were evaluated. Based on a visual
assessment of the biosolids, it was obvious that the physical characteristics of the
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biosolids had changed after over-winter storage. Figure 2-12A shows the biosolids pile
in the GIWA storage shed after winter storage. Figure 2-12B shows a close-up of the top
layer of biosolids that experienced freeze-thaw cycles over the winter. Biosolids were
very dry with a light texture. This is quite different from the physical appearance of the
fresh biosolids as demonstrated in Figure 2-13B. Figure 2-13 provides a comparison of
the freeze-dried and non-frozen biosolids. The biosolids that experienced freeze-thaw
cycles have a smaller particle diameter, and reduced pore size between particles, while
the non-frozen biosolids particles clump together, and contain large pore spaces between
the flocs. The nature of the biosolids subjected to freeze-thaw cycles at the particle scale
is illustrated in Figure 2-14 by the environmental scanning electron microscopy images
of biosolids particles from GIWA. A biosolids particle is comprised of a complex array
of structures of various shapes and sizes. Overall, biosolids properties change after
exposure to freeze-thaw cycles to a lighter and drier texture.

Figure 2-12. Freeze-dried biosolids A) in the GIWA storage shed after winter storage,
and B) in a close-up view.
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Figure 2-13. Comparison of A) freeze-dried biosolids to B) non-frozen biosolids from
GIWA. Structural changes occur after freezing which includes a less dense texture.

Figure 2-14. SEM Images of freeze-dried biosolids from GIWA. A biosolids particle
clearly is comprised of a complex array of structures of various shapes and sizes.
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2.5.1.2 Field Study
During the field study, fecal coliforms and total solids were measured at five depths
in a pile located in the enclosed biosolids storage shed at PLWSA from May 2013 to June
2014. Similar patterns were observed at all depths for temperature, total solids, and fecal
coliforms (Figure 2-15). The temperature in the biosolids followed an overall trend of
increasing from May through August, decreasing from August through November, and
increasing again from March through June. It is important to note that the iButtons had a
lower temperature limit of -5°C. Ambient temperatures below this level occurred
frequently between November 2013 and March 201499, thus it is likely that temperatures
below -5°C occurred in the pile. Overall, biosolids temperature followed temporal
patterns and variation in temperature decreased with increasing depth.
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Figure 2-15. Temperature, total solids (TS), and fecal coliforms (FC) measured at depths
of A) 0 cm, B) 5 cm, C) 10 cm, D) 20 cm, and E) 50 cm, as measured from the surface of
biosolids stored in an enclosed storage shed at PLWSA. Note that the minimum
temperature that could be measured was -5˚C, but lower ambient temperatures were
frequently observed between November 2013 and March 2014.
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From May through October, when temperatures remained above 5°C and below
27°C, regrowth of fecal coliforms occurred at all depths except 50 cm (Figure 2-15).
However, after October when freeze-thaw cycles occurred in the biosolids, fecal coliform
numbers decreased to non-detectable levels at all depths. At the 50 cm depth, regrowth
was never observed and fecal coliforms decreased to non-detectable levels by September.
Total solids steadily increased for all depths (other than 50 cm), presumably resulting
from a combination of evaporation and freeze-drying (Figure 2-15). The largest increase
in total solids occurred at the 0 and 5 cm depths after September 2013, suggesting that
freeze-drying was especially important at the top of piles. Total solids were highest at the
0 cm depth and eventually reached 79%. At the 50 cm depth, a small decrease in total
solids was initially observed, presumably resulting from the input of drainage from the
upper layers. Thus, the 50 cm depth behaved differently than the above layers. The total
solids increased at the 50 cm depth from 17% in November 2013 to 30% in June 2014.

2.5.1.3 Freeze-Thaw Cycles Pathogen Inactivation
The relationship between freeze-thaw cycles, total solids, and fecal coliform
reduction are presented in Figure 2-16 with samples from both GIWA and PLWSA.
Despite the different biosolids sources, the data suggest a similar trend in fecal coliform
reduction as a function of total solids for samples frozen at -20C. Lower percent fecal
coliform reductions were observed at low total solids (< 10% TS), and high total solids (≈
25% TS). At intermediate solids contents (10-20% TS), the percent reduction in fecal
coliforms plateaued with reductions ranging from 60-95% with many data points around
80-90%. The maximum reduction (93.5%) in fecal coliforms was observed at 16% total
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solids. These results suggest that there may be an optimum range of total solids for
maximizing fecal coliform inactivation during freeze-thaw cycles; however, additional
data points at the upper and lower total solids regions are required to confirm these
trends.
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Figure 2-16. Percent fecal coliform (FC) reduction after one freeze-thaw cycle in relation
to total solids (TS). There is an ideal total solids content that produces the highest
reduction of fecal coliforms.
2.5.1.4 Freezing Rate
Implicit in the analysis of the field- and laboratory-scale data is the assumption
that the biosolids freezing rate increases with increasing total solids content. To evaluate
the effect of total solids content on the biosolids freezing rate, the rate at which a onedimensional freezing front migrated through biosolids was determined with
thermocouples at various depths within biosolids samples. Total solids values of 8, 13,
16, and 18% were tested.
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The initial rates of temperature changes were compared for each total solid
condition and thermocouple location. As expected, the initial rate of temperature change
was slowest in the 8% total solids sample and fastest in the 18% total solids sample
(Figure 2-17). The initial rates of temperature change in the 13% and 16% total solids
samples were similar and in between those measured in the 8 and 18% total solids. These
results are consistent with our hypothesis that the freezing rate for biosolids decreases
with increasing moisture content. In addition, the similar freezing rates (between 510ºF/hour) measured at the intermediate total solids levels (13 and 16%) are consistent
with the similar levels of fecal coliform reduction at those total solids levels.
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Depth (in)
Figure 2-17. Initial cooling rate at various depths in biosolids. The largest rate of cooling
occurred at the highest total solids content.
2.5.1.5 Discussion
The field study provided anecdotal evidence that freeze-thaw cycles contribute to
the inactivation of fecal coliforms during biosolids storage. While fecal coliform die-off
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was observed at all depths during storage, the greatest reduction in fecal coliform levels
occurred in the top and driest layers (Figure 2-15). These observations suggest that the
biosolids moisture content affects the degree of fecal coliform inactivation during freezethaw cycles. Therefore, a laboratory study designed specifically to quantify the fecal
coliform reduction in biosolids during freezing at different total solids was undertaken
using samples collected at PLWSA and GIWA.
This laboratory evaluation was needed because little is known about the effects of
freeze-thaw on pathogen inactivation in wastewater solids. Sanin et al. (1994) studied the
correlation between temperature, freezing rate, and freezing time on pathogen reduction
in activated sludge (rather than digested and dewatered biosolids), and observed pathogen
inactivation after freezing and thawing77. Likewise, freezing and thawing have been used
as a pretreatment technique to improve the dewaterability of sludge through the formation
of compact aggregates that enhance sludge thickening and filtration100. However, the
effects of several important variables, such as moisture content, on the efficacy of freezethaw cycles for pathogen reduction in stored biosolids has not been studied.
The laboratory data showed that inactivation of fecal coliforms appears to be less
effective at lower (below 10% total solids) and higher total solids concentrations (above
20% total solids) compared to intermediate total solids concentrations (between 12% and
20%). To understand these results, it is important to understand that freezing
temperatures alone do not cause cell death. In fact, cells have several strategies for
preserving viability in freezing temperatures, including increasing cell membrane
fluidity, producing polyols (i.e., alcohols with multiple hydroxyl groups) and antifreeze
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proteins, and creating cold-shock proteins and cold-active enzymes101. The interactions
between ice crystals and cells produce inactivation during freeze-thaw cycles.
The rate at which freezing occurs determines the size and location (intra- or
extracellular) of ice crystals inside/outside the pathogenic microorganism79. At the lowest
total solids, pathogens cool slowly enough that water can move across the membrane via
exostosis before freezing79. Thus, the ice crystals that form are primarily outside the
pathogenic membrane, where they cause less damage than intramembrane ice crystals,
which can disturb coat proteins and nucleic acids74 and rupture pathogens if sufficiently
large. The formation of ice crystals outside of the membrane at slow freezing rates could
explain why fecal coliform inactivation is lower at the lower total solids levels. Note that
some inactivation is still expected because ice formation causes differences in the
extramembrane and intramembrane solute concentrations that can cause dehydration and
other cell damage during freezing and thawing102. When cells cool more rapidly (i.e.,
higher total solids), water may freeze (crystallize) before passing through the membrane.
The size of these intramembrane ice crystals also depends on the rate of freezing79,103.
When the rate of cooling is very fast, the rate of ice nucleation (initiation of ice crystal
structures) is faster than the rate of ice crystal growth, resulting in large numbers of small
crystals, which are less damaging than the large crystals that are expected to form at
somewhat lower cooling rates. Figure 2-18 shows a schematic of the freezing concepts.
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Figure 2-18. Conceptual model for inactivation of fecal coliforms (FC) at different total
solids (TS). At low total solids and high total solids, the fecal coliform reduction is low.
At intermediate total solids, the fecal coliform reduction is high.

2.5.2

Objective 2: Pilot-Scale Studies
Pilot-scale studies were initiated at PLWSA in July and GIWA in August of 2016.

Environmental conditions and key physical/chemical properties were monitored
throughout the study. Though poliovirus sentinel chambers were set up during this study,
the data had not yet been collected for these enteric viruses and are not included in this
dissertation. Data collection occurred from August 2016- August 2017 to demonstrate
emerging trends, though the long-term storage study continued for up to a year after 2017
and was followed by air drying.
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2.5.2.1 Environmental Conditions
Biosolids temperatures in the test boxes at PLWSA and GIWA are presented in
Figure 2-19. As expected based on ambient temperatures, biosolids temperature
decreases from August through December and increases from March through August.
Multiple freeze/thaw cycles were observed at both plants.

Figure 2-19. Ambient and Biosolids Temperatures during long-term storage at A)
PLWSA and B) GIWA. Biosolids temperatures closely followed the trends for ambient
temperatures.
2.5.2.2 Physical/Chemical Parameters
Total and volatile solids at GIWA and PLWSA contain some similarities and
differences (Figure 2-20). The total solids at both plants stayed relatively constant until
December and increased after the winter thaw. At both plants, biosolids stored indoors
dried out to a greater extent than those stored outdoors. The volatile solids at PLWSA and
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GIWA decreased indoors and outdoors. However, the volatile solids at PLWSA
experienced a large decrease (60% to 20%) between day 28 and 59 followed by an
increase to 60% VS, while the volatile solids at GIWA gradually dropped from 50% to
30%.
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Figure 2-20. Total Solids at A) PLWSA and B) GIWA, and Volatile Solids at C)
PLWSA and D) GIWA.

The pH levels observed in the test boxes are shown in Figure 2-21. Initial pH levels
at both plants started above pH 8 and dropped throughout the study. The pH at PLWSA
steadily dropped to 6.5 while the pH at GIWA drastically dropped to below 5. The pH
differences in the indoor and outdoor boxes at GIWA started to increase after winter thaw
where pH levels in the indoor boxes dropped to 6.0 while pH levels in the outdoor boxes
dropped to 4.5.
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A

B

Figure 2-21. pH at A) PLWSA and B) GIWA. pH decreased at both plants, but decreased
more drastically at GIWA.

There were no distinct trends in the bicarbonate and volatile fatty acid levels (Figure
2-22). At both WWTPs, the volatile fatty acid levels remained below 40,000 mg/kg. At
low pH values, these levels of volatile fatty acids have been shown to inactivate
pathogens46.

B

A

Figure 2-22. Volatile Fatty Acid (VFA) concentrations at A) PLWSA and B) GIWA.
VFAs decreased in both plants.
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The ammonia concentrations at PLWSA increased before winter and decreased after
winter (data not shown). There is no clear trend in ammonia at GIWA. However, after
winter, ammonia concentration increased in the indoor boxes and decreased in the
outdoor boxes at GIWA. The main trends for physical/chemical parameters included an
increase in total solids and a decrease in pH.

2.5.2.3 Pathogen Inactivation
The data from both plants followed similar trends, providing evidence into the
reproducibility of long-term storage treatment. Comparable pathogen inactivation was
observed at GIWA and PLWSA. Pathogen indicator organisms including fecal coliforms,
Ascaris ova, and coliphages were measured. Though the enteric poliovirus was spiked
into the biosolids, inactivation data for this specific pathogen is not included. Enteric
virus inactivation was measured after the completion of this report. Fecal coliforms
decreased steadily at both locations, and after winter reached Class A levels as shown in
Figure 2-23.
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A

B
Class A

Figure 2-23. Fecal Coliforms at A) PLWSA and B) GIWA. Fecal coliform reduction at
both plants follows similar trends with pathogens decreasing after winter storage.

Similar trends for Ascaris ova were observed at both plants. 2nd stage viable Ascaris
ova remained constant at both plants and did not reach the Class A requirement of a 2log10 reduction (Figure 2-24). Variability in all Ascaris ova samples is large, likely
associated with the wide error and variability associated with the Bowman method.
Ascaris ova have been shown to be inactivated to Class A levels through warmer
climates59-63 or a longer storage time of 3 years or more62,65,66.
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A

B

Figure 2-24. Viable 2nd Stage Ascaris Ova at A) PLWSA and B) GIWA. Levels
remained steady and did not decrease to Class A levels.

No clear trends were observed with the coliphage inactivation data, and therefore it
was not added to this report. Pathogens in the biosolids were affected by all of the
physical/chemical parameters measured during the study. High temperatures and
freeze/thaw cycles are known to inactivate microorganisms. Drying of biosolids can
dehydrate microorganisms and inactivate pathogens. Volatile solids act as an organic
food source for microorganisms, and low levels can cause inactivation. High pH levels
can increase the toxic form of ammonia, while low pH levels increase the toxic form of
volatile fatty acids.

2.6 Conclusions
Objective 1 combined field- and laboratory-scale experiments to determine the
relationship between total solids and pathogen reduction in biosolids subjected to freezethaw cycles. During the field study, fecal coliforms reduced after winter freeze-thaw
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cycles to undetectable levels. The lab-scale study found that intermediate total solids
levels (~16% TS) reduced fecal coliforms to the greatest extent. Observations of
significant reductions in fecal coliforms as a result of freeze-thaw cycles in both the fieldand laboratory-studies are meaningful for WWTPs that store their biosolids indoors over
winter with below-freezing temperatures. Nevertheless, additional testing will be required
to confirm the ideal range of the rate of freeze/thaw and the moisture content for
pathogen inactivation. Additionally, the impact of multiple freeze-thaw cycles should be
evaluated. Supplementary tests should also be performed to examine the effects of freezethaw cycles on other indicator organisms besides fecal coliforms.
Objective 2 evaluated pathogen inactivation under long-term storage as a function
of environmental conditions. The initial results from the long-term storage pilot-scale
study demonstrated changes in environmental conditions, physical-chemical parameters,
and microbial populations (August 2016-August 2017). Temperature profiles confirmed
that biosolids stored over winter at both GIWA and PLSA underwent multiple freezethaw cycles. The main trends observed in physical/chemical parameters over the year
were an increase in total solids and a decrease in pH. Fecal coliforms quickly reduced to
Class A levels after winter storage, however, Ascaris ova did not reach Class A levels
after one year of storage. Since Class A requirements were not met, monitoring will
continue for several years to verify that pathogen reduction complies with the EPA
methods for alternative 6 of Class A biosolids production. Longer storage time, more
drastic levels of pH, or higher temperatures would be able to decrease pathogens in the
biosolids to a Class A limit. Ultimately, the results of this study should contribute to the
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implementation and approval of LCLT treatment processes to allow for the economical
production of Class A biosolids.
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3 Arginine Enveloped Virus Inactivation and Potential
Mechanisms
3.1 Abstract
Arginine synergistically inactivates enveloped viruses at a pH or temperature that
does little harm to proteins, making it a desired process for therapeutic protein
manufacturing. However, the mechanisms and optimal conditions for inactivation are not
fully understood, and therefore, arginine viral inactivation is not used industrially.
Optimal solution conditions for arginine viral inactivation found in the literature are high
arginine concentrations (0.7-1 M), a time of 60 minutes, and a synergistic factor of high
temperature (≥ 40°C), low pH (≤ pH 4), or Tris buffer (5 mM). However, at optimal
conditions, full inactivation does not occur over all enveloped viruses. Enveloped viruses
that are resistant to arginine often have increased protein stability or membrane
stabilizing matrix proteins. Since arginine can interact with both proteins and lipids,
interaction with either entity may be key to understanding the inactivation mechanism.
Here, we propose three hypotheses for the mechanisms of arginine induced inactivation.
Hypothesis 1 describes arginine-induced viral inactivation through inhibition of vital
protein function. Hypothesis 2 describes how arginine destabilizes the viral membrane.
Hypothesis 3 describes arginine forming pores in the virus membrane, accompanied by
further viral damage from the synergistic factor. Once the mechanisms of arginine viral
inactivation are understood, further enhancement by the addition of functional groups,
charges, or additives may allow the inactivation of all enveloped viruses in mild
conditions.
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3.2 Introduction
Therapeutic proteins have improved the treatment of diseases including cancers,
autoimmunity/inflammation, infections, and genetic disorders104. As a result, there has
been continued growth in therapeutic protein sales with over 200 therapeutic protein
products currently approved105. With the growing demand for therapeutic proteins,
advancements in the manufacturing process are desired so that large quantities of
effective and safe protein products can be produced.
The Food and Drug Administration (FDA) requires two orthogonal virus
clearance steps for enveloped and non-enveloped viruses in any biotherapeutic process.
This creates a robust system that greatly reduces the chance of non-desired infectious
agents from entering the final product. Conventionally, non-enveloped viruses are
removed by nanofiltration or chromatographic separation8,9,11,106-111, while enveloped
viruses are inactivated by low pH (~3.5)112, solvent/detergent treatment113 or heat
treatment8,114. However, conventional processes for enveloped virus inactivation can
harm the desired protein product and reduce final yields. Specifically, pH values less than
4.0114,115, high detergent concentrations114,116 or temperatures above 37°C117-122 produce
conformational changes, aggregation, or precipitation that destroy the activity of
therapeutic proteins. To maintain the stability and structure of proteins during viral
clearance, more favorable solution conditions are desired.
One solution to inactivate enveloped viruses without causing aggregation or
fragmentation of the therapeutic protein product lies in the addition of the amino acid
arginine. Arginine synergistically inactivates enveloped viruses at a less acidic pH (≥ 4)815

or lower temperature (30-40°C)16 than conventional inactivation methods, increasing
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therapeutic protein stability and yield. However, synergistic arginine inactivation is not
currently used in industry since the conditions and phenomena for viral inactivation are
not clear. Understanding the physical phenomena of arginine viral inactivation could give
greater insight into a safe, effective and sustainable way of meeting therapeutic protein
viral clearance requirements while maintaining protein stability.
Arginine is a naturally occurring, highly hydrophilic and polar amino acid that is
required for protein structure and function123,124. Arginine contains a protonated
guanidinium group (Figure 3-1) that is able to form ionic and hydrogen bonds with
proteins and lipids124-126. Some common uses of arginine are to prevent protein
aggregation13,127-129 and to translocate through the lipid bilayer130. Arginine is used in the
biotechnology field for protein refolding129, protein aggregation suppression127,131,132, and
protein solubilization133. Arginine also increases column chromatography elution
efficiency134, is present in high frequency in antimicrobial (AMP) or cell penetrating
peptides (CPP)124, and inactivates enveloped viruses135.

Figure 3-1. Arginine structure at physiological pH. The guanidinium group has a +1
charge while the peptide backbone is amphiphilic.
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While there is evidence that arginine interacts with proteins and lipids, there is
little theoretical understanding of the interaction with virus. Here, virus inactivation data
for arginine and some of its derivatives is summarized. Then, potential hypotheses for the
mechanism of virus inactivation is compared to current knowledge of protein and lipid
interactions with arginine to elucidate a better understanding of the mechanism of virus
inactivation by arginine. Presented are three likely mechanisms. The goal of this paper is
to lay out directions of future study on virus inactivation by arginine. Once the
mechanism of arginine viral inactivation is better understood, the method has potential to
become a commercially viable virus inactivation processes for protein therapeutics.

3.3 Virus Biochemistry
Arginine exclusively inactivates enveloped viruses while having no effect on nonenveloped viruses, signifying that specific virus or host structures are susceptible to
arginine15. Enveloped and non-enveloped viruses contain a structural array of proteins
that form a capsid to protect the nucleic acid cargo. However, the capsid of an enveloped
virus is enclosed by a lipid bilayer while non-enveloped viruses expose the viral capsid to
the environment without the presence of the lipid bilayer136.
Enveloped viruses gain their membrane from the host cell. After viral infection,
enveloped viruses typically undergo a budding process that results in a portion of the host
cell membrane becoming the outer viral envelope137,138, although the viral lipid bilayer
can also originate from the Golgi apparatus139 or the endoplasmic reticulum140 in certain
cases. Though the lipid bilayer is derived from the host cell in enveloped viruses, proteins
incorporated into the viral membrane originate from the viral genetic code141.
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Non-enveloped viruses release from the host cell through membrane disruption
without forming an outer envelope137,138. Due to the absence of a lipid bilayer, nonenveloped viruses only contain outer proteins that compose the viral capsid. Nonenveloped viruses are generally smaller and more stable than enveloped viruses.
Considering the variation in structure and stability, non-enveloped viruses are
conventionally removed through filtration or chromatography8,9,11,106-111, while enveloped
viruses are inactivated through chemical or physical processes8,112-114 in therapeutic
protein manufacturing.

3.4 Traditional Enveloped Virus Inactivation
Physical and chemical processes that are licensed to inactivate enveloped viruses in
therapeutic protein solutions include heat8,114, low pH112 and solvent detergent
treatment113. Bonds that maintain virus integrity and protein structure are similar, and
therefore, conventional methods for virus removal inherently harm the final protein
product142. To combat negative protein interactions, stabilizers, such as sugars, are
commonly added to solution143. Sugars stabilize proteins by increasing preferential
protein hydration to minimize binding of additional solvent components that may disrupt
native protein structure144. However, stabilizers must be removed prior to final
processing, increasing yield losses, overall cost, and production time145.
The FDA and EPA require a minimum of a 4 log removal value (LRV), defined in
Eq. 3-1, for a method to be considered as a virus removal step146,147. A 4 LRV results in
99.99% removal of virus, depending on the method of detection, which is typically either
by infectious titer or polymerase chain reaction (PCR). In many cases, this requires high
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titers of virus to be tested so that the required LRV can be measured within the detection
limit of the assay. Low virus titers are rarely, if ever, studied in virus removal
verification.

𝐿𝑅𝑉

log

(Eq. 3-1)

Certified heat treatments in therapeutic protein manufacturing inactivate
enveloped viruses by destroying the structural integrity of the virus148 and altering key
viral properties required for infection149,150. The temperature necessary for inactivation
depends on many factors, including viral structure, time of exposure, and environment119.
For example, hepatitis C virus is inactivated at 37°C in 2 days and at 56°C in 40 min117.
Heat inactivation for immunoglobulin, the most common class of protein therapeutics, is
60°C for 10 hours at pH 5.5142. Though heat treatments are certified for pathogen
inactivation in therapeutic protein manufacturing, mechanisms for viral heat inactivation
can mutually harm protein products and therefore are not regularly used in production.
Low pH treatments are commonly used in therapeutic protein manufacturing to
inactivate enveloped viruses through lipid hydrolysis151-153 and protein structural
changes115,154-163. Values of pH between 3.4 and 4.2 can fully inactivate enveloped
viruses given the ideal time frame for the specific virus112,142. For example, xenotropic
murine leukemia virus is inactivated in 30 min at pH 3.8164. Though low pH treatments
are very effective at inactivating enveloped viruses, inactivation mechanisms may harm
proteins. Added stabilizers are used to increase protein yields during inactivation,
however, this adds additional downstream costs for removal.

66

Solvent detergent treatments inactivate enveloped viruses by solubilizing the lipid
bilayer142 through the addition of non-volatile organic solvents or detergents. Viruses
including HIV (human immunodeficiency virus), BVDV (bovine viral diarrhea virus) and
SuHV-1 (pseudorabies) have been successfully inactivated through solvent detergent
treatment145. Though solvent detergent treatment produces little to no protein loss, a
downstream step is required to remove added chemicals which increases production
costs145. Currently all conventional enveloped virus inactivation treatments either harm
proteins or add downstream costs, creating a need for improved processing.

3.5 Virus Inactivation with Arginine
Compared to conventional methods, arginine inactivates enveloped viruses under
conditions that do less harm to therapeutic proteins. Additionally, downstream removal of
arginine is not required since it is often found in formulations165, lowering processing and
analytical costs. Low pH treatments of pH 3.5 or less often cause protein degradation or
fragmentation10,11,13. However, when low pH is paired with arginine, viral inactivation
occurs at a more protein friendly pH of 4.0 or greater. Heat treatments without arginine
for hepatitis virus require 10 hours at pH 5.5 and 60°C142. When arginine is paired with
heat, a less elevated temperature is necessary (30-40°C) for enveloped viral inactivation
in a shorter period of time (60 min), generating fewer adverse effects on the therapeutic
proteins16. Arginine itself has been shown to cause minimal fragmentation of proteins at
high temperatures and oxygen content, likely due to the production of NOx166. However,
arginine largely interacts positively with proteins by suppressing aggregation, increasing
solubility, and preventing protein binding167. The use of arginine in protein solutions
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leads to enhanced recovery of proteins166. Though arginine improves protein yields
during virus inactivation11, optimal conditions for full inactivation of all enveloped
viruses is not known, hindering its use in manufacturing.
A range of enveloped and non-enveloped viruses have been tested for inactivation
by arginine and many are shown in Table 3-111,168-175. These viruses are models for a
variety of human viruses that contain different structures. Key viral differences include
the occurrence of an outer envelope, genome, and size.
Table 3-1. Properties of Tested Viruses
Virus
Acronym Envelope Genome Size (nm)
Minute virus of mice
MMV
No
DNA
18-24
Poliovirus
Polio
No
RNA
22-30
Herpes simplex virus 1
HSV-1
Yes
DNA
110-200
Herpes simplex virus 2
HSV-2
Yes
DNA
110-200
Pseudorabies
SuHV-1
Yes
DNA
120-200
Xenotropic murine leukemia XMuLV
Yes
RNA
100-120
virus
Influenza virus
Yes
RNA
100-300
Sendai virus
Yes
RNA
150-200
Newcastle disease virus
NDV
Yes
RNA
150-350
Compounds tested for viral inactivation at pH 4 include arginine, butyroylarginine, citrate and NaCl (Figure 3-2). Molecular structures can be found in Table 3274,75. Virus inactivation by arginine and butyroyl-arginine was first compared to survey
molecules with a guanidinium group but different charges. Butyroyl-arginine is a
derivative of arginine that contains a guanidium group, a net charge of zero at
physiological pH, and a capped amine. Butyroyl-arginine produced similar or higher
virus inactivation in comparison to arginine for all viruses (Fig. 2)10. The charge
distribution on butyroyl-arginine allows for dense, self-aggregated clusters to form,
which likely explains the enhanced virus inactivation10. Neither arginine nor butyroyl68

arginine inactivated poliovirus, a non-enveloped virus. Arginine and its derivatives do not
affect non-enveloped viruses, suggesting that inactivation occurs through lipid bilayer
interactions.

Figure 3-2. Viral inactivation at pH 4.0 on ice for 60 min with enveloped and nonenveloped viruses. Different enveloped viruses showed various levels of inactivation by
arginine, while non-enveloped viruses were unaffected. Duplicates or triplicates were
performed for all data points. Reformatted , )
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Table 3-2. Properties of Solutes and Buffers
*Partial average charges exist at pH values close to the pKa
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NaCl and citrate produced lower viral inactivation than arginine and its derivates at
pH 4. The consistently lower inactivation over all viruses by NaCl (Figure 3-2)
demonstrates that ionic strength is not the only mechanism contributing to virus
inactivation with arginine. Citrate also inactivated viruses to low levels at pH 4.
Interestingly, citrate is commonly used to inactivate enveloped viruses during low pH
treatment at pH 3.515. Either the increased acidity or the charge difference on citrate must
enhance inactivation at pH 3.5 over pH 4. At a pH of 3.5, most of the citrate molecules
have a -1 charge, which may strengthen inactivation. As the pH increases to 4, nearing
the pKa of 4.65, some of the citrate molecules will gain an additional negative
charge176,177.
Although arginine and its derivatives produce high inactivation for some
enveloped viruses, not all enveloped viruses are fully inactivated. The clear difference in
inactivation levels suggests that arginine preferentially interacts with certain viral
properties. Specifically, arginine must favor properties of HSV-1 due to its high
inactivation. HSV-1 is a large enveloped DNA virus with a diameter of 110 to 200
nm168,175. HSV-1 has a highly ordered structure (Figure 3-3) where the envelope encloses
a tegument protein layer, containing over 20 identified proteins168. Tegument proteins
participate in a range of viral functions from viral assembly to host cell entry178. Complex
formation between HSV-1 glycoproteins and cell receptors initiates the fusion between
the host cell and viral membranes, leading to viral capsid uptake179.
Influenza virus has proteins and an infection process that differ from HSV-1,
likely explaining the lesser inactivation. Influenza virus is an enveloped RNA virus with
a diameter of 100-300 nm169,180. Three proteins are imbedded in the lipid bilayer,
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including the hemagglutinin (HA), neuraminidase (NA)181, and matrix-2 (M2)180. The
hemagglutinin protein must undergo proteolytic cleavage by host cell proteases prior to
membrane fusion182. Surrounding the nucleocapsid, a matrix protein called matrix-1 (M1)
connects the lipid bilayer to the viral core169, shown in Figure 3-3. The integration of M1
into the lipid bilayer stabilizes the virus structure more than the free-floating tegument
proteins in HSV-1. Influenza virus infection is also different than HSV-1. Infection
begins through attachment of the cleaved HA protein to sialic acid receptors on the host
cell membrane, followed by uptake through the low pH endosomal pathway183. The low
pH prompts the virus and endosomal membrane to fuse, causing the release of the
nucleocapsid into the cytoplasm180.

Figure 3-3. Comparison of HSV-1 and influenza virus structure. HSV-1 contains a
tegument of proteins between the nucelocapsid and the lipid bilayer. Influenza virus
contains a M1 matrix protein that stabilizes the lipid bilayer by connecting the viral core
to the membrane. (Images created in BioRENDER)
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Sendai virus and NDV belong to the paramyxovirus family, and undergo a similar
infection process to influenza virus184. Sendai virus and NDV are RNA viruses with
diameters of 150-350 nm171. Two spike-like glycoproteins, including a fusion protein (F)
and a hemagglutinin-neuraminidase protein (HN), are imbedded in the lipid bilayer.
Similar to influenza virus, the lipid bilayer of Sendai virus and NDV overlays the matrix
protein, M1, that encloses the nucleocapsid185. Proteolytic cleavage of the F and HN
protein, either intracellularly or extracellularly, is required for virulence186,187. Distinct
from influenza virus, infection of Sendai and NDV are independent of the low-pH
endosomal pathway.
A clear difference between viruses that are highly inactivated by arginine (HSV1), compared to viruses that show lower inactivation (influenza A virus, Sendai virus, and
NDV), is the presence of the M1 matrix protein, and the requirement of proteolytic
cleavage prior to infection. The M1 matrix protein tightly associates the lipid bilayer to
the viral core, aiding in membrane stabilization188. A highly stabilized bilayer may hinder
the direct penetration of arginine into the lipid bilayer. On the other hand, increased
protein stability prior to proteolytic cleavage may suppress arginine from denaturing that
protein. Prior to proteolytic cleavage, the influenza virus uncleaved HA is highly acidstable189. Increased stability of the uncleaved HA proteins would prohibit detrimental
arginine-protein interactions. It is hypothesized that the presence of a M1 matrix protein
or the increased protein stability prior to proteolytic cleavage prevents arginine from fully
inactivating some viruses.
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3.5.1

Charge and pH
While virus properties may affect the levels of arginine inactivation, what is

special about the arginine molecule to cause virus inactivation? Arginine contains a
guanidinium moiety that is able to form ionic and hydrogen bonds with proteins and
lipids124-126, likely aiding in virus inactivation. Various guanidine-based solutes with
different charge patterns can inactivate enveloped viruses. Guanidine-based solutes that
have been tested for enveloped virus inactivation are shown in Table 3-2. Guanidine
hydrochloride at a pH of 5 completely inactivates HSV-1 in 10 min177, but this required a
concentration of 6 M. Concentrations of guanidine hydrochloride below 2 M are not
effective in virus inactivation118. The next potent solute is arginine, which inactivates
HSV-1 completely at pH 4 at a concentration of 0.7-1 M in 60 min13-15. The most potent
arginine derivative is butyroyl-arginine, which can highly inactivate viruses where
arginine fails, including influenza virus, at pH 4 and a concentration of 0.7 M in 60 min10.
At a pH between 4 and 5, guanidine hydrochloride has a +1 charge, arginine has a +1
charge and is zwitterionic, and butyroyl-arginine has a neutral charge and is zwitterionic.
Since guanidine hydrochloride requires the highest concentration to inactivate virus,
charge or the multiple binding sites on guanidine are not the dominating factors in the
antiviral properties of arginine.
The zwitterionic properties of arginine and butyroyl arginine likely enhance viral
inactivation through strong lipid binding and self-interactions. Alone, guanidinium is able
to form multiple hydrogen bonds with lipids190. However, in combination with the strong
charge distribution of arginine, the hydrogen binding of guanidinium to lipids is
strengthened190. Additionally, the opposite charge distribution on arginine and butyroyl74

arginine can cause the formation of clusters due to self-aggregation191. Clusters can also
form through like-charge pairing of guanidinium moieties192,193.
Clusters magnify localized concentrations, strengthening protein127 and lipid
interactions194-198. Specifically, arginine clusters crowd out hydrophobic protein-protein
interactions to prevent aggregation199-201. Preventing aggregation is one mechanism to
stabilize proteins. Stabilized proteins may not undergo the conformational changes
needed to initiate the virus infection cycle202. Arginine clusters can also weaken lipid
bilayers, resulting in translocation through the lipid bilayer124,130,203. It is hypothesized
that viral inactivation by arginine is due to protein or lipids interactions, and therefore,
strengthening these interactions would increase inactivation.
Butyroyl-arginine is the most effective arginine-derivative, conceivably due to its
cluster forming structure. Butyroyl-arginine contains one positive and one negative
charge that occupy different ends of the molecule to enhance self-interactions. Arginine
contains an additional positive charge, which would reduce the density of clusters due to
charge repulsion. The lesser viral inactivation of arginine as compared to butyroylarginine is presumably explained by the efficacy to form clusters.
The buffer used to control the pH during inactivation experiments may combine
with arginine to enhance viral inactivation. Buffers that have been used in arginine
inactivation experiments are found in Table 3-2. Tris buffer added to arginine at neutral
pH inactivates XMuLV and SuHV-111. Several experiments at pH 4 with acetate buffer
have been shown to inactivate a variety of viruses9,12-15. The charge on added buffers can
interact with proteins, lipids, or DNA to aid in viral inactivation. In addition to charge,
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functional groups, such as the amine group on Tris, are hypothesized to interact with viral
proteins and lipids204,205, aiding in inactivation.

3.5.2

Concentration and Time
Synergistic inactivation by arginine is amplified at higher concentrations. The

LRV of HSV-1 increases with solute concentration, shown in Figure 3-4A. Arginine has
a solubility of ~1 M, limiting the concentrations that can be tested. The need for high
concentrations of arginine suggest that the interactions of arginine with the lipid bilayer
structure are weak15. Furthermore, high arginine concentrations imply that dense arginine
clusters are required for viral inactivation194-198.
When arginine synergizes with low pH, inactivation occurs in less than 60
minutes for HSV-115. HSV-1 was reduced by 5 LRV in under 20 min at pH 4 (Figure 34B). In comparison, a gradual increase with 0.1 M citrate resulted in only 1.3 LRV over
60 min. The fast rate of arginine-induced viral inactivation indicates that the mechanism
occurs over a short period of time and is not due to pH alone.
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Figure 3-4. A) Viral inactivation of HSV-1 as a function of arginine and butyroylarginine concentration. Increasing the concentration of arginine derivatives leads to
higher virus inactivation. Inactivation occurred at pH 4.0 on ice for 60 min with 20 mM
acetate buffer. (B) Viral inactivation of HSV-1 as a function of time at pH 4 on ice. PBS
control at pH 7. Low pH arginine inactivation occurs under 60 min. Duplicates or
triplicates were performed for all data points. (Reformatted15)
3.5.3

Synergistic Factors: pH, Temperature, Buffers
Arginine synergizes with acidic pH to inactivate enveloped viruses. At pH 4,

HSV-1 is equally inactivated by arginine and butyroyl-arginine to ~6 LRV, shown in
Figure 3-5A. However, as pH continues to increase, viral inactivation decreases across
all solutions. A pH of at least 4.0 is required to synergize with arginine for enveloped
viral inactivation.
The viral inactivation of influenza virus with cleaved hemagglutinin (CHA) spike
proteins and uncleaved hemagglutinin (UCHA) spike proteins (Figure 3-5B & C), was
found to differ. CHA was inactivated to much higher levels than UCHA at pH 4 with
arginine. On the other hand, butyroyl-arginine produced high inactivation in both CHA
and UCHA at pH 4. Even up to pH 4.5, butyroyl-arginine highly inactivated CHA
influenza virus.
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Figure 3-5. Viral Inactivation of HSV-1, CHA influenza virus and UCHA influenza virus
as a function of pH on ice for 60 min. As pH increases, arginine induced viral
inactivation decreases. Duplicates or triplicates were performed for all data points.
(Reformatted10,15)
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The difference of arginine inactivation for CHA and UCHA indicates a
dependence on protein structure. CHA spike proteins are required for uptake of influenza
virus into the host cell, while UCHA must experience proteolytic cleavage to form CHA
prior to cell uptake10,180. CHA proteins undergo essential conformational changes during
the low pH endosomal pathway required for cell fusion189. UCHA proteins do not
undergo low pH conformational changes as a result of increased acid stability, hindering
viral infection202. It is speculated that arginine and low pH can denature the CHA protein,
while having no effect on the acid-stable UCHA protein. It may also be true that arginine
further stabilizes the CHA protein, inhibiting the required conformational change during
the low pH endosomal pathway to undergo infection. Considering that the magnitude of
viral inactivation is contingent on protein structure, the synergistic effects of arginine
may interact with proteins.
There are multiple cases where a difference in membrane proteins, such as with
UCHA and CHA influenza virus, could influence arginine interactions with the lipid
bilayer. For example, protein structure can modify packing density of the surrounding
lipids206. With a looser lipid packing, arginine-lipid interactions would be enhanced to
increase inactivation206. Furthermore, negative charges on proteins may attract arginine,
preventing arginine from interacting with the lipid bilayer to induce viral inactivation.
Considering the data as a whole, as pH increases, the effectiveness of arginine decreases,
leaving open the hypothesis that arginine interacts with envelope proteins or the lipid
bilayer.
High temperature, like low pH, can synergize with arginine to inactivate
enveloped viruses. The temperature dependence on viral inactivation of HSV-2 is shown
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in Figure 3-6. For reference, HSV-2 and HSV-1 are very similar in structure and
function. Classification of these virus types is based on antigenic differences, or how
viral proteins are modified to avoid an immune response207. Temperatures higher than
35°C initiated the synergistic effect of arginine at a pH of 4.4. Increasing the temperature
to 40°C improved arginine synergistic viral reduction by 2.3 LRV. Citrate followed a
similar trend to arginine but with a consistently lower inactivation. On the contrary, 0.1
M citrate/0.6 M NaCl produced insignificant inactivation up to a temperature of 40°C.
This data suggests that an increase in ionic strength decreases the effect of temperature
and pH on HSV-2 inactivation in contact with citrate. Again, it appears that ionic strength
is not the dominating force responsible for virus inactivation at higher temperatures. The
addition of salt ions to intermediate concentrations is largely known to increase protein
stability208. At intermediate salt concentrations, the added charges from salt can decrease
unfavorable interactions in solutions that could denature a protein209,210. Salts can also
shield the charge on citrate, and that charge may be an important factor in the antiviral
mechanism of citrate. Conclusively, arginine produced the highest viral inactivation
compared to citrate and NaCl with increasing temperature.
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Figure 3-6. Viral inactivation of HSV-2 as a function of temperature at pH 4.4. At 35°C,
arginine begins to synergize with temperature to inactivate HSV-2. (Reformatted14)

Similar to temperature and pH, Tris buffer seems to synergize with arginine to
inactivate enveloped viruses. The inactivation of SuHV-1, X-MLV, and MMV at neutral
pH for 60 min at 4°C with 5mM Tris buffer is shown in Figure 3-7. SuHV-1 and XMLV are both enveloped viruses that were inactivated to near 4 LRV. The following data
is the only example in literature where neutral pH and arginine inactivated enveloped
viruses, and therefore, it is assumed that Tris buffer is the synergistic factor. MMV is a
non-enveloped virus and was negligibly inactivated when exposed to arginine and Tris,
consistent with results that arginine has little effect on non-enveloped viruses10.
Compared to conventional inactivation methods, Tris buffer paired with arginine at
neutral pH and 4°C maintains the full activity of proteins11, making it a desired process in
therapeutic protein manufacturing.
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Figure 3-7. Viral inactivation with 1M arginine and 5 mM Tris buffer at pH 7.0 for 60
min at 4°C. At a neutral pH, arginine can synergize with Tris buffer to inactivate
enveloped viruses. (Reformatted11)

It is curious as to how Tris synergizes with arginine at neutral pH to inactivate
viruses. Tris undergoes multiple interactions that may disrupt biological processes to aid
in inactivation211. For example, Tris is toxic to rat nerve cells at concentrations as low as
10 mM212. Interactions of Tris with lipid bilayers may explain the observed toxicity.
When exposed to a phospholipid bilayer at room temperature, Tris buffer increased lipid
disorder213. Similarly, in strains of Escherichia coli, Tris buffer increased membrane
permeability, leading to a loss of cell membrane components214. On the contrary to the
above studies, in supported lipid bilayers, atomic force microscopy measurements
demonstrated that Tris buffer reduced membrane stress, while other ions, such as Ca2+,
increased membrane stress215. Though there are mixed results on the effects to lipid
bilayers, Tris buffer does interact with membranes.
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Aside from lipid bilayers, Tris undergoes additional interactions in biological
solutions. Tris can stabilize proteins through electrostatic and hydrogen bonding216,217 and
can associate with DNA218. The positive charge and primary aliphatic amine group of
Tris, shown in Table 3-2, are thought to be the root cause of multiple
interactions204,216,218,219. Charges on molecules interact with proteins and lipids215,220-224,
while primary aliphatic amines interact with several compounds including
DNA204,216,218,219. Either through lipid bilayer, protein or DNA interactions, Tris is
thought to synergize with arginine to inactivate enveloped viruses.
At optimal solution conditions and synergistic abilities, arginine is an effective
means of inactivating some enveloped viruses. High concentrations (0.7-1M) and a time
of 60 minutes combined with the synergistic factor of high temperature, low pH, or Tris
buffer is needed for maximum virus inactivation. After gaining a comprehensive
understanding of arginine interactions with proteins and viruses, we list three hypotheses
for the mechanisms of synergistic arginine viral inactivation.

3.6 Hypotheses for Synergistic Arginine Viral Inactivation
We propose three mechanisms for arginine induced enveloped viral inactivation and
go into greater detail on the potential phenomenon involved (Figure 3-8). Hypothesis 1
describes arginine-protein interactions leading to the loss of viral infectivity. Hypothesis
2 describes the destabilization of the viral membrane by arginine. Hypothesis 3 describes
pore formation by arginine, followed by further viral damage from the synergistic factor.
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Figure 3-8. Hypotheses on the virus inactivation mechanism of arginine. It is
hypothesized that viral inactivation occurs by either the 1) disruption of protein activity,
2) destabilization of the lipid bilayer, or 3) pore formation in the lipid bilayer. Arginine is
shown as its molecular structure and the synergistic factor is represented as a blue sphere.
Examples of synergistic factors are low pH, temperature or buffer molecules.
3.6.1

Hypothesis 1: Arginine with Synergistic Factor Interacts with Viral Proteins
Hypothesis 1 states that arginine synergizes with Tris, low pH or temperature to

directly inhibit protein function. There are two ways in which proteins are speculated to
lose their function by arginine. First, the synergy of arginine is thought to denature or
fracture viral proteins. Second, arginine may bind to or crowd out proteins to prevent
required conformational changes or attachment to host cell receptors225. Regardless of the
process, the loss or inability of viral proteins to undergo necessary functions induced by
arginine will hinder viral infection.
The combination of arginine with the synergistic factor may disrupt protein
structure. Low pH and high temp are common protein denaturants, though, the levels
used with arginine have little effect on proteins10,11,13,16. Combined with arginine, the
effects of low pH or high temp to destabilize proteins may be enhanced. Arginine
contains multiple binding opportunities that possibly disrupt protein structure. The
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cationic guanidinium group of arginine has the capacity to form up to six hydrogen bonds
with anionic species226. The binding of the guanidinium group to the carbonyl oxygen on
the protein backbone can structurally stabilize a protein’s secondary and tertiary
structure227. But when arginine is external to the protein, the bonds holding the secondary
and tertiary structure may favor binding to the external arginine rather than internal
bonds, leading to protein fracturing or denaturation. In solution, water surrounds proteins
to create a hydration shell that maintains protein structure228. When arginine binds to
proteins through hydrogen and cation-π bonds129,191,201,229, the protein hydration shell is
likely disrupted, leading to protein destabilization. Arginine is also highly common in salt
bridges230; the presence of arginine in solution could disrupt or create new salt bridges in
proteins, altering protein structure.
Though it seems plausible that arginine and the synergistic factor denatures
proteins, other evidence suggests that this is the weakest of the hypotheses. Tris buffer
was shown to synergize with arginine to inactivate virus at neutral pH11 (Figure 3-7).
Tris is known to stabilize proteins216,217, suggesting that there are no harmful effects on
protein conformation. Arginine is also largely known to prevent protein aggregation and
enhance protein solubility13,127-129. By binding to proteins through hydrogen and cation-π
bonds, arginine collects on the surface to prevent protein aggregation129,191,201,229. Despite
the positive effects on proteins, arginine has been shown to slightly fracture proteins
through NOx production at high temperatures (≥40°C)166. However, NOx production by
arginine is too insignificant at or below room temperature to denature a protein166. This
would rule out denaturation as the cause for inactivation on ice or at 4°C (Figure 3-2,
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Figure 3-4, Figure 3-5, Figure 3-7) Overall, it is unlikely that the synergistic effects of
arginine denature proteins.
Though it is unlikely that arginine denatures proteins, arginine may prevent host
cell fusion. Binding of arginine to membrane proteins could render the protein
unrecognizable to the host cell receptor to obstruct cell fusion. Levels of inactivation
across viruses could be explained by the capacity for arginine-protein binding.
Glycoproteins with negatively charged species and aromatic residues would enhance
arginine binding129,191,201,229. Additionally, the synergistic factor could promote conditions
for arginine-protein binding. For example, a drop in pH can alter the charge of amino
acid residues on the membrane proteins, allowing arginine to bind to the protein.
In addition to protein binding, arginine molecules in solution tend to selfaggregate into clusters191,192. Arginine-arginine clusters are thought to occur due to likecharge pairing of guanidinium moieties192,193 or hydrogen bonding from head to tail191.
These clusters are known to crowd out protein-protein or protein-surface
interactions167,199,201,231. Correspondingly, arginine clusters would crowd out protein
interactions with host cell receptors. Crowding may or may not entail protein binding. If
no protein binding occurred, the effects would be reversible by dilution of arginine,
though this is not the case. When diluting arginine samples prior to plaque assays,
inactivation effects for enveloped viruses remained15. For this reason, arginine-protein
binding would be required to reduce virus infectivity.
In support of arginine-protein interactions, inactivation levels vary across viruses
with different proteins10. For example, arginine at pH 4 highly inactivated influenza virus
containing CHA proteins while lower inactivation resulted for influenza virus containing
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UCHA10. UCHA differs from CHA in structure and stability202 UCHA spike proteins
must undergo proteolytic cleavage to modify into CHA structure prior to cell uptake189.
Due to the increased stability, UCHA proteins do not undergo the essential
conformational changes required for cell fusion that CHA endures during the low pH
endosomal pathway202. The structure and stability of CHA compared to UCHA could
explain differences in inactivation levels. Arginine may destabilize the CHA proteins to
prevent host cell binding, while having limited effect on the stable UCHA protein.
Alternatively, arginine may further stabilize CHA to hinder endosomal low-pH
conformational changes that are required for host cell infection. For this reason, CHA and
UCHA influenza virus inactivation data may support either arginine-induced protein
denaturation or protein stabilization.
Similar to UCHA of influenza, NDV and Sendai virus are not highly inactivated
by the synergistic effects of arginine10,15. Also similar to UCHA, NDV and Sendai both
require proteolytic cleavage of glycoproteins prior to infection. In contrast to influenza,
NDV and Sendai proteins do not undergo low pH conformational changes after
proteolytic cleavage. Accordingly, stabilization of NDV or Sendai virus proteins would
not inhibit infectivity because conformational changes are not required for infection,
favoring protein denaturation as the root cause of inactivation. If we disregard protein
denaturation as the mechanism, arginine may be more likely to bind to the proteins of
NDV, Sendai, and influenza to inhibit host cell fusion. Overall, it is not easy to explain
the difference in NDV, Sendai, and influenza virus inactivation by protein denaturation.
Protein denaturation or inhibition of host cell binding may be fundamental to
arginine-induced inactivation. However, one of the largest pieces of evidence against
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hypothesis 1 is that the synergistic activities of arginine do not affect non-enveloped
viruses10,15. Similar to enveloped viruses, non-enveloped viruses have external proteins
that induce host cell recognition and uptake225. For hypothesis 1 to have significance,
arginine would have some effect on non-enveloped virus infectivity.

3.6.2

Hypothesis 2: Arginine with Synergistic Factor Interacts with Viral Lipids
According to hypothesis 2, viral inactivation manifests through the interactions of

arginine and the synergistic factor (Tris, high temp or low pH) with the lipid bilayer to
induce membrane deformations. Deformations to the lipid bilayer may completely
destabilize the outer viral membrane to result in viral inactivation. Alternatively, lipid
bilayer deformations may prompt conformational changes to membrane proteins,
resulting in a loss of viral infectivity.
The synergistic activities of arginine exclusively inactivate enveloped viruses
while non-enveloped viruses remain unharmed10,15, suggesting that mechanisms for viral
inactivation involve the lipid bilayer. In support of hypothesis 2, arginine does interact
with the lipid bilayer through binding124-126 and lipid deformations. Specifically, argininerich peptides deform membranes in order to translocate into the cell for drug
delivery190,191,232-234. At low arginine concentrations, endocytosis has been observed as
the sole route for arginine peptide translocation235. However, studies show that at high
arginine concentrations, direct penetration of arginine peptides is favorable over
endocytosis197,235,236. Although arginine peptides do have a different charge/size ratio in
comparison to a single arginine molecule, the guanidinium group on arginine is a large
component of peptide activity237. Membrane deformations result from the guanidinium
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moiety binding to negative charges on the lipid bilayer, and/or the hydrophilic peptides
interacting with the hydrophobic lipids190,191,232-234. Arginine side chains also maintain
their charge when exposed to the hydrophobic membrane environment where no other
amino acid can, aiding further in membrane deformations237. The transport of arginine
peptides through lipid bilayers has been extensively studied where single arginine
molecules have not198. It is useful to use arginine peptides as a model for arginine to
further expose the mechanism of arginine inactivation.
Loosening of lipid packing increases peptide uptake, indicating that arginine
deforms the lipid bilayer for translocation234,238-241. High cholesterol content in lipids
decreases membrane fluidity and translocation of arginine238 203,206. In the presence of the
hydrophobic cation pyrenebutyrate, which is suspected to loosen lipid packing and
increase membrane fluidity, arginine uptake increased in the lipid bilayer234,239-241. Virus
size can also affect membrane curvature and lipid packing density. A mild degree of lipid
curvature exists in viral membranes with a large diameter. Mild curvature leads to loosely
packed lipids that deform and bend in response to arginine interactions194. In contrast, the
drastic curvature of small diameter membranes forms tightly packed lipids that are
difficult to distort194. This is schematically shown in Figure 3-9194,242. Curvature is not
likely an issue for cells or bacteria due to their large size in comparison to most viruses.
However, when exploring the interaction of arginine with small macromolecules, like
viruses, this curvature may play a role in the selective penetration of arginine into the
lipid bilayer.
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Figure 3-9. Hypothesized interaction of arginine with large and small diameter
membranes. The open spacing of lipids in a large diameter membrane increases
susceptibility to arginine deformations. Oppositely, the tightly packed lipids of a small
diameter membrane are difficult for arginine to manipulate.
The synergistic factors of low pH, high temperature, and Tris buffer all disrupt the
lipid bilayer, favoring hypothesis 2. Low pH151-153 and high temperature148 invoke lipid
hydrolysis. Tris disorders and disassembles the lipid bilayer213,214. However, Tris buffer
has also been shown to increase membrane stability215. Considering all inactivation
factors that disrupt the lipid bilayer, it is likely that the synergistic inactivation
mechanisms of arginine involves the viral membrane.
Differences in inactivation levels observed across viruses can be attributed to lipid
bilayer deformations. When analyzing synergistic arginine inactivation data, viruses that
endure low inactivation (Sendai, influenza, NDV) all contain the M1 matrix protein10,15.
The M1 matrix protein integrates the membrane to the viral core, increasing lipid bilayer
stability188. Increased lipid bilayer stability decreases viral susceptibility to membrane
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defects to increase viral survival when exposed to arginine. However, this would not
explain the high inactivation levels of CHA influenza and low inactivation of the UCHA
influenza virus in response to arginine and low pH10. Arginine combined with low pH
may deform the membrane to the extent of destabilizing integral membrane proteins.
UCHA has increased stability in comparison to CHA189. Therefore, UCHA may retain its
structure in response to membrane defects while CHA is denatured. Protein structure can
also alter packing density of lipids at the protein-lipid interface206. The differences in
structure between UCHA and CHA influence the surrounding lipid packing density to
affect arginine inactivation. The fact that arginine peptides and synergistic factors are
known to affect lipid bilayers, in combination with viral inactivation data, support
hypothesis 2.

3.6.3

Hypothesis 3: Arginine Forms Pores in the Lipid Bilayer
Hypothesis 3 considers arginine-induced pore formation in the lipid bilayer as the

fundamental component in viral inactivation. Similar to membrane deformations, pore
formation may destabilize the lipid bilayer to disrupt membrane proteins or overall virus
integrity. Alternatively, pores in the lipid bilayer may allow the passage of the synergistic
factor through the lipid bilayer and into the viral core, leading to degradation of viral
genetic material.
In several studies, arginine-rich peptides have been shown to cross the lipid
bilayer through the formation of a water pore124,194,197,198,234,242. Pores are hypothesized to
form in a similar manner to membrane deformations, through electrostatic or hydrophilic
interactions190,191,232-234. For example, preferential binding to negative charges in
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zwitterionic lipids (common in mammalian membranes) results in lipid sorting and
membrane tension. Membrane tension can lead to lipid flip flop and membrane
multilamellarity, eventually forming a pore130. In comparison to direct translocation by
membrane deformations, translocation through a pore is thought to require less energy,
and is therefore more advantageous205,242. Multiple arginine molecules can cross through
a pore at one time, lowering the translocation energy198,242,243. Additionally, passing
through a pore can lower arginine translocation energy through avoidance of the
hydrophobic lipid core198,242,243. Similar to membrane deformations, pores in the lipid
bilayer may destabilize the membrane and associated membrane proteins. This would
coincide with the data for low inactivation of viruses containing the M1 matrix
protein10,15, along with the increased stability of UCHA influenza virus at low pH10.
Arginine-induced pores may additionally allow for the synergistic factor to pass
through the protective lipid bilayer, causing oxidation or cleavage of virus capsid proteins
or nucleic acids. The membrane of an enveloped virus protects the capsid and nucleic
acids against environmental factors244,245. A pore in the membrane may allow hydronium
ions in a low pH solution245, Tris buffer218, or high temperature246 to disrupt the genetic
material and inactivate the virus. However, the levels of pH and temperature used during
arginine synergistic viral inactivation are not known to cause DNA degradation245,246.
Due to the lower energy requirement for a pore formation in comparison to membrane
deformations, arginine likely forms a pore to result in viral inactivation.
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3.6.4

Future Study
It will take a concerted effort and multiple experiments to shed light on the

mechanism of arginine in virus inactivation. The first is to determine if the virus structure
has been compromised after treatment. This simple test has not been reported in the
literature. To specifically test hypothesis 1, protein binding experiments can determine if
a protein is still active after arginine exposure. Heparin is a common cell receptor for
virus, and changes in heparin binding could be used to explore the changes in cell
attachment247. However, changes in heparin binding could also support hypothesis 2,
since lipid instability could cause changes in membrane bound proteins, disrupting
binding events.
To assess hypothesis 2 and 3, nanoindentation can measure changes in virus
stiffness248. If the virus stiffness decreases after arginine exposure, the lipid bilayer is
being compromised either by deformation or pore formation. If virus stiffness and
heparin binding are reduced, then hypothesis 2 is most likely. To discern hypothesis 2
from hypothesis 3, the integrity of the genetic material in the virus can be assessed. The
reduction in genetic material for would provide evidence that the integrity of the
membrane has been compromised, as described in hypothesis 3. While literature supports
all of the hypothesis, it is possible to better discern the mechanism of arginine
inactivation if more effort is put into this area.

3.7 Conclusions
The process of synergistic arginine enveloped viral inactivation provides greater
protein stability and increased therapeutic protein yields in comparison to conventional
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methods8-16, making arginine a desirable pathogen removal step in therapeutic protein
manufacturing. Although there are multiple studies on the synergistic effects of arginine,
information has not been compiled to determine the mechanisms and optimal conditions
for viral inactivation. Through analyzing literature data, optimal solution conditions for
the synergistic ability of arginine include high concentrations (0.7-1M), a time of 60
minutes, and a synergistic factor of high temperature (40°C), low pH (pH 4), or Tris
buffer (5 mM)8-16. However, these optimal solutions conditions do not inactivate all
enveloped viruses evenly, suggesting that inactivation mechanisms are contingent upon
certain viral structures. Viral structures that were highlighted to reduce the synergistic
inactivation of arginine included increased protein stability and the presence of a matrix
protein that integrates the capsid to the lipid bilayer. Three hypotheses were proposed for
the mechanisms of synergistic arginine inactivation that explained the lower inactivation
levels for viruses containing stabilized membrane proteins and lipid bilayers. Hypothesis
1 describes the viral inactivation by arginine through the inhibition of vital protein
function. Hypothesis 2 describes viral inactivation by arginine through the destabilization
of the viral membrane. Hypothesis 3 describes pore formation induced by arginine,
accompanied by further viral damage from the synergistic factor to inactivate the virus.
Due to the undisputable fact that arginine solely effects enveloped viruses, it is likely that
either hypothesis 2 or 3 is correct. However, additional data is required for a definite
understanding of synergistic arginine inactivation. When the mechanisms are fully
known, viral inactivation by arginine may be further enhanced by the addition of
functional groups, charges, or molecules to completely inactivate all enveloped viruses.
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4 Physiochemical Properties of Enveloped Viruses and
Arginine Dictate Inactivation
4.1 Abstract
Therapeutic protein manufacturing would benefit by having an arsenal of ways to
inactivate viruses. There have been many publications on the inactivation ability of
arginine at pH 4.0, but the mechanism of this inactivation has not been elucidated. This
study explored virus structure, arginine-derivatives, arginine clustering, hydrophobicity,
and buffer type on enhancing inactivation by arginine. Virus structure considerably
influenced arginine inactivation. Large diameter viruses (SuHV-1, HSV-1) with loosely
packed lipids were highly inactivated, whereas small diameter viruses (EAV, BVDV)
with tightly packed lipids were negligibly inactivated by arginine. SuHV-1 experienced
the highest inactivation of the viruses tested, with full inactivation at pH 7 and 1 M
arginine. Membrane cholesterol sensitivity likely explains the inactivation difference
between SuHV-1 and HSV-1. To increase the inactivation of viruses resistant to arginine,
arginine-derivatives, and arginine peptides were tested. A greater capacity for clustering
(butyroyl-arginine and R8 peptide) and added hydrophobicity (butyroyl-arginine and
CapA6R peptide) enhanced virus inactivation. Pyrenebutyrate, a hydrophobic cation,
improved the inactivation of EAV by arginine. Dynamic light scattering (DLS) and
transmission electron microscopy (TEM) detected increases in virus size after arginine
exposure, supporting lipid expansion or arginine binding as the mechanism for
inactivation. Conclusively, viruses with a large diameter and high cholesterol sensitivity
were inactivated by arginine to the greatest extent. For viruses resistant to arginine,
hydrophobicity and arginine-clustering enhanced inactivation.
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4.2 Introduction
Therapeutic proteins are a progressive treatment option for cancers,
autoimmunity/inflammation, infections, and genetic disorders104. When therapeutic
proteins are produced from mammalian cells, there is potential for the presence of
infectious viruses in solution249. Therefore, viral clearance is crucial in the manufacturing
of therapeutic proteins to ensure infectious viruses do not spread to clinical patients. FDA
regulations require a minimum of two orthogonal downstream viral clearance processes
during manufacturing250. Typically, orthogonal processes include a filtration step to
remove nonenveloped viruses and an inactivation step to remove enveloped viruses249.
Low pH treatment is commonly used to inactivate enveloped viruses because of its
simple, effective, and robust nature249. Currently, low pH treatment requires pH values ≤
4.0251, with pH values ≤ 3.6 being the most effective249. Unfortunately, acidic pH levels
below 4 can sometimes damage proteins in therapeutic solutions252. Therefore, there is a
need for an enveloped virus inactivation process that occurs at less acidic conditions.
Arginine can inactivate enveloped viruses at pH ≥ 410,15, increasing protein
stability and reducing product aggregation propensity in comparison to conventional low
pH treatment. However, optimal conditions for full inactivation of all enveloped viruses
by arginine are not known17. Several studies demonstrate the inactivation of enveloped
viruses by 0.7-1 M arginine after 1 hour at pH 4, with diminishing effects above pH
410,15. However, not all enveloped viruses are equally inactivated under these conditions.
For example, after 1 hour at pH 4 with 0.7 M arginine, HSV-1 is fully inactivated while
influenza is only inactivated to 3.1 LRV. Sendai and Newcastle disease virus (NDV)
experience insignificant inactivation at those conditions10,15. A stabilized lipid bilayer or
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stabilized membrane proteins are hypothesized to lessen the inactivation effects of
arginine17. Lipid bilayer stability can be influenced by lipid packing density or integrated
proteins. In the case of Influenza, NDV, and Sendai virus, lipid bilayer stability is
increased through the action of matrix proteins that integrate the lipid bilayer to the viral
core. These viruses also all contain uncleaved glycoproteins that have increased
stability169,186,187. Since viruses resistant to arginine contain both stabilized lipid bilayers
and proteins, it is unclear if arginine is interacting with the lipid bilayer, proteins, or both
to inactivate enveloped viruses.
Recently, pseudorabies virus (SuHV-1) and xenotropic murine leukemia virus (XMLV) were inactivated at pH 7 in a solution of 1 M arginine and 5 mM Tris after 1 hour
at 4°C11. In comparison to conventional low pH processes, inactivation at neutral pH
maintains the stability of proteins, and therefore, is desired for viral clearance in
therapeutic protein manufacturing. This is the only example in the literature where
arginine inactivated a virus at neutral pH and below 35°C16. The main differences
between this singular study and the numerous studies that demonstrated inactivation by
arginine at pH 4 were the buffers and viruses tested. Acetate or no buffer was used with
inactivation studies at pH 410,15, while Tris buffer was used at neutral pH. HSV-1 and
influenza virus were tested at pH 4 and above10,15, while SuHV-1 and X-MLV were
tested at neutral pH11. The conflicting results in the literature lead to uncertainty in how
arginine inactivates viruses at pH 7. Inactivation may be the result of virus structure or
solution conditions.
Another key to arginine virus inactivation appears to be related to charge and
hydrophobicity. Butyroyl-arginine, an arginine-derivative with a net charge of zero
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between pH 3.73-12.14 and a hydrophobic capped amine, was equally or more effective
than arginine in inactivating enveloped viruses over all conditions tested10. Because of its
pure zwitterionic nature, butyroyl-arginine more readily forms self-clusters compared to
arginine, which has an extra positive charge at physiological pH10. Arginine clusters
support lipid and protein interactions to strengthen inactivation17. Additionally, the
increased hydrophobicity of butyroyl-arginine may promote uptake into the lipid
bilayer239. Improved clustering or hydrophobicity enhances inactivation by arginine,
supporting the idea that solution conditions can enhance inactivation.
Arginine fully inactivates some enveloped viruses at pH 410,15 and pH 711.
However, not all enveloped viruses are highly inactivated by arginine under conditions
reported in the literature. Viral membrane structures or glycoprotein stability appear to
affect arginine inactivation. Additionally, the charges or functional groups on arginine or
the buffer influence inactivation. Overall, it is not clear what factors optimize inactivation
by arginine. This study goes into depth to explore virus structure, arginine-derivatives,
arginine clustering, hydrophobicity, and buffer type on the inactivation of enveloped
viruses by arginine. Pseudorabies virus (SuHV-1), herpes simplex virus (HSV-1), equine
arteritis virus (EAV), and bovine viral diarrhea virus (BVDV) were tested for inactivation
under various solution conditions. This study improves our understanding of arginine
inactivation of enveloped viruses and helps to define the ability of arginine to inactivate
enveloped viruses while retaining therapeutic protein stability during manufacturing.
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4.3 Materials and Methods
4.3.1 Materials
For cell culture and viral assays, Eagle’s medium essential media (EMEM),
Dulbecco’s modified eagle medium (DMEM), phosphate buffer saline (PBS, pH 7.2),
sodium bicarbonate, penicillin/streptomycin (pen/strep, 10,000U/ml), sodium pyruvate
(100mM) and trypsin/EDTA were purchased from Life Technologies (Carlsbad, CA).
Fetal bovine serum (FBS, Canada origin) for cell culture was purchased from HyCloneTM
GE Healthcare (Pittsburg, PA). Horse serum (New Zealand Origin) and glycerol for cell
culture were purchased from Sigma Aldrich. MTT salts (2-(3,5-diphenyltetrazol-2-ium-2yl)-4,5-dimethyl-1,3-thiazole; bromide, 98%) were purchased from Alfa AesarTM
(Haverhill, MA) and sodium dodecyl sulfate (SDS, BioReagent, ≥98.5%) was purchased
from VWR (Radnor, PA) for MTT assays.
Chemicals used during viral inactivation assays included L-arginine
monohydrochloride (99%) and agmatine sulfate (97%) purchased from ThermoFisher
Scientific (Waltham, MA) and 1-pyrenebutyric acid (PYB, 97%) and dimethyl sulfoxide
(Hybri-MaxTM, sterile filtered, ≥ 99.7%) purchased from MilliporeSigma (St. Louis,
MO). Peptides were synthesized by Biomatik (Wilmington, Delaware) to mimic
clustering and hydrophobic conditions. Peptide capA6R contained a six-chain
hydrophobic alanine tail linked to an arginine, capped with an acetyl group at the Nterminus and amidated at the C-terminus. It was received as the trifluoroacetic acid
(TFA) salt at >80% purity. Peptide R8 is a chain of eight arginine molecules, which was
received as the TFA salt at >95% purity.
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Buffers of MES sodium salt (99% Acros OrganicsTM), sodium acetate anhydrous
(fused crystals/certified ACS), Tris hydrochloride (molecular biology grade), and
potassium phosphate (ACS AR Crystal, Macron Fine ChemicalsTM) were purchased from
ThermoFisher Scientific. Buffers of sodium acetate (≥ 99% bioreagent), acetic acid
(glacial), and citric acid monohydrate were purchased from MilliporeSigma. Buffers of
sodium citrate tribasic dihydrate, glycineamide hydrochloride (≥ 99% AT), Trizma®
Base (≥ 99% bioperformance certified), glycine (99% for molecular biology), tricine, and
sodium phosphate dibasic heptahydrate (ACS reagent, 98-102%) were generously
donated by MilliporeSigma. Solution pH was adjusted with sodium hydroxide (NaOH)
from MilliporeSigma and hydrochloric acid (HCl) from ThermoFisher Scientific.
For the cholesterol assay, methyl-β-cyclodextrin (BioReagent, suitable for cell
culture) was purchased from MilliporeSigma and the Amplex Red Cholesterol Assay Kit
was purchased from ThermoFisher Scientific. For transmission electron microscopy
imaging, glutaraldehyde (Grade 1, 70% in H20) was purchased from MilliporeSigma, and
uranyl acetate was purchased from ThermoFisher Scientific.

4.3.2 Methods
4.3.2.1 Cells and Viruses
Bovine turbinate cells (BT-1, ATCC CRL-1390), rabbit-kidney cells (RK-13,
ATCC CCL-37), and Vero cells (ATCC CCL-81) were purchased from ATCC. Bovine
viral diarrhea virus (BVDV) strain NADL was purchased from the United States
Department of Agriculture Animal and Plant Health Inspection Service (USDA APHIS).
Equine arteritis virus strain Buvyrus (EAV, ATCC VR-796), human herpesvirus 1 strain
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F (HSV-1, ATCC VR-733), and suid herpesvirus 1 strain Aujeszky (SuHV-1, ATCC VR135) were purchased from ATCC. All cells were incubated at 5% CO2 and 100%
humidity during infectivity assays.
BT-1 cells were cultured in DMEM media supplemented with 1% v/v pen/strep,
1% v/v sodium pyruvate, and 10% v/v horse serum at 37°C and 5% CO2. Cells were split
every 3-4 days (or when 70% confluent) at a 1:3 ratio. BVDV was added at a
concentration of 105 MTT50/ml to BT-1 cells at 80% confluency in supplemented DMEM
media for virus propagation in a cell culture flask. Once BVDV was added to the BT-1
cells, the flask was left on a roto-shaker at low speed for one hour. After shaking, the
virus suspension was removed from the 75 cm2 flask and 15 mL of fresh media was
added to the infected cells. The infected flask was incubated at 37°C for 72 hours. After,
the monolayer was scraped with a cell scraper and the media was collected in a centrifuge
tube. The tube was spun down at 5500xg for 15 min at 4°C. The supernatant was
collected as the propagated virus sample and 10% v/v glycerol was added for storage at 80°C.
RK-13 cells were cultured in EMEM media supplemented with 1% pen/strep, and
10% FBS and incubated at 37°C and 5% CO2253. Cells were split every 2-3 days (or when
70% confluent) at a 1:3 ratio. EAV was added at a concentration of 105 MTT50/ml to RK13 cells at 70% confluency in supplemented EMEM media in a cell culture flask. The
flask was shaken at low speeds on a roto-shaker for 1 hour. After shaking, the virus
suspension was removed from the flask and fresh media was added. The cells were left to
incubate at 37°C for 3-5 days or when 100% cytopathic effect (CPE) was observed.
Flasks were then frozen at -80°C and thawed at room temperature for two freeze-thaw
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cycles. Glycerol was added at a concentration of 10% to the final virus suspension and
frozen at -80°C for storage.
Vero cells were cultured in EMEM media supplemented with 1% pen/strep, and
10% FBS and incubated at 37°C and 5% CO2. Cells were split every 2-3 days (or when
cells reached 70% confluency) at a 1:5 ratio. For HSV-1 propagation, the virus was added
at a concentration of 103.56 MTT50/ml into Vero cells at a confluency of 70% in DMEM
supplemented with 1% pen/strep, 1% sodium pyruvate and 2% FBS. The HSV-1 infected
flask was shaken for 1 hour on a roto-shaker. After shaking, the virus suspension was
removed from the flask and fresh media was added. The flask was incubated at 35°C for
3-5 days until 100% CPE was observed. Flasks underwent two freeze-thaw cycles at 80°C and room temperature254. HSV-1 virus suspensions were collected from the flask
and stored at -80°C with 10% glycerol. For SuHV-1 propagation, 104 MTT50/ml was
added to 70% confluent Vero cells in EMEM supplemented with 1% pen/strep, and 10%
FBS. The flask was shaken for 1 hour on a roto-shaker. After shaking, the virus
suspension was removed from the flask and fresh media was added. The flask was
incubated at 37°C for 3-5 days until 100% CPE was observed. Flasks were subjected to
two freeze-thaw cycles at -80°C and room temperature. SuHV-1 virus suspensions were
collected from the thawed flasks and stored at -80°C with 10% glycerol.

4.3.2.2 Virus Quantification and Purification
Virus titer was determined through an MTT colorimetric cell viability assay, as
described previously255. The MTT assay uses absorbance readings to determine the
concentration of virus that reduces the cell viability by 50%. Briefly, 96-well plates were
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seeded at a density of 2 x 105 cells/ml (for BT-1/BVDV), 8 x 104 cells/ml (for RK13/EAV), 105 cells/ml (for Vero/HSV-1), or 8 x 104 cells/ml (for Vero/SuHV-1). After
22-26 hours, cells were infected with their respective virus sample and serially diluted
across the plate at a 1:5 ratio in virus culture media. Plates were incubated for six days at
37°C for BT-1 (BVDV), RK-13 (EAV), and Vero (SuHV-1) and 35°C for Vero (HSV-1).
After incubation, MTT salts were added to the 96-well plate, incubated for four
additional hours followed by the addition of SDS at a pH of 2. Between 4-12 hours after
the SDS addition, the absorbance of each well was read with a microplate reader
(BioTek, Winooski, VT) at a wavelength of 550 nm to determine the 50% infectious
dose, reported as MTT50/ml255. Final viral concentrations were reported as a log10
reduction value (LRV), defined in Eq. 4-1.
𝐿𝑅𝑉

log

(Eq. 4-1)

Purification of viruses was performed using a 3MTM EmphazeTM AEX Series
Hybrid Purifier BVR1 that contained a pore size of 0.2µm, generously gifted by 3MTM
(Minneapolis, MN). The filter was prepared by loading 20 mM phosphate buffer at pH 7
until the buffer exited the air vent. The crude virus was mixed with an equal volume of 20
mM phosphate buffer at pH 7 and loaded into the filter at a total volume of 40 ml. The
virus was then eluted with 20 mM phosphate buffer with 0.5 M NaCl at pH 7. Eluate was
collected in 5 ml fractions and tested for virus recovery. The fraction with the highest
virus titer was used for succeeding assays. Protein reduction was measured for the HSV-1
sample by the Bradford assay256.
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4.3.2.3 Inactivation Assays
All arginine and/or buffer solutions were prepared less than 24 hours before the
experiment and stored at 4°C. Solutions were prepared with ultrapure water (resistivity of
≥ 18 MΩ cm) obtained from a Thermo Fisher Nanopure filtration system and sterilized
before biological assays with a 0.2 µm syringe filter or a 0.2 µm bottle top filter
purchased from VWR. Respective acid and base solutions were mixed for each buffer to
achieve a final concentration of 20 mM and a pH of 4 or 7, calculated by the HendersonHasselbalch equation (Eq.4- 2). Acetate buffer was prepared by mixing sodium acetate
anhydrous with acetic acid. Tris buffer was prepared by mixing Tris hydrochloride with
Trizma® Base. Citrate buffer was prepared by mixing sodium citrate tribasic with citric
acid monohydrate. The final solution pH was adjusted with 1M HCl or 1 M NaOH. For
all assays, EAV was added at a concentration between 106-107 MTT50/ml. BVDV, HSV1, and SuHV-1 were added at concentrations between 107-108 MTT50/ml. Triplicates
were taken at each time point to obtain accurate representation.
𝑝𝐻

𝑝𝐾

log

(Eq. 4-2)

For inactivation studies of arginine or agmatine, 1M arginine or agmatine at pH 4
or 7 was prepared with 20 mM Tris, acetate, or no buffer. Viruses were added to the
appropriate solution at a 1:10 v/v ratio in a 1.5 ml sterile microcentrifuge tube. Solutions
were vigorously mixed with a vortex after virus addition and before sampling. Solution
pH did not change after virus addition. Samples were stored at 4°C and assessed for virus
titer with the MTT assay at various time points.
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For inactivation by arginine peptides, peptides were dissolved in DMSO less than
1 hour before experiments to avoid error in measurement. Final solutions contained 10%
DMSO with 7.6 mM CapA6R, 0.95 mM R8, or 7.6 mM arginine buffered with 20 mM
Tris. The virus was added to the final solution at a 1:10 v/v ratio in a 1.5 ml sterile
microcentrifuge tube. Solutions were mixed after virus addition and again before
sampling with a vortex. Solutions were stored at 4°C and virus inactivation was measured
after 1 hour.
For arginine inactivation studies with added PYB, solutions were prepared by
dissolving PYB into DMSO less than 1 hour prior to experiments to avoid error in
measurements. Final solutions contained 10% DMSO with 1 M arginine, 10 mM PYB,
and 20 mM Tris buffer at pH 7 or 20 mM acetate buffer at pH 4. PBS with 10% DMSO
and 10 mM PYB was tested as a control. Mock solutions were created for comparison
that contained the same components as the primary solutions without PYB. The virus was
added to the appropriate solution at a 1:10 v/v ratio in a 1.5 ml sterile microcentrifuge
tube. Solutions were vigorously mixed with a vortex after virus addition, and again
before sampling. Solutions were stored at 4°C and virus inactivation was measured after
1 hour.

4.3.2.4 Dynamic Light Scattering (DLS) and Transmission Electron Microscopy
(TEM)
The size distribution of HSV-1 and SuHV-1 after arginine exposure was
measured by DLS with a Malvern Zetasizer Nano ZS (Westborough, MA). DLS
evaluated the hydrodynamic diameter of the virus particles after exposure to arginine
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samples at 1 and 24 hours. Samples were placed in disposable cuvettes (200 acrylate,
280-900 nm, 3.5 mL volume) purchased from Spectrocell (Oreland, PA) at a volume of 1
ml. The Malvern Zetasizer Nano ZS was set to a material refractive index of 1.450 and an
absorption of 0.00. All dispersants were set to a temperature of 21℃ at a viscosity of 1
cP. A refractive index of 1.378 was used for arginine samples and a refractive index of
1.335 was used for PBS samples. The refractive index was measured by a digital
refractometer from Reichert (NY, catalog # 13940000).
Purified virus samples or purified virus samples with 1 M arginine were prepared
for TEM imaging according to university biosafety procedures by crosslinking proteins
through fixation with 7.4 v/v% glutaraldehyde for 1 hour257. Samples were then placed
onto a plasma-treated carbon type-B 300 mesh copper TEM grid (Ted Pella catalog
#01813), and allowed to attach for 2 minutes. Following virus attachment, the grid was
rinsed with ultrapure water and negatively stained with 2 w/v% uranyl acetate in
ultrapure water. After a 2-minute staining period, the grid was washed again with
ultrapure water and dried in a desiccator for at least 24 hours before imaging. An FEI
200kV Titan Themis scanning transmission electron microscope (S-TEM) operating at
80kV was used to obtain electron micrographs.

4.3.2.5 Amplex Red Cholesterol Assay
Purified HSV-1 and SuHV-1 samples were split into two 1 ml aliquots and treated
in parallel. To extract cholesterol from the samples, methyl-β-cyclodextrin (MβCD) was
added at a concentration of 5 mM to the first aliquot in PBS buffer. The second aliquot
for each virus was left unaltered in PBS buffer. All aliquots were incubated at 37°C for 1
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hour. After incubation, virus titer and cholesterol levels were quantified. Virus titer was
quantified through the MTT assay described earlier. Cholesterol was measured in
duplicates with the Amplex Red Cholesterol Assay following manufacturer’s
instructions. Triplicates for every sample were measured. Separate mock samples for
each virus were tested to give a representative level of cholesterol in solution without the
virus. Mock samples contained a solution of cells that underwent the same propagation
and purification method as their respective virus.

4.3.2.6 Statistical Analysis
Statistical analysis of the data was performed in MATLAB using a two-sample
Student’s t-test to compare the means of two independent groups. The test assumed equal
variances between the two samples. A significance level of p < 0.05 was used. All data
sets were tested in triplicate.

4.4 Results and Discussion
4.4.1 Model Viruses
The inactivation of four enveloped viruses was compared to determine the
influence of viral physical properties on viral-arginine interactions. The viruses were
chosen based on genomic properties, size, isoelectric point, and structure, with details
shown in Table 4-1 and Figure 4-1. SuHV-1 and HSV-1 belong to the Herpesviridae
family and are similar in size, structure, and function168,258. SuHV-1 causes Aujeszky’s
disease in pigs21, while HSV-1 produces oral or genital lesions in humans20. Both are
large enveloped viruses with diameters of 110-200 nm170. Distinctive to herpesviruses,
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the nucleocapsid contains double-stranded DNA and is encircled in a tegument protein
matrix that contains over 20 identified proteins168,258. The mature capsid and tegument
layer is enclosed within a lipid bilayer bearing approximately 11 glycoproteins168,258.
EAV is a small enveloped virus with a diameter of 50-70 nm belonging to the
Arteriviridae family259. EAV is infectious in horses with symptoms including fever,
depression, skin rash and abortion in pregnant mares260. The virion is composed of a
positive-sense single-stranded RNA coated in a nucleocapsid protein (N) and enveloped
by a lipid bilayer259. The envelope is complexed with integral membrane proteins
including E, ORF5a, GP2, GP3, GP4, GP5, and M260.
BVDV is a small enveloped virus with a diameter of 40-50 nm belonging to the
Flaviviridae family261. Dengue virus, yellow fever virus and hepatitis C virus are also part
of the Flaviviridae family, thereby making BVDV ideal for modeling significant human
viruses262. The virion contains a positive-sense single-stranded RNA enclosed in a
nucleocapsid protein. The surrounding lipid bilayer contains two glycoproteins, E1 and
E2, that are necessary for cell entry261.
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Table 4-1. Properties of Tested Enveloped Viruses
Virus

Genome

Diameter
(nm)

Isoelectric
Point

Pseudorabies Virus
(SuHV-1)

dsDNA

110-200170

~7.5263

Herpes Simplex
Virus 1 (HSV-1)

dsDNA

110-200170

~4.9264

Equine arteritis Virus
(EAV)

(+)ssRNA

50-70259

N/A

Bovine Viral
Diarrhea Virus
(BVDV)

(+)ssRNA

40-50261

4.3-4.5265

Figure 4-1. Structure of SuHV-1, HSV-1, EAV and BVDV. HSV-1 and SuHV-1 are
large enveloped viruses containing a tegument protein layer. EAV and BVDV are small
enveloped viruses. Images created in Biorender.
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4.4.2 Virus Physiochemical Properties Influence Arginine Interactions
Viral properties, including a stabilized lipid bilayer or stabilized membrane
proteins, influence the inactivation efficacy of arginine17. However, it is unknown if
arginine is interacting with proteins or lipids to induce viral inactivation. Inactivation
levels of the viruses detailed in Table 1 were compared to elucidate the mechanisms of
arginine. The inactivation of SuHV-1, HSV-1, BVDV, and EAV was tested at pH 4 and
pH 7 with various solvents (Fig 4-2). Tabular data can be found in Table A1. SuHV-1
and HSV-1 are commonly used in arginine inactivation studies, and therefore, were tested
for comparison to literature10,11,15. Particularly, SuHV-1 was chosen to recreate
inactivation by arginine at neutral pH11. BVDV and EAV were selected to determine the
effect of arginine on small enveloped viruses. Acetate and Tris were chosen to determine
the influence of buffers on inactivation at pH 4 and 710,11,15. Citrate inactivates enveloped
viruses at pH 3.515 and was used as a comparison to conventional methods.
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Figure 4-2. Inactivation of enveloped viruses by arginine (arg). Inactivation occurred at
either pH 4 (1st column), pH 7 (2nd column) or pH 3.5 (citrate) at 4°C over 24 hours.
Arginine concentration was 1 M and Tris, acetate (act), and citrate concentrations were
20 mM. Open circles represent limit of detection. Tris buffer was not tested at pH 4 since
it would not remain at pH 4. All data points are in triplicate and the error bars represent
the standard deviation. Tabular data can be found in Table A1.
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Different viruses had distinct inactivation patterns. As shown in Fig. 4-2, SuHV-1
was inactivated to its limit of detection by all solutions within 1 hour at pH 4. Complete
inactivation without arginine reveals that 20 mM acetate alone at pH 4 inactivates SuHV1. HSV-1 was inactivated to its limit of detection with all arginine solutions at pH 4
within 1 hour. Without arginine, acetate buffer inactivated HSV-1 to 3.35 ± 0.37 LRV
after 24 hours, verifying that arginine is required for complete inactivation of HSV-1 at
pH 4. At pH 7, SuHV-1 was completely inactivated by all solutions containing arginine
within 3 hours, replicating the data from McCue et al. and confirming that full
inactivation was independent of buffer11. Unlike at pH 4, acetate and Tris buffer alone
produced negligible inactivation of SuHV-1. For HSV-1 at pH 7, inactivation increased
to 3.46 ±0.96 LRV after 24 hours with arginine buffered in Tris. Buffer solutions without
arginine at pH 7 produced minimal inactivation of HSV-1. EAV and BVDV were
inactivated to low levels (below 1 LRV) at pH 4 and pH 7 over all solution conditions
tested. At pH 3.5, citrate fully inactivated HSV-1 and SuHV-1, but had little effect on
EAV or BVDV. At pH 3.5, 0.1 M citrate has been shown to fully inactivate HSV-115.
The clear difference in inactivation capacity between large (HSV-1 and SuHV-1)
and small (BVDV and EAV) enveloped viruses supports the theory that arginine interacts
with the lipid bilayer to inactivate viruses. Large diameter membranes have a mild degree
of curvature that leads to loosely packed lipids, while small diameter membranes have a
large degree of curvature, creating tightly packed lipids194. Loosely packed lipids are
hypothesized to bend and deform easily in response to arginine17, supported by the high
inactivation of the larger viruses. The tightly packed lipids of small membranes restrict
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deformation by arginine to hinder inactivation. This is supported by the low inactivation
of EAV and BVDV. Overall, the data support the hypothesis that arginine interacts with
the lipid bilayer to inactivate viruses.
Though it is clear that membrane diameter is key in arginine inactivation, what
creates the difference in inactivation levels between SuHV-1 and HSV-1 at pH 7?
Interestingly, SuHV-1 is more thermal stable than HSV-1266, which is the opposite of
what would be expected from their arginine sensitivity. The two viruses have different
charges at pH 7 (HSV-1 has an isoelectric point of ~4.9264, where SuHV-1 has an
isoelectric point of ~7.5263), creating distinct electrostatic binding potentials. Though
SuHV-1 and HSV-1 contain comparable glycoproteins, many are structurally or
functionally different267. Therefore, arginine may disrupt an essential protein in SuHV-1
where it does not in HSV-1.
Differences in lipid bilayer cholesterol may explain the higher inactivation of
SuHV-1 compared to HSV-1 by arginine. Cholesterol in the lipid bilayer controls
membrane stability and aids in viral infection268. Cholesterol is singularly contained in
the lipid bilayer or can interact with sphingolipids to form lipid rafts. Singular cholesterol
and lipid rafts support many viral functions including membrane stability and protein
interactions269. SuHV-1 may contain less cholesterol than HSV-1, resulting in a less
stable membrane. Arginine would deform a less stable membrane to a greater extent to
result in higher inactivation. Alternatively, arginine may promote cholesterol loss or
migration, disrupting the infection process. The bending and deformation of lipids by
arginine may disrupt cholesterol in the membrane to hinder infection. For example,
membrane deformations have been shown to cause migration of cholesterol in lipid
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bilayers270. SuHV-1 may require cholesterol to a greater extent than HSV-1 during
infection, resulting in higher inactivation by arginine as a result of cholesterol loss or
migration. Overall, the charge, glycoproteins, or cholesterol content may explain the
discrepancy in arginine inactivation of SuHV-1 and HSV-1.
The effect of cholesterol depletion on virus inactivation was studied to explore
differences between HSV-1 and SuHV-1 resulting in varying levels of arginine
inactivation. Viral cholesterol may influence inactivation by arginine as a result of
membrane stability or the requirement of cholesterol in the infection process. To begin
the cholesterol assay, purified HSV-1, SuHV-1, and mock samples were subjected to 5
mM methyl-β-cyclodextrin (MβCD) to deplete cholesterol, or no MβCD for 1 hour at
37°C. MβCD sequesters cholesterol in its hydrophobic pocket to extract it from
membranes271. Past studies have used MβCD to remove cholesterol from the viral or
cellular membrane to observe effects on viral infectivity268,272. Cholesterol levels in all
samples decreased to low levels following MβCD exposure (Fig. 4-3A & B). Tabular
data can be found in Table A2. Similar cholesterol levels were observed in mock and
viral samples after purification. Therefore, cholesterol levels do not represent virus
cholesterol exclusively, but a combination of virus and cell fragment cholesterol
remaining in solution. Though we cannot deduce exact cholesterol levels in the virus, we
can confirm that overall solution cholesterol was reduced to low levels after MβCD
exposure.
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Figure 4-3. Effect of cholesterol depletion on the infectivity of HSV-1 and SuHV-1.
Purified virus and mock samples of (A) HSV-1 and (B) SuHV-1 were incubated for 1
hour at 37°C at pH 7with either 5mM methyl-β-cyclodextrin (MβCD) or no MβCD.
Cholesterol was reduced in all samples containing MβCD to low levels. (C) Infectivity
changes after MβCD exposure. Mock samples contained Vero cells that underwent
identical propagation and purification as virus samples. All data points are in triplicate
and the error bars represent the standard deviation. Tabular data can be found in Table
A2.
The reduction of cholesterol in the viral membrane inactivated SuHV-1 to a
greater extent than HSV-1. HSV-1 infectivity reduced by 1.4 LRV while SuHV-1
reduced by 4 LRV after MβCD exposure (Fig. 4-3C). Cell toxicity in response to MβCD
concentration can be found in Fig. A1. Again, the data in Fig. 4-3A & B represent a
reduction of viral cholesterol and not a quantitative measure of viral cholesterol resulting
from imperfect purification. This means that the LRVs are not representative of viral
cholesterol levels but instead a loss of viral cholesterol. The high LRV of SuHV-1
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suggests that cholesterol, or cholesterol-rich lipid rafts, play a larger role in the infection
process of SuHV-1 compared to HSV-1. These results are consistent with the inactivation
results by arginine, where SuHV-1 was inactivated to a greater extent compared to HSV1 at pH 7. This consistency supports the hypothesis that arginine deforms the viral
membrane to remove or disrupt cholesterol. The disruption of viral cholesterol may
highly affect SuHV-1 because of the requirement for cholesterol in membrane stability or
protein function. Though there may be other factors in play, the higher susceptibility of
SuHV-1 to inactivation is likely associated with membrane cholesterol loss by arginine.

4.4.3 Solution Properties to Enhance Inactivation of Viruses by Arginine
Not all enveloped viruses are fully inactivated by the synergistic effects of
arginine10,11,15. The results from Fig. 3-2 show that BVDV and EAV are not inactivated
by 1M arginine under any conditions. Correspondingly, past studies show that influenza,
Sendai, and Newcastle disease virus (NDV) are not fully inactivated with 0.7 M arginine
at pH 4 on ice for 60 min10,15. For this reason, various solution properties were tested to
determine if viral inactivation by arginine could be enhanced. We explored solution
properties by altering the charges on arginine, artificially inducing clustering, and adding
hydrophobic molecules to arginine or the solution. In addition to enhancing inactivation,
modifying solution conditions may also provide insight into mechanisms of arginine
inactivation.
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4.4.3.1 Inactivation with Arginine Derivatives
The guanidinium moiety on arginine is essential for virus inactivation.
Guanidinium has an affinity for hydrogen and can form ionic bonds with proteins and
lipids124. Other properties of arginine, such as charge or hydrophobicity, may also be
crucial for viral inactivation. Charges on arginine affect electrostatic interactions between
the virus and arginine itself for cluster formation124,191. Hydrophobicity is suspected to
loosen lipid packaging to allow arginine to easily bend and deform lipid bilayers239. To
observe the effect of charge and hydrophobicity on arginine viral inactivation, the
inactivation of three guanidinium-containing arginine derivatives with separate charge
patterns were compared. The three derivatives were arginine, agmatine, and butyroylarginine, and their structures are illustrated in Fig. 4-4A. Agmatine is arginine with the
carboxylic acid removed. Butyroyl-arginine is arginine with the amine capped with a
hydrophobic butyryl group. At pH 4 and 7, arginine is zwitterionic with a + 1 charge,
agmatine has a + 2 charge, and butyroyl-arginine is zwitterionic with a neutral charge176.
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Figure 4-4. Inactivation of enveloped viruses with arginine derivatives. (A) The structure
of arginine, agmatine, and butyroyl-arginine. All arginine-derivatives contain a
guanidinium group but each has a different charge pattern. Inactivation of HSV-1, SuHV1, and EAV in response to agmatine buffered with acetate at (B) pH 4 and (C) pH 7. Solid
lines represent agmatine solutions buffered with acetate, dashed lines represent solutions
without agmatine. Inactivation occurred at 4°C over 24 hours. Agmatine concentration
was 1 M and acetate concentration was 20 mM. (D) Arginine, agmatine, and butyroylarginine inactivation of HSV-1 after 1 hour at 4°C or on ice. Slashed bar graphs of 0.7 M
arginine and but-arg adapted from Katsuyama et al. *Limit of detection. All data points
are in triplicate and the error bars represent the standard deviation. Tabular data can be
found in Table A3 and A4.

The inactivation of HSV-1, SuHV-1, and EAV with 1 M agmatine was compared
at pH 4 and 7 in Fig. 4-4B&C. Tabular data can be found in Table A3. At pH 4,
agmatine produced negligible inactivation of EAV and HSV-1, while 3.55 ± 0.01 LRV
occurred for SuHV-1 after 24 hours. The inactivation of EAV and SuHV-1 at pH 4 with
agmatine (solid line) were similar to the control solution (dashed line), indicating that
agmatine did not inactivate the virus. The inactivation of HSV-1 at pH 4 with agmatine
was much lower than the control solution, demonstrating the stabilizing effect of
agmatine on HSV-1. At pH 7, agmatine and the controls inactivated all viruses to around
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1 LRV, demonstrating no effect of agmatine on virus inactivation. When looking at the
data as a whole, agmatine fails to inactivate enveloped viruses.
The inactivation efficacy of arginine, agmatine, and butyroyl-arginine is
compared in Fig 4-4D. Tabular data can be found in Table A4. The butyroyl-arginine
data was reformatted from Katsuyama et al.10. Solutions containing 1 M arginine, 0.7 M
arginine10, and 0.7 M butyroyl-arginine10 fully inactivated HSV-1 at pH 4 after 1 hour,
while 1 M agmatine produced negligible inactivation. Butyroyl-arginine and arginine
inactivate HSV-1 to the same levels at pH 4. However, as pH increases to 4.5, butyroyl
arginine is over 2-LRVs more effective than arginine at inactivating HSV-1 (data not
shown)10. Butyroyl-arginine is the most effective at inactivating enveloped viruses,
followed by arginine. Agmatine is the least effective in inactivating the tested viruses.
The difference in inactivation efficacy between butyroyl-arginine, arginine, and
agmatine is likely explained by added hydrophobicity and/or clustering. Clustering of
arginine can strengthen protein127 and lipid interactions197 to support inactivation. The
zwitterionic charge on butyroyl-arginine and arginine allow for the formation of clusters
through self-aggregation. However, the two positive charges on agmatine are not optimal
for clustering, consistent with the lesser inactivation capacity observed. Butyroyl-arginine
has an ideal charge pattern for clustering as a result of one positive and one negative
charge on opposite ends of the molecule10. Though arginine can also form clusters, it is
not as effective as butyroyl-arginine as a consequence of its extra positive charge17.
Butyroyl-arginine also contains a hydrophobic moiety where arginine and agmatine do
not15. The increased hydrophobicity of butyroyl-arginine can strengthen interactions with
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lipids, which may aid in inactivation10,15, demonstrated by increased inactivation by
butyroyl-arginine.
The difference between agmatine and arginine is charge based. Inactivation
differences between agmatine and arginine are likely a result of clustering. Agmatine is
not zwitterionic, therefore, clusters cannot form by electrostatic interaction. The inability
of agmatine to form clusters is likely the root cause of low inactivation. However, this
same lack of clustering and a high positive charge may be the reason for agmatine
appearing to provide virus stabilization in the presence of low pH (Fig. 4-4B). Acidic pH
commonly inactivates viruses through lipid hydrolysis153 or protein denaturation154.
However, with agmatine at pH 4, HSV-1 was demonstrated to be further stabilized (Fig.
4-4B). The positive charges on agmatine may bind to negative charges on HSV-1 to
counteract deterioration at acidic pH. Through HSV-1 has a positive net charge at pH 4
with its pI being ~4.9264, negative charges on the virus still exist. SuHV-1 has a higher
overall positive charge related to its higher pI, and therefore, may not be stabilized by the
positive agmatine charges. Arginine derivatives with added hydrophobicity, enhanced
clustering, or both lead to increased enveloped virus inactivation. Therefore, we decided
to study each effect independently.

4.4.3.2 Inactivation Based on Charge and Hydrophobicity
Hydrophobicity or clustering of arginine derivatives appears to enhance viral
inactivation. To further evaluate these properties, arginine peptides were synthesized
specifically for this work with added hydrophobicity or forced arginine clustering.
Hydrophobicity is suspected to loosen lipid packaging to support membrane deformations
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by arginine239, while clustering strengthens arginine interactions with lipids and
proteins127,197. CapA6R and R8 peptides were tested for inactivation, and their structures
are shown in Fig. 4-5A. CapA6R contains an arginine molecule linked to a six-chain
hydrophobic alanine tail. The peptide is capped on both ends to expose a single positive
charge on the guanidinium moiety. The single charged peptide avoids clustering to
exclusively model added hydrophobicity. CapA6R has been previously studied for its
antimicrobial activity205. The R8 peptide simulates the clustering of eight arginine
molecules. This peptide has been studied for drug delivery as a cell-penetrating peptide
and was chosen for its high cell penetration efficiency273.

Figure 4-5.Virus inactivation with arginine peptides. (A) Peptide structure of CapA6R
and R8. (B) Virus inactivation tested after 1 hour at pH 7 at 4°C in Tris buffered solutions
with 10% DMSO. Arginine and CapA6R concentrations were 7.6 mM. R8 concentration
was 0.95 mM which is equivalent to an arginine concentration of 7.6mM. Tris
concentration was 20 mM. The brackets with ** represent statistically different means
with a p<0.05 by the Student’s t-test. All data points are in triplicate and the error bars
represent the standard deviation. Tabular data can be found in Table A5.
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The inactivation of EAV and HSV-1 by CapA6R, R8, and arginine was compared
in Fig. 4-5B. Tabular data can be found in Table A5. Enveloped virus inactivation
increases with arginine concentration15, and therefore, an equivalent arginine
concentration of 7.6 mM for all species was applied for equal comparison. This low
concentration of peptide was used to demonstrate a change in the inactivation mechanism
because of costs restraints, and not to provide a method for high virus inactivation.
Solutions were buffered with Tris at pH 7 and exposed to arginine or arginine peptides
for 1 hour. As a result of high hydrophobicity, CapA6R was dissolved in DMSO and
added to the final solution at a concentration of 10% DMSO. For equal comparison, 10%
DMSO was added to each solution. CapA6R produced the highest inactivation, followed
by R8, with arginine producing the lowest inactivation at the concentration tested. By the
two-sample Student’s t-test, CapA6R inactivated EAV and HSV-1 to greater levels than
arginine, with p-values of 0.0255 and 0.009, respectively. R8 inactivated EAV a greater
level than arginine, with a p-value of 0.0075. Inactivation of HSV-1 by R8 was not
statistically different than the arginine control, with a p-value of 0.145. Interestingly, both
CapA6R and R8 inactivated EAV to a greater extent than HSV-1. Commonly, HSV-1 is
highly inactivated, whereas EAV is not inactivated by arginine solutions (Fig. 4-2). The
data supports that added hydrophobicity and clustering enhance the inactivation of
enveloped viruses under conditions where conventional arginine inactivation is low.
The increased hydrophobicity of CapA6R resulted in the highest inactivation
levels of HSV-1 and EAV as compared to arginine. To determine if hydrophobicity could
further enhance inactivation, pyrenebutyrate (PYB), a hydrophobic counter-anion, was
added to arginine solutions. PYB is commonly used to increase the uptake of arginine
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cell-penetrating peptides across the lipid bilayer by electrostatically binding to
arginine239. Added hydrophobicity is thought to allow for easier translocation of arginine
through the hydrophobic core of the lipid bilayer239.
The inactivation of EAV and HSV-1 with PYB is shown in Fig. 4-6. Tabular data
can be found in Table A6. Inactivation occurred at 4°C after 1 hour. PYB enhanced the
inactivation of EAV by 1.58 ± 0.29 LRV compared to the control with arginine and Tris
buffer at pH 7. However, EAV inactivation was not enhanced by PYB at pH 4, and HSV1 inactivation was not enhanced by any PYB solution. The difference in inactivation
capacity of EAV at pH 4 and 7 is likely explained by the charge on PYB. PYB has a -1
charge at pH 7 and is neutral at pH 4176. The negative charge at pH 7 may bind to the
positive charges on arginine or EAV for enhanced inactivation. The greater inactivation
of EAV over HSV-1 by PYB may also be a result of the virus charge. The isoelectric
point of HSV-1 is ~4.9264, whereas the isoelectric point of EAV is unknown. If the
isoelectric point of EAV is higher than HSV-1, the charges on EAV at pH 7 may be more
positive to allow for the binding of PYB. The difference in inactivation of EAV and
HSV-1 suggest that PYB is binding to the lipid bilayer to loosen the lipid packing,
instead of binding to arginine itself to aid in translocation.
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Figure 4-6. Inactivation of EAV and HSV-1 by arginine and pyrenebutyrate (PYB). Solid
bars represent samples with PYB and 10% DMSO, dashed bars represent mock samples
with only 10% DMSO. Inactivation occurred after 1 hour at 4°C. PYB was at 10 mM,
arginine was at 1 M, and Tris and acetate were at 20 mM concentration. *Limit of
detection. Note that the limit of detection for HSV-1 in Vero cells was lowered by PYB.
All data points are in triplicate and the error bars represent the standard deviation. Tabular
data can be found in Table A6.

Though PYB did increase EAV inactivation at pH 7, complete inactivation was
not reached. When PYB has been used to enhance the uptake of peptides into the cell, the
concentrations of PYB were larger than the peptide (15µM for PYB and 1.5 µM for
peptides)239. Here, PYB was 100X less concentrated than arginine as a consequence of its
solubility limit. If higher concentrations of hydrophobic cations could be used, arginine
inactivation can be hypothesized to be enhanced to fully inactivate all viruses.
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4.4.4 Functional Groups and Charges on Buffers
Since charge interactions of PYB and arginine derivatives with the virus influence
inactivation, the effect of buffer functional groups and charge were explored. It has been
shown previously that 1M arginine with Tris buffer at pH 7 can fully inactivate SuHV111. Properties of Tris that may aid in the inactivation of viruses include the amine group,
charge, or high-fat solubility. Amine groups interact with various compounds218, charges
dictate electrostatic interactions, and increased fat solubility can increase diffusion into
lipid bilayers274. However, all arginine solutions fully inactivated SuHV-1 at pH 7 (Fig.
4-2), suggesting the synergy of Tris is not the mechanism causing high inactivation.
Various buffers were tested to model Tris and acetate to determine if specific
properties aid in the inactivation of HSV-1 (Fig. 4-7). Tabular data can be found in Table
A7. Buffers were chosen for their potential inactivation properties. Structure and pKa
values of the tested buffers can be found in Table A8176. Glycine mimicked the amine
group on Tris. Glycineamide mimicked the +1 charge and amine group on Tris. Tricine
has a similar structure to Tris, but lower-fat solubility275. MES mimicked the charge on
acetate. Despite the differences, all buffers inactivated viruses to similar levels. Overall,
the data suggest that specific properties of buffers do not aid in viral inactivation by
arginine.
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Figure 4-7. Inactivation of HSV-1 with buffer mimics. Solid lines represent buffered
solutions with arginine, dashed lines represented buffered solutions without arginine.
Buffer mimics showed similar inactivation to Tris and acetate used with arginine.
Inactivation occurred at either (A) pH 4 or (B) pH 7 at 4°C. Arginine concentration was 1
M. Glycine, glycineamide, MES, and Tricine concentration were 20 mM. Open circles
represent the limit of detection. All data points are in triplicate and the error bars
represent the standard deviation. Tabular data can be found in Figure A7.
4.4.5 Viral Structural Changes after Arginine Exposure
The hypotheses for the mechanisms of viral inactivation by arginine all infer viral
structural changes17. Viral structure is speculated to change by complete disassembly,
aggregation13, deformation of proteins/lipids13, or simply arginine binding15. DLS
measurements and TEM images evaluated viral structural changes after arginine exposure
to elucidate inactivation mechanisms.
Size differences of HSV-1 and SuHV-1 before and after arginine exposure were
measured by DLS (Fig 4-8A). This data is also presented in Figure A3 in a different
form for clarification. Both viruses increased in size after exposure to arginine. Viruses
were exposed to arginine at 1 or 24 hours at pH 4 or 7. PBS at pH 7.4 was used as a
control for no arginine exposure. When HSV-1 was exposed to arginine at pH 4, size
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increased by 110 ± 25 nm after 1 hour and 243 ± 37 nm after 24 hours. Size changes to
HSV-1 at pH 4 and 7 over all conditions were comparable. Changes to SuHV-1 were
similar, with the largest size increase of 123 ± 62 nm with arginine buffered with Tris at
24 hours. Size changes in control PBS solutions were minimal for both viruses over 24
hours (Fig. A2). The peak at 1 nm is likely the arginine molecule itself. Similar to DLS
measurements, TEM images showed increased virus size after arginine exposure (Fig. 48B). HSV-1 was 158 nm and SuHV-1 was 179 nm before arginine exposure. After
arginine exposure, HSV-1 increased to 526 nm while SuHV-1 increased to 358 nm. TEM
measurements were obtained by measuring the size of the virus in the images shown. An
increased viral size could be the result of expanding lipids or viral swelling by lipids
bilayer deformations. Additionally, the binding of large arginine clusters to viral particles
could increase the size of the viral particle. However, the data suggest that virus
disassembly or viral aggregation is not the cause of inactivation.
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Figure 4-8. Size changes of HSV-1 and SuHV-1 after arginine exposure. (A) DLS after 1
and 24 hours and (B) TEM after 1-hour arginine exposure at 4°C at pH 4. Arginine was at
1 M, Tris was at 20 mM, and PBS was at pH 7.4. Inactivation occurred at 4°C. All data
points for DLS measurements are in triplicate.

4.5 Conclusions
Inactivation of enveloped viruses by arginine maintains the structure and stability
of therapeutic proteins, making it a desired viral clearance process in protein
manufacturing10,11,15. Arginine had been found to stabilize therapeutic proteins while
inactivating enveloped viruses. However, not all enveloped viruses are inactivated by
arginine to safe levels for clinical use17. This study investigated virus structure, properties
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of arginine, buffer type, and viral changes to further elucidate the mechanisms by which
the inactivation of enveloped viruses is enhanced by arginine.
Viral structure influenced the inactivation capacity of arginine. Large diameter
viruses (SuHV-1 and HSV-1) were highly inactivated by arginine, while small diameter
viruses (EAV and BVDV) were negligibly inactivated by arginine. The difference in
inactivation is hypothesized to be the result of lipid packing density17. Large diameter
viruses have loosely packed lipids for easy deformation by arginine and small diameter
viruses have tightly packed lipids that restrict deformation by arginine17. However, virus
size does not solely explain the inactivation differences between SuHV-1 and HSV-1.
SuHV-1 was completely inactivated at pH 7 by arginine with all buffer types, similar to
the results from McCue et al.11, whereas HSV-1 was only partly inactivated (3.7 LRV).
SuHV-1 and HSV-1 are comparable viruses from the Herpesviridae family168,258,
therefore, it is difficult to discern differences that influence inactivation by arginine.
Removal of membrane cholesterol inactivated HSV-1 by 1.4 LRV and SuHV-1 by 4
LRV. SuHV-1 may have a higher sensitivity to cholesterol reduction as a result of the
requirement for cholesterol in membrane stability or protein function268,272. Bending and
deforming the viral membrane likely disrupts lipid rafts and cholesterol. Therefore,
inactivation by arginine because of lipid bilayer deformations would be enhanced with a
higher sensitivity to cholesterol reduction. Overall, loosely packed lipids or high
cholesterol sensitivity of enveloped viruses support inactivation by arginine.
Various solution properties were tested to enhance the inactivation of viruses that
are naturally resistant to arginine. Charge and functional groups on arginine-derivatives
were assessed to determine the influence on inactivation. Butyroyl-arginine was the most
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effective, followed by arginine, and agmatine was the least effective. The ability to form
dense clusters and the hydrophobic capped amine of butyroyl-arginine likely aid in
inactivation. To dig deeper into these effects, arginine peptides were tested to model
added hydrophobicity (CapA6R) and forced arginine clustering (R8). Both CapA6R and
R8 enhanced inactivation over arginine itself, with CapA6R being the most effective.
Since added hydrophobicity continually enhanced inactivation, pyrebutyrate, a
hydrophobic cation, was added to arginine solutions. PYB improved inactivation of EAV
but not of HSV-1 when exposed to arginine. This difference was likely the result of virus
charge. Additionally, the impact of buffers with various functional groups and charges
were explored during inactivation by arginine. Buffers had no obvious effects on
inactivation. Collectively, the data indicate hydrophobicity and arginine clustering
enhance the inactivation of enveloped viruses.
Viral structural changes after arginine exposure were examined by DLS and
TEM. Both methods detected increasing virus size after arginine exposure for 1 or 24
hours. The results demonstrate that virus disassembly or virus aggregation do not explain
inactivation. The increase in virus size may result from lipid expansion or arginine
binding. Lipid expansion would result from arginine bending and deforming the viral
membrane. On the other hand, arginine binding to viral proteins or lipids would also
display an increased virus size. These insights correlate with earlier results where added
hydrophobicity and arginine clustering enhanced inactivation. Hydrophobicity loosens
lipid packaging to support lipid bilayer deformations239 whereas arginine clusters
strengthen lipid and protein interactions127,197. To narrow down the mechanisms further,
these findings can be related to the impacts of virus structure on inactivation. Viruses
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with loosely packed lipids or the requirement for membrane cholesterol are highly
inactivated by arginine. These viral properties would enhance inactivation through
bending and deforming the viral membrane. Combining the data as a whole, lipid bilayer
deformation is the likely mechanism for virus inactivation by arginine though no
mechanism can be completely ruled out.
The results from this study support lipid bilayer deformation as the mechanisms
for viral inactivation by arginine. This mechanism can be enhanced by added
hydrophobicity or arginine-clustering to inactivate viruses that are resistant to arginine.
Though optimal conditions for full inactivation of all viruses were outside the scope of
this work, this study provided insight into increasing inactivation by arginine. Additional
testing is required to optimize hydrophobicity, arginine-clustering, and charge for full
inactivation of all enveloped viruses. For example, increasing the concentrations of
arginine-peptides or added hydrophobic molecules may enhance inactivation. By adding
new components to arginine solutions, it would also be useful to look into the impact of
inactivation conditions on the final product quality.
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5 Influence of Buffer Type and Concentration on Virus
Inactivation during Low pH Treatment
5.1 Introduction
Viral safety is a major concern in biotherapeutic manufacturing. Infectious human
viruses may be present in solution when mammalian cells are used to produce
biotherapeutic products249. To ensure viral safety is met and infections do not spread to
clinical patients, regulations require the use of two orthogonal downstream viral removal
processes during manufacturing112,250,276,277. A filtration and an inactivation step are
commonly used to remove nonenveloped and enveloped viruses249. Low or high pH,
solvent/detergent, heat gamma irradiation, or ultraviolet radiation treatments are
examples of enveloped viral inactivation processes251. Low pH is simple and effective,
and therefore, is typically used in manufacturing with treatments of pH ≤ 3.6 being most
effective249. However, acidic pH levels under 4 can damage essential cells, tissues, or
proteins in biotherapeutic solutions252. For this reason, there is a demand for a robust
inactivation process at less acidic conditions.
Under specific operating parameters, virus inactivation has occurred at pH 4 or
above where conditions are less detrimental to the stability of essential solution
components252. Operating parameters influencing virus inactivation at pH 4 include
temperature, incubation time, and solutions conditions278. It is standard with increasing
temperature and incubation time that virus inactivation is enhanced278,279. However,
solution conditions including protein concentration, buffer type, and buffer concentration,
have a more complicated influence on virus inactivation278. High (30 mg/ml) or low
protein concentrations (0 mg/ml) increase inactivation of viruses at acidic pH278.
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Concentration and type of buffer in solution also influence virus inactivation, though the
effectiveness can depend on several solution properties249,251,252,278-280.
There are many examples in the literature where the concentration and/or type of
buffer influence the inactivation capacity of viruses in low pH solutions. Table 5-1
compares buffer effectiveness during the inactivation of viruses at low pH. It is evident
from previous work that buffer concentration and type largely influence the inactivation
of viruses at acidic pH. Buffer concentration can influence buffer effectiveness. For
example, citrate was most effective at low concentrations (0.15 M) in inactivating
Influenza A virus while acetate was most effective at high concentrations (0.6M). Virus
type also influences buffer effectiveness. Pseudorabies virus (SuHV-1) was fully
inactivated by acetate, citrate and glycine279. Acetate was the most effective buffer in
inactivating xenotropic murine leukemia virus (XMuLV)279. Citrate was most effective
buffer in inactivating murine leukemia virus251. Viral inactivation depends not only on
the buffer type, but additionally on buffer concentration, virus type, and pH.
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Table 5-1. Examples of Low pH Inactivation with Buffers.

Buffer
NaCl,
Phosphate,
Acetate, and
Citrate
Acetate,
Citrate, and
Glycine/phos
phate
Acetate
titrated with
acetic acid or
phosphoric
acid

Acetate,
Citrate, and
Glycine

Acetate,
Citrate, and
Glycine

Virus

Influenza
A

XMuLV

XMuLV

SuHV-1
and
XMuLV

Murine
Leukemi
a Virus

Conditions
 0.15-0.9
M
buffer
 pH 5
 5 min
 30° C
 pH 3.9
 30 min
 20° C
 25-100
mM
buffer
 pH 3.7
 10 min

 50 mM
buffer
 pH 3.7
 17° C

 pH 3.9
 15-25°
C

Results

Reference

Citrate most effective at low
concentrations (0.15 M) while Nishide et
acetate was the most effective al252
at high concentrations (0.6M).
Acetate fully inactivated XMLV while citrate or
glycine/phosphate produced
low inactivation.

Durno et
al278

Inactivation increased with
acetic acid titrant and buffer
concentration.

Chinnia et
al249

Complete inactivation of PRV
occurred with all buffers after
4 min.
Complete inactivation of XMLV occurred with glycine
and acetate after 2 min, and
with citrate after 15 min.
Citrate was the most effective
and glycine was the least
effective for inactivation.

Gillespie
et al279

Cameron
et al251

In this study the influence of buffer type, buffer concentration and time at pH 4 on
the inactivation of four viruses is examined. Buffers tested include citrate, acetate, and
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glycine at concentrations of 20-500 mM. Data collected will provide insight into the
matrix conditions required for high inactivation of viruses at pH 4 to improve
biotherapeutic manufacturing.

5.2 Materials and Methods
5.2.1

Materials
Buffers used during inactivation assays included sodium acetate (≥ 99%

bioreagent), acetic acid (glacial), and citric acid monohydrate purchased from Millipore
Sigma (St. Louis, MO). Glycine (99% for molecular biology) and sodium citrate tribasic
were generously donated from Millipore Sigma. Chemicals for cell culture assays
included Eagle’s medium essential media (EMEM), Dulbecco’s modified eagle medium
(DMEM), phosphate buffer saline (PBS, pH 7.2), sodium bicarbonate,
penicillin/streptomycin (pen/strep, 10,000U/ml), sodium pyruvate (100mM) and
trypsin/EDTA, purchased from life technologies (Carlsbad, CA). Fetal bovine serum
(FBS, Canada origin) was purchased from HyCloneTM GE Healthcare (Pittsburg, PA),
and horse serum (New Zealand Origin) was purchased from Sigma Aldrich. For the virus
titer determination by MTT assay, MTT salts (2-(3,5-diphenyltetrazol-2-ium-2-yl)-4,5dimethyl-1,3-thiazole; bromide, 98%) were purchased from Alfa AesarTM (Haverhill,
MA) and sodium dodecyl sulfate (SDS, BioReagent, ≥98.5%) was purchased from VWR
(Radnor, PA). The pH of buffer solutions was adjusted with sodium hydroxide (NaOH),
purchased from Millipore Sigma and hydrochloric acid (HCl), purchased from
ThermoFisher Scientific.
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5.2.2

Methods

5.2.2.1 Cells and Viruses
Vero cells (CCL-81), rabbit-kidney cells (RK-13, CCL-37), and porcine kidney
cells (PK-13, CRL-6489) were purchased from ATCC. Suid herpesvirus 1 (SuHV-1)
strain Aujeszky (VR-135), human herpesvirus 1 (HSV-1) strain F (VR-733), and equine
arteritis virus (EAV) strain Buvyrus (VR-796) were purchased from ATCC. Porcine
parvovirus (PPV) strain NADL-2 was generously gifted by Dr. Ruben Carbonell from
North Carolina State University in Raleigh, NC. Each cell line was incubated at 5% CO2
and 100% humidity at 37°C during virus propagation or infectivity assays, except Vero
cells infected with HSV-1 were incubated at 35°C. EAV was propagated in RK-13 cells,
HSV-1 was propagated in Vero cells and SuHV-1 was propagated in Vero cells, as
described previously (Chapter 4). PPV was propagated in PK-13 cells, as described
previously255.

5.2.2.2 Virus Quantification
The MTT colorimetric cell viability assay was used to calculate virus titer281.
First, 96-well plates were seeded with 8 x 104 cells/well for the combination of Vero cells
for SuHV-1 titer, RK-13 cells for EAV titer, and PK-13 cells for PPV titer. A density of
105 cells/well was required for Vero cells for HSV-1 titer. Plates seeded with cells were
incubated at 37°C, 5% CO2, and 100% humidity before virus infection. Following 22-26
hours of incubation, 25 ul of the virus sample was added to the first column of the 96well plate and serially diluted at a 1:5 ratio down the plate. Plates were incubated for six
days at 37°C for SuHV-1, EAV, and PPV and 35°C for HSV-1. After, MTT salts were
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added to each well to detect live cells by the production of purple formazan. Plates were
placed back into the incubator for 4 hours, and then SDS at a pH of 2 was added to each
well and incubated for an additional 4-12 hours to allow SDS to solubilize the formazan
crystals. Absorbance was measured in each well at a wavelength of 550 nm by a
microplate reader (BioTeK, Winooski, VT). Final viral concentrations were calculated as
the 50% infectious dose (MTT50/ml) and reported as a log10 reduction value (LRV),
defined in Eq. 5-1.

𝐿𝑅𝑉

log

(Eq. 5-1)

5.2.2.3 Buffer Inactivation Assays
To begin inactivation assays, glycine, acetate, and citrate were prepared at
concentrations of 20mM, 100mM, 250mM, and 500 mM. Buffer solutions were made
with ultrapure water (resistivity of ≥ 18 MΩ cm) collected from a Thermo Fisher
Nanopure filtration system. Acetate buffer was prepared by mixing sodium acetate
anhydrous with acetic acid to concentrations that yielded the final buffer molarity at pH
4, calculated by the Henderson-Hasselbalch equation (Eq. 5-2)282. Citrate buffer was
prepared by mixing sodium citrate tribasic with citric acid monohydrate to concentrations
that yielded the final molarity at pH 4, calculated by the Eq. 5-2282. Glycine buffer was
prepared with glycine. 1M NaOH and 1M HCl were used for final adjustments to pH 4.
Buffers were sterilized before biological assays with a 0.2 µm syringe filter from VWR
(Radnor, PA).
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𝑝𝐻

𝑝𝐾

log

(Eq. 5-2)

To begin inactivation assays, 100 µl of model virus and 900 µl of the appropriate
buffer were mixed in a 1.5 ml sterile ultracentrifuge tube. SuHV-1, HSV-1, and PPV
were added at concentrations of 107-108 MTT50/ml and EAV was added at a
concentration of 106-107 MTT50/ml. The addition of the virus did not alter the solution
pH. Samples were stored at 4°C, and virus titer was measured at 0.5, 1, 2, 3, and 6 hours
with the MTT assay.

5.3 Results and Discussion
5.3.1

Model Virus and Buffers
Pseudorabies virus (SuHV-1), herpes simplex virus 1 (HSV-1), equine arteritis

virus (EAV), and porcine parvovirus (PPV) were chosen as model viruses. Properties of
viruses are listed in Table 5-2. SuHV-1 and HSV-1 are both large enveloped viruses with
diameters of 110-200 nm belonging to the Herpesviridae family168,170,175,258.
Herpesviridae are double-stranded DNA viruses containing a capsid surrounded by a
tegument protein matrix and enclosed in a lipid bilayer258,267. EAV is a small enveloped
virus from the Arteriviridae family with a diameter of 50-79 nm259. EAV contains a
positive-sense single-stranded RNA coated in a nucleocapsid protein259 and enveloped by
a lipid bilayer260. PPV is a small non-enveloped virus with a diameter of 18-26 nm283.
PPV belongs to the Parvoviridae family and contains single-stranded DNA284.
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Table 5-2. Properties of Tested Viruses
Virus

Acronym

Envelope

Diameter
(nm)

Isoelectric
Point

Genome

Pseudorabies
Virus

SuHV-1

Yes

110-200170

~7.5263

dsDNA

Herpes Simplex
Virus 1

HSV-1

Yes

110200168,175

~4.9264

dsDNA

Equine Arteritis
Virus

EAV

Yes

50-70259

N/A

(+)ssRN
A

Porcine
Parvovirus

PPV

No

18-26283

4.8-5.1283

ssDNA

Citrate, acetate, and glycine were used as buffers during virus inactivation at pH
4. All buffers are weak electrolytes that have been used in the literature to inactivate
viruses at low pH 249,251,252,278,279. Structure, pKa, and charges of the buffers are listed in
Table 5-3. Glycine is a simple non-essential amino acid containing a hydrogen atom side
chain285. Acetate is monocarboxylic acid anion formed as a salt from acetic acid and a
base286. Citrate is commonly used as a buffer in inactivating viruses during low pH
treatment at pH 3.515. Glycine and acetate have a dominant charge of 0 while citrate has a
dominant charge of -1 at pH 4.
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Table 5-3. Properties of Tested Buffers176

Buffer

Structure

pKa

Dominant
charge
below
pKa

2.31

+1

9.27

0

4.54

0

3.13

0

4.76

-1

6.40

-2

Glycine

Acetate

Citrate

5.3.2

Inactivation Capacity of Buffers at pH 4
The inactivation of viruses at pH 4 with glycine, acetate, and citrate buffer at 20

mM, 100mM, 250 mM, and 500 mM was assessed. Inactivation experiments were co
conducted at 4°C and the LRV for each virus was measured at 0.5, 1, 2, 3, and 6 hours.
Both viral and buffer properties influenced inactivation as follows.
The inactivation of SuHV-1 by glycine, acetate, and citrate is shown in Fig. 5-1.
The effectiveness of glycine increased with buffer concentration and time, but never fully
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inactivated SuHV-1. Glycine at 20 mM produced negligible inactivation, while
inactivation increased over time at all other concentrations, reaching a maximum of 4.13
LRV after 6 hours at 500 mM glycine. Acetate fully inactivated SuHV-1 at
concentrations of 250mM or above after 30 min. Full inactivation, or limit of detection, is
represented by open shapes. Acetate at 20 mM and 100 mM inactivated SuHV-1 to
similar levels after 6 hours to 4 LRV and 3.76 LRV, respectively. Inactivation increased
over time with 20 mM and 100 mM acetate to 3 hours and then leveled off. Citrate
concentrations ≥ 100 mM completely inactivated SuHV-1 within 30 min. Citrate at
20mM reduced SuHV-1 by 3.3 LRV after 6 hours, but similar inactivation of 3.5-log10
occurred after 1 hour. Citrate was the most effective buffer, followed by acetate, and the
least effective was glycine in inactivating SuHV-1 at pH 4.
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Figure 5-1. Inactivation of SuHV-1 by various concentrations of glycine, acetate, and
citrate at pH 4. Citrate is the most effective, and after 30 min all concentrations of 100
mM or above fully inactivate SuHV-1. Acetate is the next effective with concentrations
of 250 or above fully inactivate SuHV-1. Glycine is the least effective at inactivating
SuHV-1. The limit of detection is signified by open shapes. Data points were measured in
triplicates and error bars represent standard deviation.
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Inactivation of HSV-1 was influenced by buffer concentration and type (Fig. 5-2).
Inactivation of HSV-1 by 20 mM glycine was negligible but increased at concentrations
≥ 100 mM to 1.78 LRV after 6 hours. Acetate never fully inactivated HSV-1, up to 4
LRV, at any concentration, where it did fully inactivate SuHV-1 at concentrations ≥
250mM. After 1 hour, inactivation at all acetate concentrations leveled out, whereas 20
mM produced 3.08 LRV, 100 mM produced 3.6 LRV, 250 mM produced 3.4 LRV, and
500 mM produced 3.7 LRV. The effectiveness of citrate in inactivating HSV-1 increased
with concentration. Inactivation by 20 mM citrate increased over time to 3.2 LRV after 6
hours. Inactivation by 100 mM citrate increased drastically after 1 hour to 4.22 LRV, and
reached 4.6 LRV after 6 hours. Citrate at 250 mM fully inactivated HSV-1 after 1 hour,
and 500 mM citrate fully inactivated HSV-1 after 30 min. Conclusively, citrate was the
most effective at inactivating HSV-1, followed by acetate, and the least effective was
glycine.
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Figure 5-2. Inactivation of HSV-1 by various concentrations of glycine, acetate, and
citrate at pH 4. Citrate is the most effective, and at 1 hour all concentrations of 100 mM
or above fully inactivate HSV-1. Acetate is the next effective, and glycine is the least
effective at inactivating HSV-1. The limit of detection is signified by open shapes. Data
points were measured in triplicates and error bars represent standard deviation.
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Inactivation of EAV (Fig. 5-3) and PPV (Fig. 5-4) was negligible at all buffer
concentrations at pH 4 after 6 hours. Properties of EAV and PPV may hinder inactivation
by buffers at pH 4. EAV is a small enveloped virus, creating a lipid bilayer that is tightly
packed for increased membrane stability17. This highly stabilized virus may restrict
inactivation compared to larger viruses (SuHV-1 and HSV-1) that contain loosely packed
lipids17. PPV is a non-enveloped virus, meaning it does not contain a lipid bilayer and
the protein capsid is directly exposed to the environment225. Lipid bilayers are more
sensitive to environmental degradation than proteins, and therefore non-enveloped
viruses tend to be more stable than enveloped viruses225. The stability or absence of the
lipid bilayer likely protects EAV and PPV from inactivation by buffers at pH 4.
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Figure 5-3. Inactivation of EAV by various concentrations of glycine, acetate, and citrate
at pH 4. All buffers and concentrations did not inactivate EAV. Data points were
measured in triplicates and error bars represent standard deviation.
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Figure 5-4. Inactivation of PPV by various concentrations of glycine, acetate, and citrate
at pH 4. All buffers and concentrations did not inactivate PPV. Data points were
measured in triplicates and error bars represent standard deviation.
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5.3.3

Variables Influencing Inactivation at pH 4
Inactivation levels are dependent on the virus type, buffer type, and buffer

concentration (Fig. 1-4). SuHV-1 was inactivated to the greatest extent, followed by
HSV-1, and both EAV and PPV were negligibly inactivated under all buffer conditions.
Negligible inactivation of EAV and PPV is likely explained by the absence or increased
stability of the lipid bilayer. However, this does not explain the higher inactivation of
SuHV-1 over HSV-1. For both SuHV-1 and HSV-1, citrate was the most effective and
glycine was the least effective buffer in inactivation. Increasing buffer concentration
either enhanced inactivation or had no effect on inactivation, but never decreased
inactivation. The dependence for inactivation on virus type, buffer type, and buffer
concentration provides insight into mechanisms of inactivation.
Inactivation effectiveness correlates to buffer and virus charges (Table 1 & 2).
Citrate is the most negatively charged buffer at pH 4 with a dominant charge of -1.
Acetate has a dominant charge of 0, however, partial charges of -1 exist since pH 4 is
close to the pKa of 4.54. Glycine is the least negative at pH 4 with a dominant charge of
0. As a whole, higher negative buffer charges result in enhanced inactivation of SuHV-1
and HSV-1. In regards to virus charge, SuHV-1 has an isoelectric point (pI) of ~7.5263,
whereas HSV-1 has an isoelectric point of ~4.9264 (Table 1). The higher pI of SuHV-1
leads to greater positive charges on the virus in comparison to HSV-1 at pH 4. The
greater positive charge of SuHV-1 likely promotes electrostatic interactions of the
negative charges of citrate or acetate to result in higher inactivation compared to HSV-1.
Negative buffer charges and positive virus charges appear to correlate to high
inactivation, therefore, electrostatic interactions between the buffer and the virus likely
149

influence inactivation. It is reported that charges on buffers may weakly bind to viruses
through electrostatic interactions to modify surface properties such as
proteins209,210,252,287. At low or intermediate buffer concentrations (millimolar), binding
may stabilize viral proteins by reducing unfavorable interactions209,210,288. Oppositely at
high concentrations, binding appears to promote an increase in repulsive forces that
destabilize viral proteins287,288. Brorson et al. demonstrated membrane and capsid
structure changes of X-MLV with transmission electron microscopy images as a result of
inactivation at pH 3.8 with acetate or citrate buffer289. Overall, buffers likely bind to the
virus at high concentrations (typically molar levels) to destabilize viral proteins causing
inactivation.

5.3.4

Conclusions
Low pH treatments are commonly used in biotherapeutic manufacturing to

inactivate enveloped viruses249. There is a need for an enveloped virus inactivation at pH
≥ 4 to maintain the stability of biological products in solution. This study investigated the
influence of time, buffer properties, and virus properties on the inactivation of four model
viruses at pH 4.
Inactivation levels were dependent on time, virus-type, buffer-type, and buffer
concentration. SuHV-1 reached full inactivation with acetate concentrations of ≥ 250 mM
and citrate concentrations ≥ 100 mM after 30 min. Of the viruses tested, HSV-1 was
inactivated to the next greatest extent where full inactivation occurred at citrate
concentrations ≥ 250 mM after 1 hour. EAV and PPV were negligibly inactivated over all
solution conditions, consisted with the literature, this is likely a result of the stabilized
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lipid bilayer of EAV and no lipid bilayer of PPV. The increasing inactivation levels from
glycine, to acetate, to citrate for SuHV-1 and HSV-1 correspond to the increasing
negative charges on the buffer. Similarly, the greater inactivation of SuHV-1 over HSV-1
corresponds to the greater positive virus charge. Electrostatic interactions between the
negatively charged buffers and positively charged viruses likely destabilize viral proteins
to result in inactivation209,210,252,287.
Inactivation of viruses at pH 4 is a function of virus and buffer properties. Viral
structures, including a stabilized lipid bilayer, can resist inactivation at pH 4. Resistant
viruses likely require harsher conditions for full inactivation. For viruses that are not
resistant to pH 4 inactivation, enhancing electrostatic interactions between the buffer and
the virus can increase inactivation levels.
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6 Conclusions and Future Work
6.1 Conclusions
Infectious diseases considerably impact worldwide health1. For example, the 2019
novel coronavirus (SARS-CoV-2) sparked a global pandemic by causing a deadly
respiratory disease3. The SARS-CoV-2 outbreak reminds us that even though society
enacts practices to protect the public from infectious diseases4, challenges in treatment
and prevention remain. For this reason, continual improvements to health measures must
be made to control infectious diseases. Wastewater treatment and viral clearance during
pharmaceutical applications are examples of health measures that can be improved to
prevent the spread of infectious diseases.
Chapter 2 investigated a low-cost, low-tech biosolids treatment method to
improve the sustainability of wastewater treatment operations. Many WWTPs are looking
to upgrade their biosolids treatment processes to Class A standards to open additional
avenues for sustainable reuse. However, current options for upgrades to biosolids
treatment typically require high-cost, high-tech processes that are not feasible for smaller
WWTPs with limited resources. Therefore, there is a need for a low-cost, low-tech
process that produces high-quality biosolids. During this study, a low-cost, low-tech
treatment option for Class A biosolids was investigated through long-term storage in
northern climates. The effects of freeze/thaw cycles, temperature, moisture, volatile
solids, ammonia, and pH on pathogen inactivation were evaluated for one year. After one
year of long-term storage at two northern WWTPs, fecal coliforms decreased to
regulatory standards but Ascaris ova remained constant. Therefore, more than one year of
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storage in northern climates is required for Class A biosolids treatment to affect proper
helminth ova inactivation. Freeze/thaw cycles significantly reduced fecal coliform levels
in all biosolids tested. Specifically, 16% TS produced the highest inactivation of fecal
coliforms during freeze/thaw cycles. Ultimately, the results of this study provided
information on minimum process parameters for low-cost, low-technology biosolids
treatment.
Chapter 3 hypothesized the mechanisms for enveloped virus inactivation by
arginine. Enveloped virus inactivation by arginine maintains protein stability, and
therefore, is a desirable process in therapeutic protein manufacturing8-16. However,
optimal conditions for full inactivation of all enveloped viruses by arginine are not
known. Viruses containing stabilized membranes or stabilized proteins are not highly
inactivated by arginine17. For this reason, arginine may be interacting with proteins or
lipids to inactivate viruses. Three hypotheses were developed to explain the potential
mechanisms of inactivation by arginine. Hypothesis 1 described inactivation by arginine
through inhibition of protein function. Hypothesis 2 described inactivation by arginine as
a result of viral membrane destabilization. Hypothesis 3 described inactivation by
arginine through membrane pore formation. To reject a hypothesis, the effect of arginine
on protein function or membrane stability needs to be determined. Understanding the
mechanisms of arginine will provide insight into developing treatment methods that
enhance
virus inactivation.
Chapter 4 examined the influence of viral and arginine properties on inactivation.
Viral membrane structures largely affected inactivation by arginine. Viruses with stable
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membranes (EAV and BVDV), resulting from small diameter membranes with tightly
packed lipids, were negligibly inactivated by arginine. Viruses with less stable
membranes (HSV-1 and SuHV-1), resulting from large diameter membranes with loosely
packed lipids, were highly inactivated by arginine. Additionally, viruses that were
sensitive to membrane cholesterol reduction were also inactivated to high levels by
arginine. Overall, the mechanism of membrane deformation was supported by the
influence of viral membrane properties on arginine inactivation. In regards to arginine
structure, hydrophobicity and arginine-clustering increased inactivation of viruses
resistant to arginine. An increasing virus size after arginine exposure was measured by
DLS and TEM images, alluding to lipid expansion or arginine binding as the mechanism
for inactivation. Overall, the data from this study supports lipid bilayer deformation as
the mechanism of arginine inactivation and added hydrophobicity or arginine-clustering
to enhance inactivation.
Chapter 5 investigated buffer type and concentration on the inactivation of several
enveloped viruses at pH 4. Similar to arginine, viruses with highly stable membranes
(EAV) or no membranes (PPV) were negligibly inactivated at pH 4. Full inactivation (~5
LRV) occurred for viruses with less stable membranes (SuHV-1 and HSV-1) at pH 4
under various buffer conditions. Citrate produced the highest inactivation, and glycine
produced the lowest inactivation of SuHV-1 and HSV-1. Increasing electrostatic
interactions between the virus and buffer enhanced inactivation. Conclusively, this study
provided insight into the conditions (buffer type and time) for virus inactivation by
buffers at pH 4 which preserves biopharmaceutical protein activity as opposed to lower
pH treatments.
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6.2 Future Work
Meaningful results for the improvement of pathogen inactivation in biosolids and
pharmaceutical applications are presented in this dissertation. However, gaps in
information remain that hinder the further development and widespread use of the
pathogen inactivation processes studied. Future research into biosolids treatment, virus
inactivation by arginine, and low pH virus inactivation by buffers are required to create
well-established processes.

6.2.1 Biosolids Treatment
To develop a universal long-term storage Class A biosolids treatment, additional
freeze-thaw and long-term storage studies are required. To start, studies to predict the
influence of freeze-thaw conditions on pathogen inactivation are needed. Fecal coliform
reduction in biosolids at two WWTPs after one freeze-thaw cycle with total solids
contents varying from 5-28% was studied in Chapter 2. Since conditions can vary
tremendously across plants, the influence of several variables on pathogen inactivation is
required for an understanding of freeze-thaw cycles. Variables to adjust and analyze for
pathogen inactivation would include 1) number of freeze-thaw cycles, 2) temperature
gradient, and 3) biosolids origin. Furthermore, the effect of freeze/thaw cycles on
pathogen inactivation for enteric viruses and Ascaris ova is needed for Class A
requirements. After the data is collected, the impact of freeze-thaw conditions on
pathogen inactivation could be analyzed through multivariate regression to model sitespecific WWTP pathogen inactivation.
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Further long-term storage field- and lab-scale studies are required to develop a
universal low-cost, low-tech Class A biosolids treatment method. Chapter 2 demonstrated
the influence of biosolids properties on pathogen inactivation during long-term storage at
two WWTPs over one year. Key information was collected on the inactivation of fecal
coliforms during winter storage; however, the data indicate that the specific treatment
conditions did not minimum Class A treatment requirements. To determine the minimum
conditions required for long-term storage at individual WWTPs, it is necessary to
conduct field-scale studies across various climates at longer storage times. During the
field-scale studies, biosolids properties (VS, TS, ammonia, temperature, VFA, and
pathogen content) and environmental conditions (precipitation, humidity, temperature,
UV, and wind) should be monitored to determine minimum storage times required to
reach Class A standards under different climates and biosolids conditions. The field-scale
study could be paired with a lab-scale study to strengthen the data. In the lab-scale study,
variables to be altered and quantified for their influence on pathogen inactivation include
1) pH, 2) temperature, 3) ammonia content, 4) VS, 5) VFA, and 6) TS. The data could
then be analyzed under multivariate regression to determine the significance of each
variable on pathogen inactivation. Additionally, a model could be constructed to predict
pathogen inactivation at WWTPs with known biosolids conditions.

6.2.2 Virus Inactivation by Arginine
Greater information on the mechanisms and optimization of enveloped virus
inactivation by arginine is needed to create a safe and reliable viral clearance process for
therapeutic protein manufacturing.
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6.2.2.1 Arginine Mechanisms
In Chapter 3, mechanisms for enveloped virus inactivation by arginine were
hypothesized including 1) inhibition of protein function, 2) deformation of the lipid
bilayer, and 3) holes in the lipid bilayer. Overall, the data collected in Chapter 4
supported the mechanisms of lipid bilayer deformation. However, supplementary studies
are necessary to assess and confirm all hypothesized mechanisms.
Experiments to assess protein function and structure before and after arginine
exposure are required to evaluate hypothesis 1. Protein binding experiments with
enzyme-linked immunosorbent assay (ELIZA), bio-layer interferometry technology
(BLITz), or immunohistochemistry could elucidate protein changes after arginine
exposure. ELIZA and BLITz work by immobilizing a specific host cell receptor to
measure the binding capacity of an associated protein. For example, heparin is commonly
used as a cell receptor for viruses, and differences in heparin-binding before and after
arginine exposure could signify a disruption in protein function247.
Immunohistochemistry uses the process of immunostaining to identify specific proteins
(antigens) through the binding of antibodies. For example, antibodies that bind to HSV-1
proteins include polyclonal rabbit anti-HSV-1290 and Monoclonal CHA 437 antibody291.
Quantifying the protein-antibody binding before and after arginine exposure would
elucidate protein changes. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS PAGE) separates proteins by molecular weight and could illuminate general protein
differences in the virus before and after arginine exposure. Though all these studies
evaluate hypothesis 1, changes in protein binding or structure could also support
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hypothesis 2, since lipid instability may alter the efficacy and function of membranebound proteins.
Nanoindentation experiments, such as atomic force microscopy (AFM), could
measure changes in virus stiffness to evaluate hypotheses 2 and 3. If the virus stiffness
decreases after arginine exposure, the lipid bilayer is being compromised either by lipid
deformations or pores. If virus stiffness and protein structure or binding are being
changed, then hypothesis 2 is most likely. To test hypothesis 3, the reduction in genetic
material after arginine exposure could be measured by polymerase chain reaction (PCR).
Holes in the lipid bilayer likely expose the inner virus to harsh outer conditions,
degrading the genetic material. While our data supports hypothesis 2, future studies are
required to assess all potential hypotheses for the mechanisms of viral inactivation by
arginine.

6.2.2.2 Arginine Optimization
Added hydrophobicity and arginine clustering improved viral inactivation by
arginine, however, full inactivation of all enveloped viruses was not reached. To
determine the optimal conditions for full inactivation of all enveloped viruses by
arginine, additional studies are required.
The influence of membrane cholesterol on HSV-1 and SuHV-1 infectivity was
examined in Chapter 4. Cholesterol reduction increases membrane fluidity238 203,206,
which may aid in the destabilization of lipids by arginine. To evaluate the effects of
membrane cholesterol reduction on inactivation by arginine, future studies are required.
To begin the studies, membrane cholesterol would be reduced in several viruses (both
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resistant and non-resistant to arginine inactivation) by MβCD. After cholesterol
reduction, viruses would be exposed to arginine. LRV would be calculated from the titer
before and after arginine exposure. A higher LRV compared to the arginine LRV without
cholesterol reduction would signify that an increase in membrane fluidity enhances
inactivation by arginine. If this is the case, other membrane disrupters could be used in
combination with arginine to produce high inactivation. The membrane disruptor
pyrenebutyrate (PYB) was tested at low levels of 10 mM in Chapter 4. PYB loosens lipid
packing and increases membrane fluidity234,239-241, similar to cholesterol reduction.
Though PYB did enhance arginine inactivation, it did not fully inactivate viruses due to
low solubility limits. Other hydrophobic molecules (isoleucine, valine, or leucine) or
membrane disruptors (detergents) with higher solubility limits could be tested to enhance
inactivation by arginine.
Testing higher concentrations or different conformations of arginine peptides may
uncover conditions for full virus inactivation. Chapter 4 studied the effect of CapA6R
(added hydrophobicity) and R8 (added arginine clustering) peptides at 7.6 mM equivalent
arginine concentration on the inactivation of viruses. Though these peptides inactivated
viruses to higher levels than 7.6 mM arginine, the low concentrations were unable to fully
inactivate any viruses. Higher concentrations of peptides likely improve inactivation
levels. Additionally, different conformations of peptides could be tested. For example, a
more hydrophobic amino acid (isoleucine, valine, or leucine) could be replaced for
alanine in the tail of CapA6R. Also, larger and smaller arginine peptides could be tested
and compared to R8. Literature shows there may be an ideal number of arginine
molecules required to disrupt the lipid membrane197. While our results provided insight
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into the mechanisms and optimization of inactivation by arginine, additional studies are
required to more effectively use arginine.

6.2.3 Low pH Virus Inactivation by Buffers
Additional information is required to determine the effects of buffers on the
inactivation of viruses at low pH. Chapter 5 established that viruses with stable
membranes or no membrane were resistant to inactivation at pH 4. To determine
minimum conditions to inactivate resistant viruses, lower pH values must be tested. For
example, testing the inactivation of PPV and EAV with acetate, glycine, and citrate at
500 mM with decreasing pH values below 4 would determine minimum conditions for
inactivation. For viruses with less stable membranes, enhancing the electrostatic
interactions between the virus and the buffer improved inactivation, however, this was
only studied with two viruses. For a greater statistical significance, additional viruses
should be tested for inactivation at pH 4 by buffers with several charges. Viruses tested
must be large enveloped viruses that are not resistant to inactivation at pH 4 such as
Influenza or xenotropic murine leukemia virus. Largely, supplemental tests are required
to decipher the minimum conditions for full inactivation of viruses with buffers at low
pH.
This dissertation improved public health by determining mechanisms and optimal
conditions for pathogen inactivation in wastewater treatment and pharmaceutical
applications. While key insights into pathogen inactivation were found, continual
research is required to protect public health against infectious diseases.
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Viral Inactivation Data: Chapter 4

Table A1: Log10 reduction values for Figure 4-2. Inactivation of enveloped viruses by
arginine. Inactivation at 4°C over 24 hours. Arginine concentration at 1 M. Tris, acetate,
and citrate concentration at 20 mM

Virus

Solvents

HSV-1

Arg
Arg +
Tris
Arg + Act
Tris
Act
Citrate

SUHV-1

Arg
Arg +
Tris
Arg + Act
Tris
Act
Citrate
Arg

EAV

Arg +
Tris
Arg + Act
Tris
Act
Citrate

BVDV

Arg
Arg +
Tris
Arg + Act
Tris
Act
Citrate

pH
4
7
4
7
4
7
7
4
7
3.5
4
7
4
7
4
7
7
4
7
3.5
4
7
4
7
4
7
7
4
7
3.5
4
7
4
7
4
7
7
4
7
3.5

Time (hours)
3

1

6

Average

STDEV

Average

STDEV

Average

STDEV

3.76
0.39
3.51
0.10
3.82
0.27
0.11
2.56
-0.30
4.48
4.05
3.39
3.82
3.27
3.99
3.16
0.08
3.67
0.07
4.30
0.21
0.13
-0.07
0.12
0.08
0.17
0.24
0.04
0.23
0.20
0.08
0.12
0.44
0.25
0.33
0.28
0.41
0.52
0.14
0.06

0.24
0.61
0.31
0.21
0.37
0.46
0.17
0.12
0.18
0.04
0.39
0.89
0.13
0.90
0.45
0.45
0.28
0.63
0.34
0.10
0.45
0.20
0.36
0.32
0.81
0.17
0.24
0.44
0.52
0.69
0.43
0.15
0.17
0.38
0.24
0.36
0.36
0.14
0.39
0.10

3.62
1.16
3.72
1.36
3.66
1.14
0.52
2.75
0.26
4.49
4.06
4.10
3.87
4.05
4.15
4.00
0.29
4.00
0.35
4.29
1.04
0.14
0.04
-0.04
-0.03
0.26
0.18
0.48
0.24
0.27
0.28
0.14
0.56
-0.05
0.29
0.36
0.44
0.46
0.33
0.20

0.21
0.75
0.10
1.00
0.06
0.49
0.73
0.54
1.15
0.01
0.40
0.41
0.21
0.32
0.46
0.33
0.27
0.40
0.35
0.12
1.20
0.23
0.14
0.22
0.43
0.21
0.27
0.40
0.23
0.65
0.19
0.28
0.47
0.10
0.29
0.60
0.40
0.22
0.19
0.27

3.70
1.41
3.66
1.24
3.76
1.22
0.12
2.77
0.61
4.49
4.00
4.01
3.85
3.97
4.10
4.07
0.44
3.82
0.23
4.30
0.24
0.24
0.48
0.23
0.70
0.03
0.09
0.74
0.07
0.38
0.42
0.14
0.38
0.33
0.38
0.11
0.53
0.63
0.37
0.29

0.25
0.51
0.37
0.49
0.44
0.10
0.27
0.41
1.24
0.01
0.46
0.45
0.11
0.37
0.37
0.40
0.32
0.49
0.25
0.07
0.23
0.29
0.09
0.64
0.20
0.49
0.44
0.20
0.27
0.34
0.47
0.33
0.37
0.47
0.37
0.18
0.39
0.15
0.55
0.30
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Table A1 Continued

Virus

Solvents
Arg

HSV-1

Arg + Tris
Arg + Act
Tris
Act
Citrate

SUHV-1

Arg
Arg + Tris
Arg + Act
Tris
Act
Citrate
Arg

EAV

Arg + Tris
Arg + Act
Tris
Act
Citrate
Arg

BVDV

Arg + Tris
Arg + Act
Tris
Act
Citrate

pH
4
7
4
7
4
7
7
4
7
3.5
4
7
4
7
4
7
7
4
7
3.5
4
7
4
7
4
7
7
4
7
3.5
4
7
4
7
4
7
7
4
7
3.5

Time (hours)
12
24
Average
STDEV
Average
STDEV
3.71
0.17
3.70
0.25
2.13
0.35
2.67
0.93
3.71
0.25
3.42
0.55
1.81
0.78
3.46
0.96
3.77
0.21
3.71
0.15
2.00
0.58
2.62
0.61
0.59
0.28
0.07
1.20
3.16
0.21
3.35
0.37
0.87
0.77
0.96
0.47
4.51
0.02
4.54
0.07
4.07
0.37
3.97
0.40
4.03
0.40
4.03
0.37
3.90
0.25
3.79
0.08
3.91
0.40
3.98
0.38
4.04
0.37
4.03
0.38
4.09
0.36
3.97
0.42
0.44
0.30
0.75
0.22
3.86
0.46
3.89
0.42
0.45
0.42
0.82
0.56
4.22
0.13
4.67
0.19
-0.11
0.39
0.12
0.17
0.17
0.29
-0.21
0.13
0.15
0.39
0.10
0.04
0.54
0.77
-0.07
0.03
0.37
0.48
0.33
0.18
0.22
0.52
0.14
0.30
-0.04
0.16
0.00
0.19
0.47
0.60
0.50
0.35
0.23
0.55
0.09
0.23
0.11
0.36
0.61
0.58
0.73
0.12
0.99
0.36
0.36
0.27
0.49
0.37
0.69
0.37
0.76
0.35
0.35
0.59
0.56
0.16
0.59
0.44
1.17
0.61
0.39
0.17
0.71
0.53
0.87
0.55
0.90
0.50
0.87
0.19
1.06
0.43
0.65
0.20
0.97
0.48
0.51
0.04
0.98
0.47
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Table A2: Cholesterol and titer values for Figure 4-3A& B. Effect of cholesterol
depletion on the infectivity of HSV-1 and SuHV-1 after 5mM methyl-β-cyclodextrin
(MβCD) exposure.
Sample
HSV-1
SuHV-1
HSV-1
Cells
SuHV-1
Cells

Titer
(MTT50/ml
)

Cholesterol
(ug/ml)

Measurement

No MβCD
Average
STDEV
7.74
0.3
1.03
0.15

MβCD
Average
STDEV
1.07
0.09
0.36
0.04

10.65

2.29

1.13

0.07

1.09

0.37

0.4

0.07

HSV-1

6.8

0.13

5.4

0.15

SuHV-1

7.21

0.36

3.27

0.44

120

Cell Viability (%)

100
80
60
40
20
0
1E-08

HSV-1 Mock
SuHV-1 Mcok

0.00001

0.01

10

10000

MβCD (µM)

Figure A1: Toxicity measurements for Vero cells seeded with HSV-1 and SuHV-1 Mock
samples based on MβCD concentration. Mock samples for each virus were tested to give
a representative level of cholesterol in solution without added virus. Mock samples were
comprised of cells that underwent the same propagation procedure as their respective
virus.
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Table A3: Log10 reduction values for Figure 4-4B&C. Inactivation of enveloped viruses
by agmatine. Inactivation occurred at 4°C over 24 hours. Agmatine concentration at 1 M
and acetate concentration at 20 mM.
Time (hours)

EAV

SuHV-1

HSV-1

Virus

Solvents
Agm + Act
Act
Agm + Act
Act
Agm + Act
Act

pH

1

3

6

Average

STDEV

Average

STDEV

Average

STDEV

4

-0.35

0.24

-0.14

0.29

-0.24

0.24

7

-0.39

0.31

-0.46

0.10

-0.75

0.49

4

2.56

0.12

2.75

0.54

2.77

0.41

7

-0.30

0.18

0.26

1.15

0.61

1.24

4

3.03

0.10

3.45

0.00

3.53

0.04

7

-0.15

0.22

-0.04

0.34

0.04

0.01

4

3.70

0.60

4.00

0.40

3.80

0.50

7

0.07

0.34

0.35

0.35

0.23

0.25

4

0.03

0.29

0.02

0.18

0.00

0.33

7
4

0.04
0.04
0.23

0.32
0.44
0.52

-0.08
0.48
0.24

0.26
0.40
0.23

0.37
0.74
0.07

0.16
0.20
0.27

7

Time (hours)

SuHV-1

HSV-1

Virus

Solvents
Agm + Act
Act
Agm + Act
Act

EAV

Agm + Act
Act

pH
4

12
Average
0.49

24
STDEV
0.22

Average
1.89

STDEV
0.10

7

0.11

0.20

1.83

0.24

4

3.16

0.21

3.35

0.37

7

0.87

0.77

0.96

0.47

4

3.37

0.11

3.55

0.01

7

0.24

0.27

0.69

0.14

4

3.90

0.50

3.90

0.40

7

0.45

0.42

0.82

0.56

4

0.03

0.05

0.51

0.04

7

0.02

0.15

0.27

0.11

4

0.47

0.60

0.50

0.35

7

0.23

0.55

0.09

0.23
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Table A4: Log10 reduction values for Figure 4-4D. Comparison of arginine, agmatine,
and butyroyl-arginine in the inactivation of HSV-1 after 1 hour at 4°C or on ice. 0.7 M
arginine and but-arg represent data reformatted from Katsuyama et al.10
Solvent

LRV

STDEV

1M Agm

3.80

0.37

1M Agm

-0.35

0.29

0.7 M Arg
0.7 M ButArg

5.00

N/A

5.00

N/A

Table A5: Log10 reduction values for Figure 4-5. Virus inactivation by arginine peptides.
Inactivation occurred after 1 hour at pH 7 in Tris buffered solutions with 10% DMSO.
Arginine and CapA6R concentration at 7.6 mM. R8 concentration at 0.95 mM which is
equivalent to an arginine concentration of 7.6mM. Tris concentration at 20 mM.

Solvents

Average

STDEV

CapA6R+ 10% DMSO

1.29

0.35

R8 + 10% DMSO

0.23

0.07

HSV-1

Virus

10% DMSO

0.19

0.15

Arg + 10% DMSO

0.06

0.11

Arg

-0.02

0.07

CapA6R+ 10% DMSO

1.65

0.63

0.56

0.07

10% DMSO

0.27

0.31

EAV

R8 + 10% DMSO
Arg + 10% DMSO

0.05

0.12

Arg

0.50

0.20

Table A6: Log10 reduction values for Figure 4-6. Inactivation of EAV and HSV-1 by
arginine with added Pyrenebutyric acid (PYB). Inactivation occurred after 1 hour at 4°C.
PYB at 10 mM, arginine at 1 M, and Tris and acetate buffer at 20 mM.

EAV

HSV-1

Virus

Solvents

pH

Arg + Tris

7

PYB

DMSO

Average

STDEV

Average

STDEV

-0.32

0.22

-0.32

0.22

Arg + Act

4

3.22

0.13

4.55

0.03

PBS

7.2

-0.03

0.24

-0.36

0.18

Arg + Tris

7

1.38

0.38

-0.20

0.32

Arg + Act

4

0.01

0.47

0.06

0.17

PBS

7.2

0.37

0.31

0.24

0.26
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Table A7: Log10 reduction values for Figure 4-7. Inactivation of HSV-1 with Buffer
Mimics. Inactivation occurred at 4°C over 24 hours. Arginine concentration at 1 M.
Glycine, Glycineamide, MES, and Tricine concentration at 20 mM.

Virus

Solvents
Arg + Glycine
Arg +
Glycineamide

HSV-1

Arg + MES
Arg+ Tricine
Glycine
Glycineamide
MES
Tricine

pH
4
7
4
7
4
7
4
7
4
7
4
7
4
7
4
7

Time (hours)
3

1
Average

STDEV

Average

STDEV

Average

STDEV

4.49
0.04
4.45
0.07
4.56
-0.07
4.37
0.05
0.33
-0.12
-0.07
-0.12
0.27
-0.19
0.26
-0.09

0.29
0.37
0.17
0.37
0.21
0.22
0.08
0.30
0.56
0.37
0.29
0.21
0.78
0.45
0.42
0.25

4.54
0.44
4.46
0.57
4.53
0.44
4.52
0.22
0.04
0.18
-0.02
-0.09
0.61
-0.18
-0.16
-0.10

0.19
0.48
0.43
0.72
0.19
0.84
0.17
0.81
0.79
0.35
0.60
0.67
0.51
0.56
0.04
0.26

4.63
0.84
4.60
0.74
4.50
1.31
4.57
0.90
0.72
0.21
-0.22
-0.01
0.72
0.21
0.32
0.01

0.23
0.51
0.21
0.58
0.17
0.69
0.15
0.15
0.78
0.82
0.53
0.77
0.68
0.66
0.43
0.43

Time (hours)
Virus

Solvents
Arg + Glycine
Arg +
Glycineamide

HSV-1

Arg + MES
Arg+ Tricine
Glycine
Glycineamide
MES
Tricine

pH

6

12
Average

24
STDEV

Average

STDEV

4

4.48

0.17

4.48

0.21

7

1.39

0.62

2.01

0.67

4

4.43

0.19

4.26

0.09

7

1.62

0.49

2.41

0.41

4

4.42

0.18

4.46

0.14

7

1.73

0.44

2.41

0.56

4

4.54

0.16

4.56

0.24

7

1.69

0.66

2.15

0.44

4

1.03

0.89

1.51

0.86

7

0.57

0.37

0.80

0.81

4

0.68

0.43

0.09

0.61

7

0.71

0.62

0.11

0.93

4

1.23

0.54

1.20

0.60

7

0.39

0.42

0.32

0.50

4

0.40

0.60

0.78

1.01

7

0.31

0.65

0.79

0.55
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Table A8: Structure at pH 7 and pKa values of the buffer mimics tested in Figure 4-7176.
Buffer mimics showed similar inactivation to Tris and acetate when used with 1 M
arginine at pH 4 and 7.
Buffer

Structure at pH 7

pKa
Values

Tris

8.95,14.16

Glycine

2.31,9.24

Glycineamide

8.15

MES

-1.52,6.51

Tricine

2.86,7.61
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SuHV-1

HSV-1

Intensity (%)

20

20

164

255

220
10

295

10

0

0
0.1

10

1000

0.1
Size (nm)
1 hr

10

1000

24 hr

Figure A2: Size changes of control HSV-1 and SuHV-1 in PBS at pH 7.4 measured by
DLS after 1 and 24 hours at 4°C. PBS control data over 24 hours for both viruses show
minimal changes.

Figure A3. DLS size changes of HSV-1 and SuHV-1 after 1 (solid) and 24 (hashed) hours
in comparison to a PBS control. Arginine was at 1 M, Tris was at 20 mM, and PBS was at
pH 7.4. Inactivation occurred at 4°C. All DLS measurements showed increasing virus
size after arginine exposure. All data points for DLS measurements are in triplicate.
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